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SUMMARY
Chemical syntheses and receptor binding studies (and 
some structure activity comparisons) of some imidazo- 
[1,2-bJpyridazines, imidazo [ 1,2-a ] pyr idines , imidazo- 
[1,2-a]pyrimidines and imidazo[1,2-a]pyrazines are reported 
in this thesis. 1H n.m.r. spectra are also recorded and 
discussed.
Several new series of 2-aryl-6-substituted-3- 
unsubstituted[3-dimethylaminomethyl, 3-acetamidomethy1, 
3-benzamidomethyl and 3-(substituted benzamidomethyl)] 
imidazo[1,2-b]pyridazines have been prepared. The 3- 
unsubstituted imidazo[1, 2-b]pyridazines were prepared from 
the appropriate 6-substituted pyridazin-3-amines with 
bromoacetyl compounds, and substituents were introduced at 
the 3-position by Mannich reaction or by heating with N- 
hydroxymethylamides. New 2-aryl-6-(N-benzyl-N- 
methylamino)-3-methoxy- and 2-aryl-3-methoxy-6-(substituted 
benzylamino)imidazo[1,2-b]pyridazines were prepared from 
the relevant 6-benzylaminopyridazin-3-amine 2-oxides with 
bromoacetyl compounds followed by diazomethane methylation 
of the imidazo[ 1,2-jb]pyridazin-3 (5H) -ones.
Many 6-(variously substituted)-3-methoxy- 
(acylaminomethyl and dimethylaminomethyl)-2- 
benzyl(phenethyl, biphenyl-4'-yl, 6'-methylnaphthalen-2'- 
yl, t-butyl, and cyclohexyl)imidazo[1,2-b]pyridazines have 
also been prepared to measure the effect of significant 
changes in size and conjugation of the 2-substituent. All 
these compounds were subsequently tested for their ability
iv
to bind to specific binding sites in rat brain 
preparations. The results of the binding studies of each 
series of compounds are presented and discussed in each 
chapter. The most active compounds in displacing 
[H]diazepam from rat brain preparation were 
3-benzamidomethyl-2-(3',4'-methylenedioxyphenyl)- 
6-methylthioimidazo[1,2-b]pyridazine with IC50 2 nM and 
3-methoxy-6-(3',4 '-methylenedioxybenzylamino)-2-(3",4M- 
methylenedioxyphenyl)imidazo[1,2-b]pyridazine with IC50 
1 nM (cf. diazepam 4.2 nM). Some of these compounds which 
exhibit high binding affinity are being examined (by 
others) for pharmacological activity in rats.
The binding affinity of the imidazo[1,2-b]pyridazines 
prepared in this work varied considerably. Of the 
compounds with 3-benzamidomethyl(3-acetamidomethyl, or 3- 
dimethylaminomethyl) groups or those which were 
unsubstituted at the 3-position, the 3-benzamidomethyl 
compounds generally bound most strongly. Further 
substitution in the phenyl ring of the 3-benzamidomethyl 
group generally had a detrimental (or marginally 
beneficial) effect on the displacement of [3H]diazepam from 
rat brain membrane preparations. N-Methylation, as in 6- 
(N-benzyl-N-methylamino)-3-methoxy-2-phenylimidazo- 
[1,2-b]pyridazine, generaly decreased binding ability by ca 
2-fold relative to each N-demethyl analogue. Amongst the 
compounds with variable substituents at the 2-position the 
order of activity was Ph > PhCH2 > PI1CH2 CH2 > CgF^Ph-p (6'- 
methylnaphthalen-2 ' -yl, cyclo-CgH^, Bu1-) .
The effects of removing N-5 from imidazo[l/2-b]- 
pyridazines and its replacement by CH, as in imidazo- 
[1,2-a]pyridines, and the effects of shifting the ring 
nitrogen atom at the 5-position in imidazo[1,2-b]- 
pyridazines into the 7- or 8-position in imidazo[1,2-a]- 
pyrazines and imidazo[1,2-a]pyrimidines, respectively, on 
the ability to displace [3H]diazepam from rat brain 
membrane have been examined. Generally the imidazo[1,2-a]- 
pyridines were less active than the corresponding 
imidazo[1,2-b]pyridazines (one exception recorded), and 
amongst corresponding derivatives of the triazabicyclic 
systems the order of activity was imidazo[1,2-b]pyridazine 
>> imidazo[1,2-a]pyrimidine 2 imidazo[1,2-a]pyrazine.
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CHAPTER I
1CHAPTER I INTRODUCTION TO ANXIOLYTICS AND RELATED 
CNS-ACTIVE COMPOUNDS
1-1 Historical background
Anxiety, which has been recognized as an inherent part 
of man's being, is an ubiquitous emotional state common to 
everyday life.1 It is related to fear which is a response 
to current tangible threats; anxiety occurs in anticipation 
of a threat not yet present. Various studies have 
suggested that from about three to eight per cent of the 
population has clinically significant anxiety at any one 
time.2 As for the pervasiveness of anxiety disorders and 
the extent of usage of antianxiety drugs, in the year 
1984/1985 Australian medical practitioners wrote some five 
million prescriptions for drugs of the benzodiazepine group 
and cost the pharmaceutical benefit scheme some twenty-two 
million dollars.3 In the USA, multicenter epidemological 
surveys of three communities in the period 1980-1982, 
showed that anxiety disorders had a life-time prevalence 
rate of between ten per cent and twenty-five per cent4 and 
a six-month prevalence rate of between six per cent and 
fifteen per cent.5 In 1985, psychotropic drugs prescribed 
within the United States cost approximately one billion 
dollars.6
Throughout history, various classes of chemicals and 
plant products have been used to treat anxiety conditions. 
These include the barbiturates, such as phenobarbita1 (Fig.
21-1) amobarbital and butabarbital, propanediols 
[meprobamate and tybamate (Fig. 1-1)] antihistamines, 
benzodiazepines [such as diazepam (Fig. 1-1)], opiate 
alkaloids and belladonna derivatives.
Alcohol is one of the oldest and most commonly-used 
antianxiety agents. Alcohol possesses anxiolytic and 
sedative-hypnotic properties in both laboratory animals and 
man, but frequently it has other socially unacceptable
neffects. 2-Methyl-2-propyl-l,3-propanediol dicarbamate 
(meprobamate), synthesized by Ludwig and Piech8 in 1951, 
was discovered to possess antianxiety activity three years
Qlater. In 1955 the introduction of meprobamate (under the 
trade name 'Miltown') and 1957 (as 'Equanil') provided the
Me
0
Phenobarbital
Tybamate
M o Cl
Diazepam Hydroxyzine (HC1)
Fig. 1-1
3first generally useful replacement for the overly-sedating 
barbiturates in the treatment of anxiety.10 Before the 
benzodiazepines were discovered, the substituted 
propanediols were considered to be important antianxiety 
agents. Although meprobamate has been in some disfavour of 
recent years, it still appears to be a reasonably effective 
and a reliable drug.11 Barbiturates and various other 
compounds which are chemically unrelated, such as 
hydroxyzine hydrochloride (Fig. 1-1) and chlormezanone, 
also have potent anxiolytic activities. In the last 85 
years many hundreds of barbiturates have been prepared. 
These have been used as hypnotics and in lower doses as 
sedatives, anxiolytics and antiepileptics. Hydroxyzine 
hydrochloride was first synthesized by Morren et al. in 
1954,12 and was widely used as a sedative. The 
arylthiazanone derivative, chlormezanone, which was less 
frequently used as an antianxiety drug, was synthesized by 
Surrey et al. in 1958.13
The use of the above-mentioned drugs is limited 
because of several side effects and of concerns about their 
serious toxicity at high dosage. Since the early 1960s, 
the use of barbiturates and other drugs as prescription 
anxiolytics has been displaced almost entirely by the 
benzodiazepines, such as chlordiazepoxide and diazepam.
4NHMe
Chlordiazepoxide
(Librium, 1963)
Flurazepam
(Dalmane,1970)
OH
Oxazepam
(Serax,1965)
Me
Clobazam
(Urbanyl,1975)
5-Phenyl-2,3-dihydro-l ,4-benzodiapin-2-one
Fig. 1-2
51-2 Benzodiazepines
Although the first centrally-acting 1,4-benzodiazepine 
compound, chlorodiazepoxide, was synthesized by Sternbach 
and colleagues in 1955,14 it was not until the 1960s that 
animal studies carried out with chlordiazepoxide indicated 
that the compound had hypnotic, sedative and anticonvulsant 
effects similar to those of meprobamate, in mice and cats. 
Chlordiazepoxide (under the trade name 'Librium'; 1960,
Fig. 1-2) was the first 1,4-benzodiazine15 introduced into 
clinical use and was soon followed by other more potent 
compounds such as diazepam ('Valium' 1963 ; Fig. I — 1), 
oxazepam ('Serax' 1965, in USA) and flurazepam ('Dalmane' 
1970; Fig. 1-2).
The benzodiazepines consist of a bicyclic nucleus 
formed by the fusion of a benzene ring with a partially 
unsaturated seven-membered heterocycle containing two 
nitrogen atoms in the 1,4-positions. Benzodiazepines 
possessing biological activity usually have a phenyl group 
at the 5-position, and an electronegative substituent at 
the 7-position.16 The benzodiazepines are extensively used 
in clinical practice as anxiolytics, anticonvulsants, 
hypnotics and muscle relaxants because they are very 
effective and were considered to have mild side effects, 
were safe on overdosage and lack drug interactions with
nserious clinical consequences. Thousands of 
benzodiazepine derivatives have been synthesized and 
screened pharmacologically; about two dozen assorted
6benzodiazepine drugs are available in clinical use world­
wide. The pattern of consumption for anxiolytics and 
hypnotics in Australia for the period 1975-1984 is shown in 
Fig. 1-3.7 It has been suggested that 10-20% of adults in 
the Western world regularly ingest antianxiety agents. 
Chronic usage of these drugs has been reported to be 
widespread, with a large proportion of all 'repeat' 
prescriptions being for benzodiazepine drugs. Although in 
the short-term, benzodiazepines have proved to be 
beneficial in the treatment of anxiety and related 
disorders, their long-term use has been seriously 
questioned because it has been demonstrated that 
benzodiazepine drugs give rise to physical and 
psychological dependence18 and tolerance. The 
benzodiazepines have achieved a world-wide use due to their 
wide spectrum of nervous system activity. They also set 
the stage for a greatly increased understanding of the 
pharmacology, the biochemistry and chemistry of anxiety and 
of central nervous system receptor structure and function.
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Fig. 1-3 Patterns of consumption for anxiolytics and hypnotics in Australia for the 10-year 
period 1975-1984. The figures are based on the number of prescriptions for drugs 
available on the Pharmaceutical Benefits Scheme. These are not all prescriptions 
written for these drugs, but are representative of the pattem of use during this period. 
Data from Ref. 7
81-3 Structure-activity relationships for benzodiazepines
Most synthetic benzodiazepines have been shown to 
possess muscle relaxant and sedative properties in 
animals.16 A large number of the fundamental studies of 
the structure-bioactivity relationships within the 
benzodiazepine compounds (Fig. 1-2) has been summarized by 
Sternbach et al.15'19'20'21 They suggested that, in the 
1,4-benzodiazepine ring system,14'15'19' 20'21 the presence 
of the seven-membered imido-lactam ring and the 5-phenyl 
substitutent were essential; that substitution, in 
particular, with electronegative substituents in the 7- and 
2'- positions, markedly increased biological activity; and 
that further substitution was advantageous only at the 1- 
and 3-positions.
Since the 'discovery' of specific high-affinity 
central nervous system (CNS) binding sites for 
benzodiazepines in 1977, simple in vitro binding tests were 
devised which were relatively well suited to the screening 
of a large series of benzodiazepines and non-benzodiazepine 
compounds. Appropriate studies were able to define common 
structural features required for high affinity binding to 
benzodiazepine receptors in in vitro assays. The 
published binding data from a total of 29 drugs, comprising 
benzodiazepines and compounds from other structural 
classes, were used by Crippen to identify common three 
dimensional features and determine the free energy of 
binding; a possible binding site model for a subset of 18
9compounds, comprising 15 site points and 5 adjustable 
energy parameters, was deduced by applying distance 
geometry analysis.24 Crippen drew the conclusion that five 
non-hydrogen atoms of each ligand can occupy corresponding 
points in the site and thus constitute a possible 
benzodiazepine pharmacophore.
Theoretical (chemical) technigues25'26 have been used 
in a study of the molecular discriminants of receptor 
affinity and activity of a series of benzodiazepines.
Gilli and coworkers27 developed a model based on the X-ray 
structures of benzodiazepines. They concluded that small 
conformational differences among the benzodiazepines have 
little effect on activity and the major determinant of 
activity is the electronegativity of the substituent in the 
7-position because it affects the strength of potential 
hydrogen bonds formed at N-l.
Leow et al. proposed that the receptor possesses 
three cationic sites that interact with an electron- 
withdrawing group at C-7, the C-2 oxo group and the imino 
nitrogen atom, N-4. A better model was developed by 
Codding and Muir;28 it showed the positions and the types 
of binding groups characterized by the differences between 
antagonist and agonist ligands for the benzodiazepine 
receptor. It was notable that agonist benzodiazepines 
possess a consistent arrangement of the carbonyl oxygen 
atom, the aromatic "A" ring (Fig. 1-2) and the imino 
nitrogen atom (N-4) and that the two electronegative atoms
10
(0 and N) are always on the same side of the MA" ring. 2 9
Definitive studies to determine the absolute 
stereochemistry of the active conformation of 
benzodiazepines and the chiral nature of the 1,4- 
benzodiazepine ring system were carried out2 9 , 3 0  by single­
crystal X-ray and by n.m.r. analysis. These showed that 
the S-enantiomer of C-3 methyl substituted benzodiazepines 
is more active in the [ H]diazepam binding, in all cases, 
than is the corresponding R-enantiomer. 3 0 Fryer and 
coworkers, ' with the assistance of computer graphics 
analysis, have developed a three dimensional molecular 
model based on structural correlations of compounds (both 
benzodiazepines and non-benzodiazepines such as those shown
in Fig. 1-4) which possess high affinity (IC5 0 values in
(See, f)'7o)
the low nM range)^for CNS benzodiazepine binding sites.
It was designed to fit all known ligands for the 
benzodiazepine receptor and as a predictive tool for the
o 1design of in vitro active drugs. The Fryer model x (Fig. 
1-5) has been helpful. In this model there are two major 
binding sites. The first site is an aromatic or 
heteroaromatic "A" ring which is capable of undergoing (7T- 
7T) stacking interactions with aromatic or heteroaromatic 
groups within a receptor; and the second, a proton- 
accepting source (tt^ ) bearing a spatial relationship to the 
"A" ring. An auxiliary binding site namely, a second 
electron-enriched region (7^ ), also spatially related to 
the "A" ring,29,jl was proposed. Other auxiliary binding
11
Diazepam Midazolam Ro 11-6896
Me
Ro 22-8515 Ro 15-1788 Zopiclone
Fig.I-4
12
sites were also envisaged.
The results of calculations based on the Fryer et al. 
model are presented in (Table 1-1). A relationship between 
the in vitro activity of a series of compounds and their 
"A" to T^i distance was established.31'33 Thus for 
compounds acting as agonists, the distance from mid "A" to 
7 T is from 3Ä to about 6.5Ä; as antagonists the range is 
from about 6.5Ä to 7.5Ä; and as inverse agonists the 
distance begins at approximately 7.5Ä. It was proposed 
that with the "A" ring placed in the xy plane of a set of 
cartesian coordinates with its centre at (0,0,0), the 
proton-attracting group for active compounds always had 
positive values for x,y and z coordinates (Fig. 1-5).
Table 1-1. Coordinates for 7T^ for various ligands at the 
benzodiazepine receptorA
Compounds X(&) Y(Ä) Mid " A ,,-7T1 (Ä)
Diazepam 4.50 1.76 4.91
Midazolam 3.88 2.75 4.78
R022-8515 4.83 2.36 5.44
R022-9187 3.82 2.81 4.75
R022-7244 4.71 3.85 6.11
Zopiclone 3.56 3.56 5.00
ZK93423 3.20 4.34 5.45
CGS-17867A 3.16 2.28 3.90
CL218,872 4.6 1.0 4.80
A Data taken from (Ref. 33)
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A study of steric effects has revealed that the 
conformations of agonist-receptor and antagonist-receptor 
are different and it has been possible to differentiate the 
conformational requirements for both full agonists and full 
antagonists. 34
( ^ )  Aromatic or heteroaromatic ring lying in the xy plane 
(f tj)  Proton-accepting atom or group, mid 'A' to n ! distance s=3.0-6.5 A0 (for agonists)
*► Mid 'A' to Ttj distance, x, y, defined as positive
Indicative of structural skeleton fixing the relationship 'A' to ft} should be 
at least partially unsaturated, may be part of aromatic or heteroaromatic ring
Fig. 1-5 Schematic three-dimensional model for binding of ligands at the BZR
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1-4 Mechanisms of action of benzodiazepines 
1-4.1 GABA/Benzodiazepine receptors
^  C  CLA receptor ' is a tissue site which can selectively 
bind a compound of a specific chemical structure and which, 
following the binding, mediates a particular biological 
response. Most receptor sites of interest to 
neuroscientists are proteins which exist in the plasma 
membrane of neurones, with their binding sites facing 
toward the extracellular environment. In 1967, 
electrophysiologists discovered that benzodiazepines 
potentiate inhibitory nerve transmission at sites in which 
the amino acid, 7-aminobutyric acid (GABA), is the 
inhibitory synaptic transmitter.35'36 Later it was shown 
biochemically that GABA can potentiate the binding of 
radioactively labelled benzodiazepines to mammalian brain 
membranes and, conversely that benzodiazepines can
o opotentiate GABA binding to the membranes. Benzodiazepine
receptors are coupled to both GABA receptors and chloride
channels in a GABA-receptor/benzodiazepine-receptor/
• 3 9chloride ionophore complex (Fig. 1-6).
It is generally accepted that this complex functions 
to regulate the flow of chloride ions across neuronal 
membranes. The nerve-cell membrane is normally impermeable 
to chloride ions but when the chloride channels in the 
membrane are opened they allow chloride ions to enter,
15
c a u s i n g  a n  i n c r e a s e  i n  t h e  n e g a t i v e  p o t e n t i a l  a c r o s s  t h e  
m em b ran e  a n d  m a k in g  t h e  c e l l  m ore  d i f f i c u l t  t o  e x c i t e .  The  
p r o b a b i l i t y  o f  c h l o r i d e  c h a n n e l  o p e n i n g  i s  m a r k e d l y  
i n c r e a s e d  by  GABA^ r e c e p t o r  o c c u p a n c y  a n d  i n  t h i s  GABA a c t s  
a s  a n  i n h i b i t o r y  n e u r o t r a n s m i t t e r .  B e n z o d i a z e p i n e s  a l o n e  
c a n n o t  c a u s e  c h l o r i d e  c h a n n e l s  t o  o p e n  a n d  i n h i b i t  n e u r o n e s  
b u t  w hen  GABA i s  r e l e a s e d  on  t o  a n e u r o n  i n  t h e  p r e s e n c e  o f  
t h e  b e n z o d i a z e p i n e ,  a  g r e a t e r  c h l o r i d e  i n f l u x  i s  p r o d u c e d  
t h r o u g h  t h e  m em brane  t h a n  w i t h  GABA a l o n e .  T h u s  
b e n z o d i a z e p i n e s  e n h a n c e  t h e  t r a n s f e r  o f  G A B A -m ed ia ted  
i n h i b i t o r y  s i g n a l s  i n  t h e  v e r t e b r a t e  CNS. The  p o t e n t i a t i n g  
e f f e c t  o f  b e n z o d i a z e p i n e s  on  G A B A -m ed ia te d  c h l o r i d e
ground state activated state
F i g . I - 6 A model of the GAB A-receptor/benzodiazepine-receptor/chloride 
ionophore complex.
16
conductance appears to be due to an increase in the 
frequency of chloride channel openings rather than on the 
duration of each channel opening (as is the case with 
barbiturates).
Benzodiazepine receptors are wide-spread and densely 
situated throughout the CNS, with phylogenetically-older 
areas (e.g. pons and medulla) containing fewer receptors 
than phylogenetically newer structures (e.g. cerebral 
cortex). Nevertheless, the regional differences in 
receptor density are smaller than for many other 
neurotransmitter receptors. This can probably be explained 
by functional and structural heterogeneity at these 
receptors in the various areas of the brain.
Although early work suggested a homogeneous 
population of benzodiazepine receptors in the mammalian 
CNS, this is now known to be incorrect. On the basis of 
pharmacological studies, several subclassifications of 
receptor sites are known to exist, and specific CNS 
benzodiazepine receptors have been classified into Type I 
and Type II sites.40'41 Research with a group of 
triazolopyridazine compounds (including CL 218,872) (Fig. 
1-7)40 revealed that those compounds had anxiolytic 
activity but possibly did not cause sedation (ataxia).
This led to the proposal that the triazolopyridazine- 
selective receptors (Type I sites) were more closely 
involved in the anxiolytic actions of the benzodiazepine, 
whereas Type II sites were related more closely to
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sedation. The subclassification of receptor sites promises 
to hasten the development of compounds with significantly 
more selective anxiolytic, sedative/hypnotic or muscle- 
relaxant actions. The elucidation of receptor subtypes has 
been aided in recent years by rapid progress in molecular 
biological techniques.
1-4.2 Molecular biology
To aid in understanding the possible mechanism of 
action of the benzodiazepines via GABAergic transmission, a 
hypothetical model of the benzodiazepine-receptor/GABA- 
receptor/chloride channel complex was proposed by Haefely 
et al.42,43 They assumed that it was a tetrameric 
glycoprotein consisting of four identical or similar 
protomers (subunits). These four structurally related 
subunits were assembled to generate an integral ion pore 
which could close or open in response to small 
conformational changes in the subunit(s).
More recently, with the application of molecular 
biology cell techniques, it has been suggested that the 
GABA-gated chloride channel consists of a pentameric 
structure. It was considered initially that only two types 
of subunit (a and ß) were needed to form channels that 
matched the behaviour of endogenous GABA receptors.44 But 
more recent investigations showed that a third type of 
subunit, a 7-subunit, of the GABA-benzodiazepine receptor 
in the brain,45 was required for more robust regulation of 
the channel by benzodiazepines.46 Haefely and coworkers47
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have recently proposed that the hetero-oligomeric GABAA 
receptor chloride ion channel complex consists of subunits 
( a r ß , 7 , 5 in varying stoichiometry). These form a 
transmembrane anion channel gated by the primary ligand 
GABA and modulated by secondary (allosteric or heterotopic) 
ligands. The binding site for GABA is related primarily to 
the /3-subunit, while the »-subunit includes the binding 
site for benzodiazepines. Each of the subunits of the GABA 
receptor, when expressed alone in a cultured cell (e.g. 
oocyte), is capable of forming a GABA-activated chloride 
ion channel, the opening of which is blocked by picrotoxin 
and potentiated by pentobarbital.46 However, high 
concentrations of GABA (^ 100 jxM) are needed to open these 
model channels. At a meeting on "Drug Action at the 
Molecular Level: Differences Between Agonist and
Antagonists" in 1989, Schofield48 reported that thirteen 
different GABAA receptor subunits had been cloned.
Changing »-subunit combinations appeared to alter the 
affinity of receptor for ligand, while the presence of the 
Ö2*-subunit was needed to observe the full benzodiazepine 
pharmacology, involving allosteric potentiation of GABA 
receptors and the effects of inverse agonists. There is 
experimental evidence supporting the idea that changing 
various combinations of »-subunits with a single /3-subunit 
results in GABAA receptors with different GABA 
sensitivity.49 Thus, different combinations of the various 
»-, /3, and 5-subunits will result in a large number of 
pharmacologically different GABAA-benzodiazepine receptor
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subtypes.40 Evidence from molecular biological 
investigations (as briefly outlined above) suggesting a 
possible multiplicity of somewhat different benzodiazepine- 
receptor/GABA-receptor/chloride ionophore complexes within 
the CNS, offers the possibility of selectively modulating 
specific GABA neurones in various brain regions by the 
synthesis of appropriate benzodiazepine-like ligands.
1-4.3 Agonists, antagonists and inverse agonists
Small amounts of ethyl ß-carboline-3-carboxylate 
(ß-CCE) have been isolated from human urine and mammalian 
brain extracts^ (see Chapter 1-4.4). The pharmacological 
effects of jS-CCE are opposite to those of the clinically 
useful benzodiazepines. It was reported50 that ß-CCE 
reverses the anxiolytic effects of benzodiazepines and 
exhibits anxiogenic activity.51 In contrast, the related 
compounds, ethyl 6-benzyloxy-4-methoxymethyl-ß-carboline-3- 
carboxylate (ZK93423) and its 5-benzyloxy isomer (ZK91296) 
are anticonvulsants and have been classified as full 
agonist and partial agonist, respectively, at the 
benzodiazepine receptor. The different pharmacological 
activities of these benzodiazepine (and non-benzodiazepine) 
receptor ligands have been shown in Table 1-2.
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Table 1-2 Action of some benzodiazepine receptor ligands
Actions Compound
^  <
Anxiolytic
Anticonvulsant
Benzodiazepines 
Triazolopyridazines 
CGS 9896
Antagonists ^
ZK 91296 
R015-1788
Anxiogenic
Ro15-1788 
CGS 8216
Inverse €
agonists Convulsant
ß-CCE
ß-CCM
DMCM
i. Agonists
Agonists are defined as drugs which interact with 
their receptor to exert a biological response (i.e. they 
have positive intrinsic efficacy). Examples are diazepam 
and chlordiazepoxide which have characteristic therapeutic 
effects (such as anticonvulsant, sedative, muscle relaxant, 
anxiolytic and hypnotic activities).
ii. Antagonists
Receptor antagonists are defined as drugs with a high 
affinity for their receptor, but having no relevant 
biological effects of their own at the receptor other than
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to block the effects of both agonist and inverse agonist 
ligands (i.e. no intrinsic efficacy).
To date, no 'pure' antagonists at benzodiazepine 
receptors have been reported. Ro 15-1788 (Fig. 1-9) has 
been found to inhibit specifically [3H]diazepam binding to 
brain synaptosomal fractions and to antagonise specifically 
the behavioural, electrophysiological and biochemical 
effects of clinically useful benzodiazepines in a variety 
of experimental paradigms.22 Although many investigators 
have confirmed these observations, it has also been 
reported that Ro 15-1788 does possess some intrinsic 
pharmacological effects. For example, high doses of the 
compound have been shown to have anticonvulsant 
effects.52,53 Thus although Ro 15-1788 is classified as a 
benzodiazepine antagonist, it may have some slight 
intrinsic partial agonist activity in some cases.
iii. Inverse agonists
These are drugs which combine with their receptors to 
exert a biological response which, when compared to 
agonists, have the reverse profile of activity i.e. they 
show a 'mirror image' biological response.
Examples are the /3-carboline derivatives, such as 4- 
ethyl-6,7-dimethoxy-0-carboline (DMCM), which have effects 
opposite to those of the 'classical' benzodiazepine
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agonists and possess pro-convulsant and anxiogenic 
properties.52
1-4.4 Endogenous ligands
Recent investigations have shown that several 
benzodiazepines occur naturally in the brain of various 
species, including rats and humans.54“58 It has been 
suggested that benzodiazepines which occur in brain are 
possibly of dietary origin because they are found in 
numerous plants that serve as food, and also in cows
c  S' C  -7milk. ' It also has been suggested, with some limited 
evidence (e.g. from their presence in neuroblastoma or 
glioma cell cultures) that they may be endogenously 
synthesized but the biosynthetic pathways to such 
benzodiazepines are as yet unknown.
The isolation of N-demethyldiazepam, a metabolite of 
diazepam, has been achieved from bovine and rat brains, and 
purified by immuno-affinity chromatography employing a 
monoclonal antibody to the benzodiazepine, 3-hemisuccinyl- 
oxyclonazepam.54'59 The isolated compound was identical 
with synthetic N-desmethyldiazepam in binding studies, 
further identified by gel filtration and reverse-phase 
HPLC, and finally characterized by mass spectrometry (GC- 
MS).54 A compound with the same absorption spectrum and
C a  C QHPLC profile as oxazepam was also reported. ' The same 
group detected benzodiazepine immunoreactivity in human 
brain kept in paraffin since 1940, sixteen years before 
benzodiazepines were first synthesized by the
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pharmaceutical industry.54 Benzodiazepine-like 
immunoreactivity has been noted also in various rat tissues 
(liver, kidney, spleen, brain) but the CNS had the highest
C  Qlevels. More recently, benzodiazepine-like material has 
been found in human milk (4 to 8 mg lorazepam units/ml). 
Klotz also reported the isolation of diazepam from 
cherries harvested in 1958. In an attempt to explain the 
origin of the naturally-occurring benzodiazepines, various 
plants were screened for these compounds. Diazepam and 
desmethyldiazepam have been identified by specific mass 
spectrometry (GC-MS) with selective ion monitoring (SIM)55 
in extracts from wheat. In addition to diazepam and 
desmethyldiazepam, several other benzodiazepine, including 
delorazepam, deschlorodiazepam, delorometazepam, 
lormetazepam, and isodiazepam have been identified in 
aqueous acid extracts of wheat and of potato tubers by GC- 
MS.61 Benzodiazepine-like compounds55 have also been 
reported from radioreceptor binding assays (RRA) to occur 
in several other products (fish powder, barley, corn, 
millet, oats, rice, buck wheat and soya beans). The 
authors of this work considered it unlikely that the trace 
amounts of benzodiazepine found in brains would have any 
direct pharmacological effect.
Some other non-benzodiazepine compounds which may be 
possible endogenous ligands include the following. Inosine 
and 6-hydroxypurine (degradation products of the 
nucleoside, adenosine) have a relatively low affinity for 
benzodiazepine receptors, although there is evidence that
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such levels may substantially increase during stress or 
hypoxia.39 Ethyl /3-carboline-3-carboxylate, which has been 
isolated from bovine brain and human urine extracts39'62 
(1.78 mg from 1800 litres of urine), binds very tightly to 
benzodiazepine receptors. Initially it was believed39 to 
be a product formed during the extraction process but it is 
now considered to be an endogenous component of bovine 
brain.
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1-5 Benzodiazepines and the development of new drugs
Since the discovery of chlordiazepoxide and diazepam,
many thousands of benzodiazepine derivatives have been
synthesized and screened for pharmacological activity with
the aim of finding compounds with more selective
pharmacological activities. This has been a relatively
fruitful area of research. Anxioselective compounds, such
as clobazam, which do not possess the undesirable side
effects of some benzodiazepine derivatives, (Fig. 1-2) have
shown a good separation between anxiolytic and sedative
dosages. A class of non-benzodiazepine compounds, which
has a wide separation between anxiolytic and anticonvulsant
or sedative doses, is the triazolopyridazine derivatives
(e.g. CL 218,872; 3-methyl-6-(3'-trifluoromethylphenyl)-
1,2,4-triazolo[4,3-b]pyridazine, Fig. 1-7). Unfortunately,
CL 218,872 cannot be used clinically as it has been
reported to have hepatotoxic effects in animals.42 In
1985, Bourguignon and coworkers66 synthesized SR 95195 (3-
methyl-7-phenyl-l, 2,4-triazolo[4,3 — Jb]pyridazine, Fig. 1-7)
in which the phenyl ring was attached to the 7-position
(i.e. on the pyridazine ring). It has inverse agonist
7activity at the benzodiazine receptor site. Yokoyama and 
coworkers68 reported the synthesis of CGS 8216, CGS 9895 
and CGS 9896 (Fig. 1-7) which possessed different intrinsic 
activities at the benzodiazepine receptor: CGS 8216 was a 
potent benzodiazepine receptor antagonist, ' CGS 9896 
was a partial agonist (and important structural lead) and
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CGS 9895 was a full agonist at low, and an antagonist at
7 nhigh doses. Recently Francis and coworkers have reported 
that another series of non-benzodiazepine-type compounds 
(e.g. CGS 13767, Fig. 1-7), shows benzodiazepine binding 
affinity (IC50 value of CGS 13767 is 4 nM).
Parenthetically, a new development in the 
psychopharmacology of anxiety was the introduction of 
buspirone (Fig. 1-7) as a non-benzodiazepine anxiolytic 
drug. This lipophilic, heterocyclic compound is one of a 
new class of agents known as azaspirodecanediones.
Buspirone was reported initially to be effective only in 
female patients, was less effective and took longer to 
work than diazepam. However, more recent studies found 
that buspirone was effective in benzodiazepine-sensitive 
anxiety states, but without the side-effects of sedation 
and dependency.74 Chemically, buspirone is unlike the 
benzodiazepines and it has been found that it does not 
interact with either benzodiazepine or GABA binding sites. 
However, there is evidence to indicate that buspirone and 
its analogue (MJ 13805; Fig. 1-7) can affect specifically
7 S5-HT-mediated processes in the CNS. A related compound, 
ipsapirone (Fig. 1-7) also possesses anxiolytic effects in 
animals but does not have sedative, ataxic or 
anticonvulsant effects. The proposal that the anxiolytic 
effects of buspirone and ipsapirone are mediated by an 
effect on 5-HTIA sites76 is supported by 
electrophysiological and behavioural data.
0-Carboline derivatives (Fig. 1-8) also interact with
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Fig. 1-8 Some ß-carboline derivatives that interact with benzodiazepine receptors
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benzodiazepine receptors.22 Ethyl /3-carboline-3- 
carboxylate (/3-CCE) was isolated from human urine and 
mammalian brain extracts by Braestrup et al.62 in 1980. A 
series of unique ß-carbolines has been developed and this 
has led to the concept of bidirectional agonism. The 
pharmacological effects of ß-CCE are opposite to those of 
the clinically useful benzodiazepines. Jensen and 
coworkers have studied the bidirectional effects of some 
/3-carbolines on seizure activity and suggested that ZK 
93423 (ethyl 6-benzyloxy-4-methoxymethyl-/}-carboline-3- 
carboxylate and its 5-benzyloxy isomer, ZK 91296) are 
anticonvulsants: they have been classified as full agonist 
and partial agonist respectively. The inverse agonists, FG 
7142 (N'~methyl-ß-carboline-3-carboxamide), ZK 90886 (ethyl
4-ethyl-5-methoxy-/3-carboline-3-carboxylate) and DMCM 
(methyl 4-ethyl-6,7-dimethoxy-j3-carboline-3-carboxylate) 
have effects opposite to those of the 'agonists' and thus 
possess convulsant and anxiogenic properties. The 
antagonist, ZK 93426 (ethyl 5-isopropoxy-4-methyl-/J- 
carboline-3-carboxylate) has no effect in these convulsant 
tests. The compound ZK 91296 has been reported to possess 
clear benzodiazepine-like agonist effects in squirrel- 
monkeys78 and enhances GABA binding in rat cerebral cortex 
membranes.79 The compound ZK 95962 is a partial agonist. 
Results of studies with the 0-carbolines ZK 91296, ZK 95962 
and ZK 93426 in healthy human patients have been 
reviewed.80 Abecarnil (ZK 112119)47'81'82 is effective in 
lower doses than diazepam in tests predictive of
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antianxiety activity and in some models of epilepsy, but it 
is less effective in tests measuring sedation and muscle 
relaxation and it is weaker than ethanol and hexobarbitone.
The first specific benzodiazepine antagonist, the 
imidazobenzodiazepine Ro 15-1788 (trade name 'Flumazeni1', 
Fig. 1-9) was reported22 in 1981. It is largely devoid of 
any intrinsic activity in most behavioural and 
electrophysiological experiments (see Section 1-4.3) but 
blocks all CNS effects of compounds which act through 
binding at benzodiazepine receptors.83-85 Some partial 
agonist properties have been reported for this compound.86 
Effects such as sedation, muscle relaxation, sleep and even 
coma which are induced by some benzodiazepine agonist drugs 
can be reversed by Ro 15-1788.87-89 The congener Ro 15- 
3505 (Fig. 1-9) showed a higher potency in human 
pharmacological studies;90 Ro 19-1880 is a full agonist 
and Ro 19-4603 is an inverse agonist. Bretazenil (Ro 16- 
6028; Fig. 1-9) possesses about a ten-fold higher affinity 
than diazepam for the benzodiazepine receptor.47 Its 
profile of activity in relation to benzodiazepine receptor 
full agonists has been studied.47
Some imidazo[1,2-a]pyridines and imidazo[1,2-a]- 
pyrimidines interact with benzodiazepine receptors; these 
have been reviewed by Gardner91 and Haefely et al.42 The 
pharmacology of zopiclone (Fig. 1-9), an anxiolytic- 
hypnotic, has been examined.92
The pharmacological profile of suriclone (Fig. 1-9) is 
that of a typical agonist,93 but its binding
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characteristics differ (independent of GABA concentration94 
and unaffected by photolabelling the receptor with the 
covalently bound flunitrazepam95) suggesting that it may 
bind to a novel site linked allosterically to the 
benzodiazepine receptor.96 The imidazo[1,2-a]pyridine 
compounds, zolpidem and alpidem (Fig. 1-9), have been 
claimed to possess preferential affinities for particular 
receptor subtypes in both animals and man. Zolpidem is a 
hypnoselective agent whereas alpidem has been reported to 
be anxiolytic in clinical studies on over 1500 patients 
with situational anxiety, general anxiety disorders and 
psychotic syndromes.97,98 Alpidem has anxiolytic-like 
effects in some (but not all) animal tests, and also 
anticonvulsant effects without sedation and muscle 
relaxation.99'100 The ketone (RU 31719; Fig. 1-10) has all 
the pharmacological properties of a classical 
benzodiazepine agonist and it was orally active in a 
conflict screen.101 The imidazo[1,2-a]pyrimidines RU 32698 
(Divaplon; Fig. 1-10) and RU 32514 have activity similar to 
that of chlordiazepoxide in various models.47 Oxadiazole 
(Fig. 1-10) has an IC50 of 630 nM for the displacement of 
[3H]flunitrazepam from rat-brain preparations and yet 
displays antianxiety properties of similar potency to those 
of chlordiazepoxide in animal models, while demonstrating 
negligible myorelaxant effects.102 Divaplon (RU 32698) 
shows broad anticonvulsant activity. Both RU 32698 and RU 
32514, exhibit little or no activity in tests measuring 
sedation/motor performance impairment.
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Fig. 1-10 Some Imidazo[l,2-a ]pyrimidines and an imidazo[l,2-a ]pyridine
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1-6 Syntheses and reactions of some imidazo[1,2-b] 
pyridazines
1-6.1 Structure and nomenclature
Imidazo[1,2-b]pyridazine (1.1) is a heteroaromatic 
bicyclic system possessing 10 TT-electrons; it consists of a 
7r-excessive imidazole ring and a 7r-deficient pyridazine 
ring. The orientation of rings is as shown below with the 
positions numbered according to IUPAC rules.
2
3
1.1 Imidazo[l,2-fr Jpyridazine
1-6.2 Syntheses
The synthesis of imidazo[1,2-b]pyridazines was first 
reported by Yoneda and coworkers103 in 1964; and 
derivatives of this ring system have now attracted much 
attention because of their potential usefulness. Such 
compounds are most conveniently synthesised from suitably 
substituted pyridazines. The synthesis, and the physical 
and chemical properties have been reviewed by Tisler and
35
Stanovnik104 and by Maury.105.
The parent imidazo[1,2- b ]pyridazine (1.1) has been 
synthesised by two methods. Armarego106 in 1965 reported 
the preparation of imidazo[1,2-b]pyridazine (1.1) from 3- 
methylthiopyridazine (1 .2). Compound (1 .2) with 
ethanolamine gave 3-(/J-hydroxyethylamino) pyr idaz ine (1.3) 
which with thionyl chloride afforded the corresponding ß -  
chloro compound which was cyclised to 2,3-dihydroimidazo- 
[1,2-b]pyridazinium chloride (1.4). This was oxidized by 
potassium ferricyanide to give compound (I.l) in 5% yield.
In the second synthetic method 6-chloropyridazin-3-amine 
(1.5) was condensed with bromoacetaldehyde to give 6- 
chloroimidazo[1,2-b]pyridazine (1.6) which was 
dechlorinated, by hydrogen in the presence of palladized 
charcoal and triethylamine, to compound (I.l) in 75% 
yield.107-108
Substituted imidazo[1, 2-b]pyridazines are usually 
prepared from substituted pyridazin-3-amines with an 
appropriate a-halogenocarbonyl compound. For example, the 
pyridazin-3-amine (1.7; R1=H) with a-halogenoaldehydes such 
as bromo-,107'109 and chloro-acetaldehyde110'111 gave the 
imidazo[1,2-b]pyridazines (1.8; R1=H); and with a- 
halogenoketones such as phenacyl bromide,103'112'113 
various substituted phenacyl bromides,103,112'114 
chloroacetone111'115 and bromoacetone113 gave 2-aryl and 2- 
methyl 3-unsubstituted imidazo[ 1,2-jb] pyridazines (1.9); and 
3-bromobutan-2-one116 similarly gave the 2,3-dimethyl
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analogues (I.10).
In 1968, Lombardino110 reported that the reaction of 
6-methoxypyridazin-3-amine with ethyl bromopyruvate or with 
ethyl 2-chloroacetoacetate gave ethyl 6-methoxy- 
imidazo[1,2-b]pyridazine 2-carboxylate and ethyl 6-methoxy- 
2-methylimidazo[1,2-b]pyridazine-3-carboxylate 
respectively; and Ostroversnik and coworkers117 have used 
1,2-dibromoethane and ethyl chloroacetate to prepare 
imidazo[1,2-b]pyridazines. The condensation with halogeno- 
ketones is usually carried out in refluxing ethanol or 1,2- 
dialkoxyethane but reactions with halogenoaldehydes are 
usually carried out at room temperature. Such 
condensations could lead to either compound (1.13) or 
(1.14) (assuming the formation of C-N bonds exclusively) 
but, in fact, only the compound (1.13) was generally 
obtained. It has been suggested104 that the more favoured 
intermediate arises from the attack by compound (1 .12) on 
the ring nitrogen atom of compound (I.11); this is 
supported by the isolation of compound (1.15) from the 
condensation of pyridazin-3-amine and phenacyl bromide.103
A two step mechanism has been proposed104 involving 
the formation of both N-l and N-2 quaternized intermediates 
of which only the N-2 quaternized compound (e.g. 1.15) 
undergoes ring closure to the imidazo[1,2-b]pyridazine. 
Yields in these reactions are usually less than 60%.
Simple mono- and di-aminopyridazines with iodomethane have 
been found to give both 1- and 2-methyl derivatives, with 
no evidence for quaternization at the exocyclic nitrogen
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atom.118 In 1982 Barlin and coworkers119 reported that the 
condensation of 4-methylaminopyridazin-3-amine with 
pyruvaldehyde dimethyl acetal in methanolic hydrogen 
chloride gave 3-methoxy-2-methyl-8-methylaminoimidazo- 
[ 1,2-jb]pyridazine (1.16) and in 1983 they described the 
condensation of 6-chloropyridazin-3-amine (1.5) with 
phenylglyoxal in ethanolic hydrogen chloride to give 
compound (1.17) which was methylated by diazomethane to 
give the 3-methoxy analogue (1.20; R1=C1, R2=Ph). This 
work was extended in 1986120 and in subsequent papers.
More recently Barlin and coworkers121,122 have described 
the condensation of 6-benzylamino- (and 6-phenoxy)- 
pyridazin 3-amine 2-oxides121'122 (1.18) with phenacyl 
bromide to give the hydroxy compound (1.19) which was 
methylated with an excess of ethereal diazomethane to give 
compound (1 .20) .
Yoshiro and coworkers123 have reported the reactions 
of pyridazine (1 .21) with tetracyanoethylene oxide to give 
pyridazinium dicyanomethylide (1 .22) which condensed in the 
presence of sodium methoxide to give the 3- 
cyanoimidazo[1,2-b]pyridazine (1.23). Another synthesis 
has been described by Podergajs and coworkers124 in which 
N,N-dimethyl-N'-pyridazinylformamidine (1.24) and analogous 
compounds were condensed with a-bromoacety1 ketones and 
gave the 3-acyl compounds (1.25). Stanovnik and
1 o ccoworkers have also reported that 6-(2',2'- 
dimethoxyethylaminotetrazolo[1,5-b]pyridazine (1.26) in the
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presence of polyphosphoric acid underwent simultaneous ring 
closure, and ring opening of the tetrazole ring, to give 6- 
azidoimidazo[ 1,2-jb] pyridazine (1.27) .
1-6.3 Chemical and physical properties 
i Physical properties
HMO calculations104 of the TT-electron densities in
i n rimidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine have 
been carried out and the results are shown in formulae
(1.28) and (1.29). These indicate that in imidazo[1,2-b]- 
pyridazine and imidazo[1,2-b]pyridine, the 3-position is 
most susceptible to electrophilic substitution, whereas the 
6- and 8-positions of imidazo[1,2-b]pyridazine (1.28) and 
the 5- and 7-position of imidazo[1,2-a]pyridine (1.29) 
should be the most active towards nucleophilic 
substitution.
Protonation studies106 on imidazo[1,2-b]pyridazine
(1.28) and imidazo[1,2-b]pyridine (1.29) showed that 
compounds (1.28) and (1.29) have pKa values of 4.57106 and 
6.72127 respectively; whereas that of pridazin-3-amine and 
pyridin-2-amine are 5.19 and 6.82128 respectively. It has
0.955 1.321 1.267 1.462
0.977
0.956
0.8541.144
1.28 1.29
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been claimed that imidazo [ 1,2-b] pyridazine protonates at 
N-l.106 The iower basic strength of (1 .28) relative to 
(1.29) is due to the presence of the second doubly bound 
ring nitrogen atom in the imidazo[1,2-b]pyridazine.
n.m.r. and 13C n.m.r. studies of imidazo[1,2-b]- 
pyridazine have been reported by Kobe et al.108 and Pugmire 
et al.,129,130 respectively.
ii Electrophilic reactions (excluding methylation)
The susceptibility of imidazo[1,2-b]pyridazine to 
electrophilic reactions has been studied108•131'132 by 
means of chlorination with phosphorus pentachloride at 
elevated temperatures. The order of reactivity is 3 > 2 
(in agreement with the results of HMO calculations) 
and 7 > 8 > 6. Mannich reactions were also effected on 6- 
methoxyimidazo[1,2-b]pyridazine and its 2-methyl 
derivative.110,111 However forcing conditions were 
required in some instances to effect the reaction. 
Bromination107'108 of imidazo[1,2-b]pyridazine with N- 
bromosuccinimide (NBS) or bromine in acetic and gave 3- 
bromoimidazo[1,2-b]pyridazine and nitration131 of 2-phenyl- 
imidazof1,2-b]pyridazine has been shown to proceed 
initially at the 3-position.
iii Nucleophilic reactions
Nucleophilic displacement of the chloro-substituent 
from 6-chloroimidazo[1,2-b]pyridazine has been investigated 
for the preparation of 6-variously substituted imidazo-
1 Q O[1,2-b]pyridazines. Yoneda et al. have described
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reactions of 6-chloro-2-phenylimidazo[1,2-b]pyridazine with 
hydroxide and alkoxide ions and dialkylamines to give 6- 
hydroxy, alkoxy and dialkylamino analogues, respectively; 
also the chloro substituent was removed by catalytic 
reduction. Stanovnik and Tisler109'113 reported that with 
hydrazine hydrate the chloro substituent at the 6-position 
was replaced to afford the 6-hydrazino compound in 90% 
yield. They also reported107 replacement of the chloro 
substituent by thiophenoxide ions but attempted 
replacements with ammonia or with potassium hydrogen 
sulphide were unsuccessful.
The reactions of perchloroimidazo[ 1,2-jb]pyridazine 
(obtained from imidazo[ 1,2-jb]pyridazine by the reaction 
with phosphorus pentachloride at 260-280°) towards
13 3dimethylamine and methoxide ions have been studied.
Whereas aqueous dimethylamine under reflux displaced the 
chloro substituent from the 8-position, methoxide ions in 
refluxing methanol caused replacement of the chloro 
substituents at both the 6- and 8-position (see Scheme 
1 - 1 ) .
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iv Methylation, methyl group migration and some 
cycloaddition reactions
The methylation of 2-phenylimidazo[1,2-b]pyridazin- 
6(5H)-one (1.30) with methyl iodide reported in 1964 by 
Yoneda and coworkers103 was reinvestigated by Furlan, 
Stanovnik and Tisler.134 They found that both the 6- 
methoxy compound (1 .31) and the 5-methyl compound (1.32) 
were formed and that some starting material remained. It 
has also been reported120'135 that the methylation of 2- 
phenylimidazo [ 1,2-jb ] pyridazin-3 (5H)-one and analogues with 
excess ethereal diazomethane gave the corresponding 3- 
methoxyimidazo[1,2-b]pyridazine.
Migration134 of the methyl groups was observed when 6- 
methoxy-2-phenylimidazo[1,2-h]pyridazine (1.31) was heated 
at 240° for 2 h. It gave a mixture of unchanged 6-methoxy 
compound (1.31), the N-methyl compound (1.32) and the 
anhydro salt (1.33) in the ratio of 25:61:14. Thus 
migration of the methyl group from oxygen occurred to the 
neighbouring N-5 and to the more distant N-l. When 6- 
ch loro-1-methyl-2-phenyl imidazo [ 1,2-jb ] pyr idaz in-4-ium
iodide134 (1 .34) was treated with methoxide ions it gave,
c
by nuleophilic substitution, the methoxy compound (1.35)A
and with hydroxide ions it gave the anhydro salt (1.33). 
When the anhydro salt134 (1 .33) was methylated with methyl 
iodide it gave a mixture of the 1,5-dimethyl compound 
(1.36) and the 6-methoxy compound (1.35) in the ratio of 
1:5. Also when compound134 (1.31) was heated with methyl 
iodide under pressure it gave compounds (1.36) and (1.35).
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MeO
1.32
Me
1.36
CD-,0
1.37
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Compound (1.36) was also obtained134 by thermal 
rearrangement of compound (1.35) or by quaternization of 
compound (1.32) with methyl iodide at 160°. The conversion 
of compound (1.35) to compound (1.36) has been studied134 
with the deutero-compound (1.37) and it has been shown that 
the CD3 group migrated to N-5 only and that no interchange 
of methyl groups occurred. This methyl group migration was 
probably intermolecular;134'136 and the driving force for 
the rearrangements was the greater stability of the amido
13 7structure.
Cycloaddition reaction of imidazo[1,2-b]pyridazine 
with diazomothane,138 2-diazopropane,139 and 2- 
diazobutane140 have been reported; diazomethane was the 
most reactive. Addition occurred across the C7-C8 double 
bond and is highly regiospecific. The reaction of 
6-chloroimidazo[1,2-b]pyridazine (1.38, Scheme 1-3) in a 
mixture of dimethyIformamide and chloroform with 
diazomethane is illustrated. The mechanism138 proposed by 
these workers involved 1,3-dipolar cycloaddition of 
diazomethane across the polarized C7-C8 double bond of 6- 
chloroimidazo[1,2 - b ]pyridazine to give the primary 
cycloadduct (1.39) which underwent oxidative transformation 
to compounds (1.40). This was followed by 1,3 and/or 1,5- 
sigmatropic rearrangement to the tautomeric intermediates 
(1.41 and 1.42) and further methylation with diazomethane 
gave compounds (1.43 and 1.44).
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Scheme 1-3
CH,N
MeN ^
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1-7 Syntheses and reactions of some imidazo[1,2-a]- 
pyrimidines, imidazo[1,2-a]pyrazines and imidazo[1,2-a] 
pyridines
Derivaties of imidazo[1,2-a]pyrimidines, imidazo- 
[ 1,2-a]pyrazines and imidazo[ 1,2-a]pyridines (10 7r-electron 
systems) have been synthesized, usually in good yield, by 
condensations of the readily available pyrimidin-2-amine, 
pyrazin-2-amine and pyridin-2-amine with a-halogeno- 
carbonyl compounds.
The condensation of pyrimidin-2-amines with the a- 
halogenocarbony1 compounds has been described by Paudler 
and Kuder.141 The structures of the products formed from 
these condensations were unequivocal if the pyrimidin-2- 
amine used was either unsubstituted or monosubstituted at 
position 5 or symmetrically disubstituted at positions 4 
and 6. The products from a 4-substituted pyrimidin-2-amine 
with a-bromoacetaldehyde were either a 7-substituted (1.46) 
or a 5-substituted imidazo[1,2-a]pyrimidine (1.47).
Recently, Rival and coworkers142 have reported the 
synthesis and in vitro antifungal activity of some 
imidazo[1,2-a]pyrimidine derivatives. The synthesis 
involved the condensation of a pyrimidin-2-amine with an
1.45 R 1.471.46
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appropriate a-bromoketone and then introduction (initially) 
of a nitro, nitroso, or bromo (by bromination with NBS in 
CCI4) substituent at the 3-position.
There are two principal methods for the preparation of 
derivatives of imidazo[1,2-b]pyrazines from pyrazines. The 
first involves the cyclization of appropriately substituted 
pyrazin-2-amine. Thus cyclization of the pyrazin-2- 
ylaminoacetal (1.48, Scheme 1-4) in concentrated sulphuric 
acid gave imidazo[1,2-a]pyrazine (1.49) in low yield,106 
and the pyrazin-2-ylaminoacetic acid (1.50) with sodium 
alkoxide afford imidazo[1,2-a]pyrazin-3-(2H)-ones 
(I.51).143 The second involved the reaction of pyrazin-2- 
amine with bifunctional reagents. For example, pyrazin-2- 
amines (1.52) with a-keto aldehydes gave compounds 
(I.53),144'145 and pyrazin-2-amines with a-halogeno- 
carbonyl compounds gave compounds (I.54).143'146-151 Also 
imidazo[1,2-a]pyrazin-3-amine (1.55; R=R1=H) was prepared 
by the reaction of pyrazin-2-amine with sodium cyanide and 
the bisulfite addition compound from formaldehyde.152 
Imidazo[l,2-a]pyrazines have also been prepared by 
cyclization of imidazoles. For example, 2-benzoylimidazole 
(1.57) was alkylated with compound (1.56) in DMF and the 
intermediate (1.58) when refluxed with acetic acid 
containing ammonium acetate cyclised to 8-phenyl-
I C Oimidazo[1,2-a]pyrazine (1.59)
The preparation of imidazo[1,2-a]pyridines has been 
achieved mostly from pyridin-2-amine by closure of the 
imidazole ring, but also from the imidazole by closure of
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Schem e 1-4
CH(OEt)2
1.48
1.59
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the pyridine ring. For example, the pyridin-2-amine (1.60) 
with bromoacetaldehyde gave the imidazo[1,2-a]pyridine 
(I.61),154 which was also obtained from imidazole with 
hexane-2,5-dione.154
The chemistry and structure-activity relationships of 
the new hypnotic agent [SL 80.0750-23N; N,N,6,-trimethyl-2- 
(4'-tolylimidazo[1,2-a]pyridine-3-acetamide (1.62) 
(hemitirtrate-Zolpidem)] has been reviewed by George and
I C Ccoworkers. The synthesis commenced from 5-methyl-
pyridin-2-amine (1.63), which with a-bromo-4'-methyl- 
acetophenone gave the substituted imidazo[1,2-a]pyridine 
(1.64; 93% yield), and this underwent the Mannich reaction 
with formaldehyde and dimethylamine in acetic acid to 
afford compound (1.65; 79% yield). Alkylation of the side- 
chain nitrogen of the latter with methyl iodide afforded 
the quaternary ammonium salt (1.66) which with sodium 
cyanide gave the corresponding nitrile (1.67; 81% yield). 
This nitrile was hydrolyzed in aqueous acid to the 
carboxylic acid (1.68; 91% yield) which was converted to 
the N,N-dimethylamide (1.62; 85% yield).
For the large scale preparation of zolpidem, a new 
process was developed. Thus treatment of the 3- 
unsubstituted imidazo[1,2-a]pyridine (1.64) with the 
appropriate glyoxylic amide (prepared in situ from the 
corresponding ketal) generated the a-hydroxyacetamide 
(1.69) in high yield. The latter with thionyl chloride 
gave compound (1.70) which was then reduced (under various 
conditions) to the acetamide (1.62).
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CHL—  C—NMe.
1.62
R= H
1.65, R= CH2NMe2
1.66, R= CH2N+Me3 I"
1.67, R=CH2CN
1.68, R=CH2COOH
1.69, R= CH(OH)CONMe2
1.70, R= CHClCONMe2 
1.62, R= CH2CONMe2
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1-8 Previous pharmacological and biological studies of 
some imidazo[1,2-b]pyridazines, imidazo[1,2-a]pyridines, 
imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyrazines
Pharmacological activity of some imidazo[1,2-b]- 
pyridazines was first reported by Nitta and coworkers in 
1965.156 They discovered that these heterocyclic compounds 
possess analgesic, sedative and antispasmodic properties 
and were shown to be useful as "inhibitors of central 
nerves". Almirante and coworkers114 in 1966 synthesized a 
series of derivatives of imidazo[ 1,2 —jb]pyridazine (and 
imidazo[1,2-a]pyrimidine) which were found also to possess 
antiinflammatory, antipyretic and hypothermal activity as 
well as anticonvulsant activity. Three years later some 
imidazo[1,2-b]pyridazines with halogeno or alkoxy groups at 
C-6, alkyl group at C-2 and different Mannich side chains 
at C-3 were synthesized and reported to show activity 
against hypertension and were potent antiinflammatory 
agents.111 Abignente and coworkers have reported157 the 
synthesis of some imidazo[1,2-b]pyridazines (and 
imidazo[1,2-a]pyrimidines) with attached carboxamide or 
acetamide groups at the 2-position and various substituents 
on the six-membered ring: these were evaluated for 
antiinflammatory, analgesic and antipyretic activity. 
Bristol and Lovey158 synthesized other imidazo[1,2-b]- 
pyridazine compounds for the treatment of ulcers.158 Other 
groups have reported some 6-(pyridin-3'-yl) or 6-(3'- 
trifluoromethylphenyl)-2-(or 3-)alkylimidazo[1,2-b]-
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pyridazines as anxiolytic agents159 and some 
imidazopyridazinylacrylamides as anti-hypertensives, 
diureties and saluretics.160 More recently, Barlin and 
coworkers120-22'161-167 have made a large number of 2,3,6- 
trisubstituted imidazo[1,2-b]pyridazines for screening for 
more selective pharmacological activity than the 
benzodiazepine class of compounds in the central nervous 
system. They reported that certain classes of these 
compounds, such as 2-(4'-aminopheny1)-3-methoxy-6-(3"- 
methoxybenzylamino)imidazo[1,2-b]pyridazine121 with IC50 
1.0 nM (cf [3H]diazepam with IC50 of 4.2 nM), exhibited 
higher activity in the displacement of [3H]diazepam from 
rat brain membranes than diazepam. Derivatives of 
imidazo[1,2-b]pyridazine have shown other biological 
actions including their use as bronchodilators,168 
ino' tropic,169 antithrombotic169 and cardiovascular 
agents,170 antibiotics,171-173 antibacterial 174-176 and 
antimicrobial agents,177-179 antiprotozoal agents180-183 
herbicides and synergistic herbicides,184-192 
pesticides,193'194 antitumour agents,195 cardiotonic 
agents and insecticides; they have been used for 
control of hemorrhagic colitis in swine198 and of foot rot, 
liver lesions in ruminant animals199 and plant growth 
regulants.188
In 1965 Almirante and coworkers114'200 also reported 
that some imidazo[1,2-a]pyridines showed analgesic, 
antiinflammatory, antipyretic and anticonvulsant activity. 
Recently other groups201'203 have reported other
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imidazo[1,2-a]pyridines which were useful as sedatives, 
anxiolytics and anticonvulsants. Other biological uses 
have been reported for imidazo[1,2-a]pyridines such as 
ionotropic agents,204 synergistic herbicidal 
agents,187'189-191 herbicides,185'192 antibiotics,172,173 
and cardiotonic agents.205
Imidazo[1,2-a]pyrimidines have been reported to show 
analgesic,200 antiinflammatory,157'200 antipyretic,200 
hypothermal,200 anticonvulsant,200 herbicidal,205 
antithrombic,170 cardiovascular,170 and antifungal 
activity.142
Derivatives of imidazo[1,2-a]pyrazines have been 
examined and claims have been reported for
antiinflammatory,206'207 ^-blocking,208 uterine-relaxing209 
and antibronchospastic activity.209 Also 3-amino-8- 
benzyloxy-2-methylimidazo[l,2-a]pyrazine210'211 has been 
reported to have antiulcer activity and 2-(2',4'- 
dimethoxyphenyl)imidazo[1,2-a]pyrazine and related 
compounds show inotropic activity.212
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1-9 Present work
In the present work a large number of substituted 
imidazo[1, 2-b]pyridazines, and some imidazo[1,2-a]- 
pyridines, -pyrimidines, and -pyrazines have been 
synthesised and tested for binding to rat brain plasma 
membrane. This research was directed to the identification 
of compounds (or compound types), which bound relatively 
strongly to benzodiazepine receptors, for further 
evaluation (by others) for possibly more selective 
pharmacological actions in the central nervous system, than 
have the benzodiazepine class of compound.
The research reported in this thesis includes: in
Chapter II, the syntheses of 3-unsubstituted-2-ary1-6- 
(variously substituted)imidazo[1,2-b]pyridazines (from the 
relevant 6-substituted pyridazin-3-amine with bromoacetyl 
compounds) which were then converted by Mannich reaction to 
the 3-dimethylaminomethyl derivatives, and by reaction with 
N-hydroxymethylamides to the 3-acetamidomethy1 and 3- 
benzamidomethy1 derivatives; in Chapter III, the syntheses 
of 3-(substituted benzamidomethyl) derivatives by similar 
procedures; and in Chapter IV, details of the syntheses of 
6-(N-benzyl-N-methylamino)-3-methoxy-2-phenyl (and 
substituted phenyl)imidazo[1,2-b]pyridazines and some new 
6-(substituted benzylamino) analogues. In Chapter V, 
syntheses are reported for a large number of imidazo- 
[ 1,2-jb ] pyridaz ines in which larger conjugating and 
nonconjugating aromatic substituents were incorporated at
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the 2-position: these included 2-benzyl [phenethyl,
(biphenyl-4'-yl) or (naphthalen-2 ' -yl) ]-imidazo[ 1,2 — Jb] - 
pyridazines.
All compounds were examined for their ability to 
displace [ H]diazepam from rat brain plasma membrane as a 
measure of their ability to interact with benzodiazepine 
receptors of the central nervous system. The results are 
discussed and compared with existing data.
The role of the N-5 ring nitrogen atom of imidazo- 
[1,2-b]pyridazines has been examined in work described in 
Chapter VI. Derivatives of imidazo[1,2-a]pyridines, 
imidazo[1,2-a]pyrimidines, and imidazo[1,2-a]pyrazines have 
been prepared and their binding abilities compared with 
those of the corresponding imidazo[1,2-b]pyridazines.
Some compounds, prepared in the present work and which 
exhibit high binding affinity at benzodiazepine binding 
sites, have been subjected (by others) to behavioural tests 
in rats. These have revealed significant anxiolytic 
effects without sedation but these data do not form part of 
the present thesis.
CHAPTER II
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CHAPTER II. Synthesis and binding studies of some 3- 
(acylaminomethyl and dimethylaminomethyl)-2-phenyl (and 
substituted phenyl)-6-(variously substituted)imidazo- 
[1,2-b]pyridazines
II-l Introduction
In this chapter the syntheses of some 3-(acetamido- 
methyl, benzamidomethyl or dimethylaminomethyl)-2- 
phenyl(and substituted phenyl)-6-(halogeno, alkylthio, 
alkoxy, phenylthio, phenoxy, benzylthio, or benzyloxy) 
imidazo[l,2-b]pyridazines are described; and the results 
from an examination of these compounds for their ability to 
displace [ H]diazepam from rat brain membrane preparations 
are described also.
This work was prompted by literature213 reports that 
3-acylaminomethyl-2-aryl-6-substituted (and unsubstituted) 
imidazo[1,2 - a ]pyridines showed anxiolytic, sleep-inducing, 
hypnotic, anticonvulsant, analgesic and antiulcer 
properties; that 6-aryl-2-(and 3-)dialkylaminomethy1- 
imidazo[ 1,2-jb]pyridazines214 were M^-muscarinic receptor 
agonists, useful where cortical cholinergic deficits were 
manifest and particularly for Alzheimer-type dementias; 
and by published research work from this group with 6- 
(variously substituted)-2-aryl-3-methoxyimidazo[1,2-b]- 
pyridazines120-122'161-167 (predominantely) and related 
compounds.
In the work described in this chapter 6-(variously 
substituted)-3-(acetamidomethyl, benzamidomethyl and
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dimethylaminomethyl) -2-phenylimidazo[ 1,2-b]pyridazines were 
prepared and tested for their ability to displace 
[3H]diazepam from rat brain plasma membrane. Attempts were 
then made to optimise this activity by introducing 4'- 
methyl and 3',4'-methylenedioxy substituents into the 2- 
phenyl group.
II-2 Syntheses
The starting materials required for the preparation of 
these compounds were the relevant 6-substituted pyridazin- 
3-amines (II.1, Scheme II-l). Many of these compounds have 
been prepared in good yield by Barlin and Ngu163-166 from 
6-chloropyridazin-3-amine by heating with appropriate 
nucleophiles. The compounds (II.1) were then condensed 
with suitable bromoacetyl compounds (II. 2) to give the key 
intermediates, viz. the 2-aryl-3-unsubstituted-6-(variously 
substituted)imidazo[1,2-b]pyridazines (II.3a-n). Such 
condensations have been used by Yoneda and coworkers to 
prepare some 6-chloroimidazo[1,2-b]pyridazines. The 3- 
dimethylaminomethylimidazo[1,2-b]pyridazines (II.4, Scheme 
II-2) required for the present work were prepared from the 
corresponding 3-unsubstituted imidazo[1,2-b]pyridazines 
(II.3) by a Mannich reaction with dimethylamine and aqueous 
formaldehyde (or paraformaldehyde), or more conveniently by 
a modification thereof in which compounds (II.3) were 
heated with bis(dimethylamino)methane215 and a catalytic 
amount of phosphoric acid in acetic acid at ca 120°C. The
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Scheme II-1
Cl
Cl
SMe
SMe
SMe
OMe
OMe
SPh
SPh
OC^OMe-o
SCH2C6H4OMe-m
OCHiPh
o i rlatter reaction has been used by Ledincer and Hauser to
prepare N,N-dimethylaminomethylferrocene (methiodide). In
lthis way were prepared the 3-dimethylaminomethyA- 
imidazo[1,2-b]-pyridazines (II.4a-g, Scheme II-2) which 
contained at the 6-position methylthio, methoxy, 
phenylthio, benzoxy and (2'-methoxyphenoxy) groups; and at 
the 2-position phenyl or 3',4'-methylenedioxypheny1 groups. 
In all cases yields of 24-74% were obtained. The reaction 
with bis(dimethylamino)methane gave a better yield and the 
products were more readily purified than by use of the 
standard Mannich reaction with excess dimethylamine and 
aqueous formaldehyde. The 3-acylaminomethylimidazo[1,2-b]- 
pyridazines containing 3-acetamidomethyl and 3- 
benzamidomethyl groups were prepared by a method similar to
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PhCONHCH2OH
MeCONHCH^OH
ChLNHCOMe
II. 4 Rl R2 II. 6 R 1 R2
a. Cl H a. F H
b. Cl 0CH20 -3 W  b. Cl Me-p
c. SMe H c. Cl 0CH20-3',4 '
a. OMe H d. SMe Me-p
e. SPh H e. SMe 0CH20-J',4'f. OCgH^OMe-o H f. OMe Me-p
g. OCH2Pb H g. SPh H
h. Cl Cl -p  h. OCH2Ph H
i. SCH2Ph H i. F Me-p
j. Cl H
II. 5 R1 R2 k. SMe H
l. OMe H
3.. F H m . OC^P^OMe-o H
D. Cl H n. SCH2Ph H
C. Cl 0CH20-3'.4'
d. SMe H
e. OMe H
f. SPb H
g- SPh M e-p
h. OC^P^OMe-o H
i. OCH2Ph H
j- SCH2Ph H
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that described for the preparation of 3- 
acylaminomethylimidazo[1,2-a]pyridines.213 Thus 3-
unsubstituted-2-aryl-6-(variously substituted)imidazo- 
[ 1,2-jb] pyridazines (II.3) were heated at reflux with N- 
(hydroxmethyl)acetamide or N-(hydroxmethyl)benzamide216 in 
glacial acetic acid containing a catalytic amount of 
concentrated sulphuric acid to give 3-acetamidomethy1- and 
3-benzamidomethyl-imidazo[1,2-b]pyridazines (II.5a-i and 
II.6a-h), respectively (Scheme II-2), which were isolated 
as free bases by adjusting to pH 10 with aqueous ammonia. 
However in certain preparations, such as that of 3- 
acetamidomethy1-6-(2'-methoxyphenoxy)-2-phenylimidazo- 
[1,2-b]pyridazine (II.5h), it was necessary to restrict the 
quantity of sulphuric acid in the reaction (No desired 
product was isolated from reactions with higher 
concentrations of acid). The products prepared in this 
work were purified by chromatography and were obtained in 
moderate (10-84%) yield.
The compounds (II.3o-q), (II.4i), (II.5j), (II.6i-n)
and (II.7a-i) have been described previously: references to 
relevant literature are given in Table II-4.
Scheme II-3 II. 7 I Rl I R2
a. F H
b. Cl H
c. Cl Me-p
d. SMe H
e. OMe H
f. SPh H
g- OQRtOMe-o H
h. SCH2Ph H
i. OCH2Ph H
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II-2 1H n.m.r. spectra
All compounds prepared in this work were examined by 
1H n.m.r. spectroscopy at 90 MHz as described in the 
Experimental section. The n.m.r. spectrum of 
unsubstituted imidazo[ 1,2-jb]pyridazine, in 
deuterochloroform, has been reported104'108 and it shows 
that the protons attached to the five-membered (imidazole) 
ring appear as an AB quartet. The chemical shifts of 
protons at C-2 and C-3 were found to be at 67.89 and 7.99, 
respectively, each with a coupling constant of J2/3 1.0 Hz. 
Those on the six-membered (pyridazine) ring moiety appeared 
as an ABX system with long-range coupling across the 
bridgehead atoms. The chemical shifts and coupling 
constants of these protons were 69.30 (H6), 7.00 (H7), 7.95 
(H8) ; with J 6 r 7 4.5, J7 g 10.0, J g g 2.0 and J3 g 0.8 Hz.
The 1H n.m.r. spectrum of the 2,6-disubstituted 
imidazo [ 1,2-b ] pyridazine, 6-chloro-2-methylimidazo [ 1,2 - jb ]  -
1 nopyridazine has been reported in perdeuteroacetone 
(CD3COCD3) and the chemical shifts were observed at 58.03, 
7.30 and 8.09 for H3, H7 and H8, respectively.
Some 1H n.m.r. spectral data obtained for the 
compounds prepared in the present work are presented for 
compounds (II.3) in Table II-l, compounds (II.4) in Table 
II-2 and compounds (II.5) and (II.6) in Table II-3. Those 
of the 3-unsubstituted imidazo[1,2-b]pyridazine (II.3) 
derivatives revealed a signal due to the proton at C-3 as a 
singlet in the region 57.81-8.20. In the compounds (II.3c,
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Table II-l Some 1H n.m.r. spectral data (6)A for 
3-unsubstituted-2-aryl-6-(variously substituted)imidazo- 
[1,2-b]pyridazines
Formula
number
R1 R2 H3 H7 H8
II.3b F Me-p 8.11 6.85 B
3oc Cl H 8.20 7.02 7.78
3c Cl Me-p 8.18 7.03 7.89
3pC Cl Cl-p 8.16 7.04 7.88
3d Cl 0CH20-3',4' 8.10 7.04 7.87
3e SMe H 8.17 6.87 7.77
3 f SMe Me-p 8.12 6.74 7.83
3g SMe 0CH20-3',4' 8.05 6.85 7.69
3h OMe H 8.06 6.70 7.81
3 i OMe Me-p 8.01 6.67 7.80
3 j SPh H 7.81 6.77 B
3k SPh Me-p 8.10 6.76 B
31 OC6H4OMe-o H 7.90 6.86 7.86
3m SCH2C6H4OMe-m Me-p 8.11 6.77 B
3n OCH2Ph H 8.07 6.75 B
^Reported as parts per million (5) downfield from
tetramethylsilane (T.M.S.) as internal standard in 
deuterochloroform (CDCI3).
BComplex signal 
cPrepared by Dr M.M.L. Ngu
II.3p and II.3d) with a common substituent at C-6 (e.g. 
chloro), insertion of substituents in the 2-phenyl group 
(such as methyl, chloro or methylenedioxy) had a small 
effect and only on the position of the signal due to H-3. 
The hydrogen atoms at C-3 in 2-phenyl-6-phenylthio[1,2-b]- 
pyridazine (II.3j) and 6-(2'-methoxyphenoxy)-2-phenyl- 
imidazo[1,2-b]pyridazine (11.31) are relatively more 
shielded and occur at the 67.81 and 7.90, respectively.
The shielding of the hydrogen atoms at C-3 in the 6-
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methylthio-2-substituted phenyl compounds (II.3e-g) is 
similar to the 6-chloro-2-substituted phenyl analogues.
Table II-2 Some n.m.r. spectral data (6)A for 
3-dimethylaminomethylimidazo[1,2-b]pyridazines
Formula
number
R1 R2 ch2 (Me)2N H7 H8
II. 4a Cl H 3.97 2.32 7.05 7.89
4hB Cl Cl-p 3.93 2.31 7.05 7.89
4b Cl 0CH20-3',4 ' 3.94 2.32 7.03 7.87
4c SMe H 3.95 2.32 6.85 7.72
4d OMe H 3.92 2.32 6.67 7.79
4d SPh H 3.77 2.14 6.82 7.75
4 f OCßt^Me-o H 3.64 2.09 6.92 7.90
4g OCH2Ph H 3.93 2.32 6.70 7.83
4iB SCH2Ph H 3.95 2.30 6.85 7.74
AReported as parts per million (6) downfield from 
tetramethylsilane (T.M.S.) as internal standard in 
deuterochtoroform (CDCI3)
BPrepared by Dr M.M.L. Ngu
In the 2,3,6-trisubstituted imidazo[1,2-b]pyridazines 
reported here, the methylene protons in compounds (II.4) 
(Table II-2) and (II.5) (Table II-3) occurred in the ranges 
63.64-3.97 and 54.77-5.02, respectively. The methylene and 
both methyl groups of the dimethylaminomethyl substituent 
in compound (II.4) appear to be more shielded by the 6- 
phenylthio and the 6-(2'-methoxyphenoxy) groups, and the 
chemical shifts of the methylene and dimethylamino groups 
in compound (II.4f) are at 63.64 and 2.09, respectively.
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Chemical shifts for the methylene protons in 6-(variously 
substituted)-3-benzamidomethy1-2-phenylimidazo[1,2-b]- 
pyridazines (Table II-3) were found to occur in the range 
64.63 [for the 6-(2'-methoxyphenoxy) compound (II.6m)] to 
5.26 [for the 6-methylthio compound (II.6k)].
All protons on C-7 and C-8 appeared as an AB quartet 
with a coupling constant of J7 9.5 Hz. Chemical shifts 
for H7 occurred in the ranges 66.66-7.09 (in II.5) and 
66.57-7.09 (in II.6); whereas that for H8 were at 67.69- 
7.89 (in II.3), 67.72-7.90 (in II.4), 67.57-7.97 (in II.5) 
and 57.88-8.06 (in II.6), respectively.
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Table II-3 Some n.m.r. spectral data (6)A for 3- 
acylaminomethylimidazofl/a-blpyridazines (II.5 and II.6).
Formula
Number
R1 R2 Me c h 2 H7 H8
II.5a F H 2.02 4.99 6.73 B
5b Cl H 2.03 5.02 7.09 7.92
5c Cl 0CH20-3',4' 2.04 4.97 7.07 7.88
5d SMe H 2.03 4.98 6.86 7.64
5e OMe H 2.02 4.97 6.70 7.76
5f SPh H 1.85 4.79 6.87 7.86
sg SPh Me-p 1.85 4.78 6.86 B
5h OC6H4OMe-o H 1.81 4.77 7.00 7.97
5i OCH2Ph H 1.97 4.88 6.66 7.57
5j SCH2Ph H 1.93 4.97 6.89 7.67
II. 6a F H 5.20 6.91 B
6iC F Me-p 5.18 6.88 8.01
6jC Cl H 5.23 7.09 7.91
6c Cl 0CH20-3' , 4 ' 5.21 6.95 B
6b Cl Me-p 5.19 7 .01 B
6kc SMe H 5.26 6.94 B
6d SMe Me-p 5.25 6.92 B
6e SMe 0CH20-3' , 4' 5.14 6.78 B
61C OMe H 5.02 6.93 8.06
6f OMe Me-p 5.13 6.57 B
eg SPh H 5.00 6.82 B
6mc OCg^OMe-o H 4.63 6.88 7 .88
6nc SCH2Ph H 5.18 6.77 B
6h OCH2Ph H 5.19 6.74 B
^Reported as parts per million (6) downfield from 
tetramethylsilane (T.M.S.) as internal standard in 
deuterochloroform (CDCI3)
Complex signal
pPrepared by Dr M.M.L. Ngu
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II-4 In vitro binding studies
Three benzodiazepine radioligands, [3H]flunitrazepam,
[ H]diazepam and [ H]clonazepam, commonly are used for 
labelling benzodiazepine receptors.217 [3H]Diazepam and 
[3H]flunitrazepam characteristically bind to the same 
species of binding sites in central nervous system 
receptors, they bind in a similar regional distribution and 
are used interchangeably for in vitro investigations in the 
mammalian central nervous system. In the work described in 
this thesis, [ HJdiazepam can also be used to determine 
benzodiazepine binding to peripheral-type benzodiazepine 
receptors in tissues such as kidney, heart and adrenal 
gland.
II-4.1 Biochemical characteristics of [3H]diazepam binding
[3H]Diazepam binds to benzodiazepine receptors from 
rat brain membrane with high affinity. The dissociation 
equilibrium constant for [3H]diazepam at 0° is ca 3.2 nM 
(dissociation equilibrium constant KD = affinity constant = 
binding constant); the association and dissociation rate 
constants at 0°C are 6.8 x 107 M”1 min-1 and 0.16 min-1, 
respectively.218 Specific [3H]diazepam binding to brain 
membranes is saturable,219'220 thus showing the presence of 
a limited number of binding sites.
Equilibrium between bound and unbound [3H]diazepam is
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reached within fifteen minutes in the standard binding 
assay (0°C).221
Specific [3H]diazepam binding shows a linear 
dependency on membrane protein (up to 3.0 mg protein using 
a crude extract) and a pH-optimum between pH 7.0 to pH 7.4. 
This binding is temperature-dependent, with the highest 
binding at 4°C.221 Using membranes prepared from adult rat 
forebrain and [ HJdiazepam as ligand, an Hill coefficient 
near 1.0 is found indicating noncooperative interaction 
between benzodiazepine binding sites. Parenthetically it 
may be noted that further work indicated the presence of at 
least two pharmacologically, biochemically and functionally 
distinct molecular classes of binding sites222'224 (see 
previous Chapter).
[ HJDiazepam binding does not distinguish between 
these two sub-populations of benzodiazepine binding sites. 
However, [3H]diazepam binding is known to be 
stereospecific.30,219 The in vitro binding of the 
radiolabel has been observed to undergo competitive 
displacement by unlabelled drugs which interact 
isosterically with the benzodiazepine receptor 
site.219'220'225 Many researchers (e.g. Braestrup and 
Squires225) have found that there is a very good 
correlation between [3H]diazepam displacing potency IC50 
values for a diverse range of compounds and their ED50 (or 
MED) values in several "in vivo" pharmacological tests that 
are very predictive of anxiolytic activity in man.
69
A similar correlation was obtained also by Möhler and 
Okada219 in 1977. Receptor-binding techniques have 
identified a large number of non-benzodiazepine drugs which 
possess a similar spectrum of pharmacological activity as 
the benzodiazepines.
In order to assess the affinity of new compounds for 
benzodiazepine receptors a simple and efficient in vitro 
binding assay has been devised which involves the 
displacement of [ HJdiazepam from an appropriate brain 
membrane preparation. Submilligram quantities of material 
are required for the in vitro test whereas much larger 
quantities are required for whole animal tests. In this 
way one can determine rapidly, accurately and cheaply the 
binding of new compounds to benzodiazepine receptors, and 
thus facilitate structure-activity studies.
II-4.2 Results of in vitro testing
The 3-acylaminomethyl, 3-dimethylaminomethyl and 3- 
unsubstituted imidazo[ 1,2-jb]pyridazines prepared in this 
work were tested for their ability to bind to rat brain 
plasma membrane. This was determined in a competitive 
[3H]diazepam binding assay in which the ability of the 
compound under test to displace [2H]diazepam was 
determined. The details of this biological test procedure 
are outlined in the Experimental section II-5.3. The
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results are presented in Table II-4 as IC50 values (the 
concentration of drugs that result in 50% displacement of 
specific [ HJdiazepam binding in the standard assay) or the 
percentage displacement at a specified concentration, 
together with the data for some 3-methoxy analogues, 
prepared previously by other workers,162'163,166'167 for 
comparison. The IC50 values are related to Kiapp (apparent 
inhibition constant) where Kiapp=IC50/ (1+C/Kd), where C = 
concentration of [3H]diazepam (0.7 ± 0.1 nM). Thus, IC50 
values assess the affinity of the test compounds for 
benzodiazepine receptors. Unlabelled diazepam was used as 
a control.
II-4.3 Discussion of results
The results shown in Table II-4 for the in vitro 
binding by the imidazo[ 1,2-Jb]pyridazines reveal that the 3- 
unsubstituted imidazo[l,2-Jb]pyridazines (II.3) had lower 
binding potencies than the 3-(substituted aminomethy1)- 
imidazo[1,2-b]pyridazines (II.4, II.5 or II.6), with the 
exception of 3-dimethylaminomethyl-6-chloro (and 6- 
benzyloxy)-2-phenyl(3' ,4'-methylenedioxypheny1 and possibly 
4'-chloropheny1)imidazo[1,2-b]pyridazines (II.4a, II.4b,
II.4h and II.4g). Whereas the 3-dimethylamino group had 
only a small beneficial effect in the 6-methylthio, 6- 
methoxy and 6-(2'-methoxyphenoxy) compounds (II.4c, II.4d
The assays were carried out by Mr S.J. Ireland and
Dr L.P. Davies
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Table II-4 Results for the displacement of [3H]diazepam 
from rat brain membrane by some substituted imidazo- 
[1,2-b]pyridazines
Formula Imidazo[1,2-b]pyridazine Ic50 (nM)A
number (or % displ.B)
II.3a 6-F-3-H-2-Ph (21%)
3b 6-F-3-H-2-C6H4Me-p 383
5a 6-F-3-CH2NHAc-2-Ph 679
6a 6-F-3-CH2NHBz-2-Ph 68r>6i 6-F-3-CH2NHBz-2-C6H4Me-p 8C
7a 6-F-3-OMe-2-Ph 3 2 Ou
3o 6-Cl-3-H-2-Ph >3 000C
3c 6-C1-3-H-2-C6H4Me-p (63%)
3d 6-C1-3-H-2-C6H3(3',4'-OCH2 0-) 1427 c13P 6-C1-3-H-2-C6H4Cl-p (46%)^4a 6-Cl-3-CH2NMe2-2-Ph (0%)
4b 6-Cl-3-CH2NMe2-2-C6H3(3',4/-0CH20-) 2043
4h 6-C1-3-CH2NMe2-2-C6H4Cl-p 1370^
5b 6-C1-3-CH2NHAc-2-Ph 474u
5c 6-C1-3-CH2NHAc-2-C6H3(3',4'-0CH20-) 152 
14 0C6j 6-C1-3-CH2NHBz-2-Ph
6b 6-C1-3-CH2NHBz-2-C6H4Me-p 18
6c 6-C1-3-CH2NHBz-2-C6H3(3',4'-0CH20-) 25n7b 6-C1-3-OMe-2-Ph 7 7 2 ur>7c 6-C1-3-OMe-2-C6H4Me-p 148°
3e 6-SMe-3-H-2-Ph (21%)
3f 6-SMe-3-H-2-C6H4Me-p (35%)
3g 6-SMe-3-H-2-C6H3(3',4'-OCH20-) (40%)4c 6-SMe-3-CH2NMe2-2-Ph (30%)
5d 6-SMe-3-CH2NHAc-2-Ph 55
6k 6-SMe-3-CH2NHBz-2-Ph 19.5U
6d 6-SMe-3-CH2NHBz-2-C6H4Me-p 7
6e 6-SMe-3-CH2NHBz-2-C6H3(3',4'-OCH20-) 2c7d 6-SMe-3-OMe-2-Ph 8 8 4 u
3h 6-OMe-3-H-2-Ph (18%)
3 i 6-OMe-3-H-2-C6H4Me-p 1704
4d 6-OMe-3-CH2NMe2-2-Ph (20%)
5e 6-OMe-3-CH2NHAc-2-Ph 523c61 6-OMe-3-CH2NHBz-2-Ph 79u
6 f 6-OMe-3-CH2NHBz-2-C6H4Me-p 23c7e 6-OMe-3-OMe-2-Ph 829u
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Table II-4 Continued
Formula
number
Imidazo[1,2 - b ]pyridazine IC50 (nM)A
(or % displ. )
3 j 6-SPh-3-H-2-Ph (43%)
3k 6-SPh-3-H-2-C6H4Me-p (22%)
4e 6-SPh-3-CH2NMe2-2-Ph (44%)
5f 6-SPh-3-CH2NHAc-2-Ph 24
sg 6-SPh-3-CH2NHAc-2-CgH4Me-p 14
eg 6-SPh-3-CH2NHBz-2-Ph 9
7 f 6-SPh-3-OMe-2-Ph 117 E
31 6-OC6H4 0Me-o-3-H-2-Ph (45%)
4f 6-OC6H4 0Me-o-3-CH2NMe2-2-Ph 333
5h 6-OC6H4OMe-o-3-CH2NHAc-2-Ph (60%)
6m 6-OC6H4OMe-o-3-CH2NHBz-Ph (not significant)L
7g 6-OCgH4 0Me-o-3-OMe-2-Ph 70F
3g 6-SCH2C6H4OMe-m-3-H-2-Ph 3 3 0C
3m 6-SCH2C6H4OMe-m-3-H-2-C6H4Me-p (26%)
4i 6-SCH2Ph-3-CH2NMe2-2-Ph 58l
5j 6-SCH2 Ph-3-CH2NHAc-2-Ph 5 5C
6n 6-SCH2Ph-3-CH2NHBz-2-Ph 445u
7k 6-SCH2Ph-3-OMe-2-Ph 2 5F
3n 6-OCH2Ph-3-H-2-Ph (53%)
4g 6-OCH2Ph-3-CH2NMe2-2-Ph (31%)
5i 6-OCH2Ph-3-CH2NHAc-2-Ph 208
6h 6-OCH2Ph-3-CH2NHBz-2-2-Ph (65%)
7 i 6-OCH2Ph-3-OMe-2-Ph 2 0G
a IC5o values (nM) are the concentrations required in the 
presence of 100 /iM 5-aminobutyric acid to displace 50% 
of specific [3H]diazepam binding to rat brain membrane 
preparations 
BAt 1000 nMr>Prepared by Dr M.M.L. Ngu 
°Ref. 162 
ERef. 167 
FRef. 163
GRef. 166
73
and II.4f) and a negligible effect in the 6-phenylthio 
compound (II.4e), it had a significant enhancing effect in 
the 6-benzylthio compound (11.41, IC50 58 nM). All the 3- 
dimethylaminomethyl compounds (II.4) bound less strongly 
than their corresponding 3-methoxy analogues (II.7). The 
most active compound in this series was the 6-benzylthio-3- 
dimethylaminomethyl-2-phenylimidazo [ 1,2-Jb ] pyr idaz ine 
(II.4i, IC50 58 nM) which was signicantly more active than 
6-benzyloxy-3-dimethylaminomethyl-2-phenylimidazo- 
[ 1,2-jb]pyridazine (II.4g, 31% displacement at 1000 nM) . 
Likewise the 6-methylthio analogue (II.4c, 30% displacement 
at 1000 nM) was more active than the 6-methoxy compound 
(II.4d, 20% displacement at 1000 nM).
The 3-acetamidomethyl group in the 3-acetamidomethyl- 
imidazo [ 1,2-jb] pyridazine compounds (II.5) had a significant 
beneficial effect in increasing binding compared with the 
3-unsubstituted imidazo[1,2-b]pyridazine analogues (II.3). 
For example 3-acetamidomethyl-6-phenylthio (and 6- 
methylthio) -2-phenylimidazo[ 1,2-jb]pyridazines (II. 5f and 
II.5d) had IC50 values of 24 and 55 nM, whereas the 
corresponding 3-unsubstituted compounds (II.3j and II.3e) 
gave 43% and 21% displacement at 1000 nM, respectively.
The 3-acetamidomethyl group was probably least effective in 
3-acetamidomethyl-6-(2'-methoxyphenoxy)-2-phenylimidazo- 
[ 1,2 — Jb ] pyridaz ine (II.5h, 60% displacement at 1000 nM) 
compared to the 3-unsubstituted analogue (11.31, 45% 
displacement at 1000 nM). The most active compound in this 
series was the 3-acetamidomethyl-6-phenylthio-2-(4'-toly1)-
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imidazo[1,2-6]pyridazine (II.5g) with IC50 14 nM. The 3- 
acetamidomethyl-6-methylthio (and 6-benzylthio)-2-pheny1- 
imidazo[1,2-b]pyridazines (II.5d, IC50 55 and II.5 j , IC50 
55 nM) showed ca ten-fold and four-fold increases in 
binding activity as compared with their corresponding 6- 
methoxy and 6-benzyloxy analogues (II.5e and II.5i, IC50 
values 523 and 208 nM), respectively.
The 3-benzamidomethyl substituent in the 6-fluoro 
(II.6a, IC50 68 nM), 6-chloro (II.6j, IC50 140 nM and 
11.6c, IC50 25 nM), 6-methylthio (II.6k, IC50 19.5 nM), 6- 
methoxy (11.61, IC50 79 nM) and 6-phenylthio (II.6g, IC50 9 
nM) compounds had a greater beneficial effect in increasing 
binding than the 3-acetamidomethyl group in compounds 
(II.5a-f), respectively. This effect was evidently 
greatest in 3-benzamidomethyl-6-fluoro-2-phenyl- 
imidazo[1,2-b]pyridazine (II.6a, IC50 68 nM) which bound ca 
ten-fold more strongly than 3-acetamidomethyl-6-fluoro-2- 
phenylimidazo[1,2-b]pyridazine (II.5a, IC50 679 nM). It 
was detrimental in the 6-(2'-methoxyphenoxy) compound 
(II.6m, displacement not significant at 1000 nM), 6- 
benzylthio compound (II.6n, IC5Q 445 nM) and 6-benzyloxy 
compound (11.6h, 65% displacement at 1000 nM) as compared 
with their corresponding 3-acetamidomethyl analogues 
(II.5h, 60% displacement at 1000 nM, II.5j, IC50 55 nM and 
II.5i, IC50 208 nM), respectively. It appears that the 
presence of aromatic groups in all three substituents at 
2-, 3- and 6-positions may be detrimental to binding; 
however, 3-benzamidomethyl-2-phenyl-6-phenylthioimidazo-
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[ 1,2-jb]pyridazine (II. 6g, IC50 9 nM) which contains a 
phenyl ring in all three substituents at the 2-, 3- and 6- 
positions, bound ca 3-fold more strongly than its 3- 
acetamidomethyl analogue (II.5f, IC50 24 nM). The most 
active member of this series was the 3-benzamidomethyl-2- 
(3',4'-methylenedioxyphenyl)-6-methylthioimidazo[1,2-b]- 
pyridazine (II.6e, IC50 2 nM); and eight of these compounds 
(II. 6) reported in this chapter had IC50 values of 25 nM or 
less. The 3-benzamidomethyl compounds (II.6), which 
contained two aromatic substituents as in the 6-fluoro 
compound (II.6a, IC50 68 nM), the 6-chloro compounds 
(II.6j, IC50 140 nM and 11.6b, IC50 18 nM), the 6- 
methylthio compound (II.6k, IC50 19.5 nM) and the 6-methoxy 
compound (11.61, IC50 79 nM), were more active than the 
corresponding 3-methoxy compounds [(II.7a), IC50 320;
(II.7b), IC50 772; (II.7c), IC50 148; (II.7d), IC50 884 ; 
and (II.7e), IC50 829 nM, respectively] which contained 
only one aromatic ring at the 2-position. Consistent with 
the data presented above for 3-benzamidomethyl and 3- 
acetamidomethyl compounds, the 3-benzamidomethyl compounds 
which contained three aromatic groups, such as 3- 
benzamidomethyl-6-benzyloxy-2-phenylimidazo[1,2-b]- 
pyridazine (II.6h, 65% displacement at 1000 nM) was 
significantly less active than the 6-benzyloxy-3-methoxy-2- 
phenylimidazo[1,2-b]pyridazine (11.71, IC50 20 nM) which 
contained two aromatic rings. The 6-phenylthio compound 
(II.6g, IC50 9 nM) proved an exception, in that it was 
significantly more active than its 3-methoxy analogue
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(II.I f , IC50 117 nM).167 The results of the in vitro 
competitive binding studies reveal that the 6-substituted 
imidazo[ 1,2-jb]pyridazines (II.4, II.5 and II. 6) which 
contained the 6-methylthio group were more active than 
their analogues which contained a 6-methoxy group. The 6- 
fluoro compounds were also more active than their 6-chloro 
analogues. The presence of an electron-donating group such 
as 4'-methyl or 3',4'-methylenedioxy (or an electron- 
withdrawing group such as chloro) in the 2-phenyl 
substituent in the series of 6-fluoro (chloro, methylthio, 
methoxy and phenylthio)-2-phenylimidazo[1,2-b]pyridazines 
increased affinities for the receptor compared to the 2- 
phenyl analogues but 6-(3'-methoxybenzylthio)-2-(4'-toly1)- 
imidazo[1,2-b]pyridazine (II.3m, 26% displacement at 1000 
nM) was significantly less active than the 6-(3'- 
methoxybenzylthio)-2-phenylimidazo[1,2-b]pyridazine (II.3q, 
IC50 330 nM).
As pointed out previously, on the basis of structure- 
activity studies on a large number of benzodiazepines and 
non-benzodiazepines, Fryer has suggested a model which 
produces the necessity, among other factors, of an aromatic 
or heteroaromatic ring which is spatially related to a 
proton-accepting group to assure effective binding of these 
molecules to the receptor. The aromatic ring is probably 
involved in 7T-7T stacking interactions with the aromatic 
rings of amino acid side chains within the receptor whereas 
the proton-accepting group may be involved in hydrogen 
bonding with amino acids containing SH, NH2, OH or imidazo 
NH groups within the receptors.
77
In the present work the "A" ring proposed in the Fryer 
model may be represented by the 2-aryl substituent and the 
7T region may be located at N-l or N-5 (or other areas) .
All the 6-fluoroimidazo[1,2-b]pyridazines listed in Table 
II-4 bound more strongly than the 6-chloro analogues; and 
6-alkylthioimidazo[1,2-b]pyridazines bound more strongly 
than their 6-alkoxy analogues. These differences in 
binding ability are not dependent only on electronic 
effects. Whereas the Hammett function (0para) for a p- 
fluoro substituent is +0.06226 and that for a p-chloro 
substituent is +0.23, the values for a p-methylthio group 
is 0.00 and that for a p-methoxy group is -0.27.226 
Obviously other factors such as bulk, shape, and 
lipophilicity of substituents are important in determining 
overall binding ability.
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II-5 Experimental 
II-5.1 General topics
i) Melting points (m.p.s) were taken in Pyrex capillaries 
with an electrothermal melting point apparatus and were 
uncorrected.
ii) 1H n.m.r. spectra were generally recorded at 90 MHz 
and 30° with a Jeol FX 90Q fourier-transform spectrometer, 
with tetramethylsilane (in CDCI3, unless otherwise stated) 
as an internal standard (6 0.0 ppm). Data were presented 
in the following order. Chemical shift (ppm) relative to 
tetramethylsilane; multiplicity; coupling constant (J) in 
Hz; assignment (if appropriate). The following 
abbreviations were adopted: s (singlet); d (doublet); t 
(triplet); dd (doublet of doublets). Exchangeable protons 
were identified by their disappearance upon addition of 
deuterium oxide.
iii) Microanalyses were conducted by the Australian 
National University Analytical Services Unit, Canberra. 
Solids for analysis were dried at 70-100°C/0.1 mmHg for 12- 
15 h unless otherwise specified. Some compounds, analysed 
with water (or solvent) which could not be removed entirely 
without incipient decomposition.
iv) Analytical thin layer chromatography (t.l.c.) was 
performed on glass or aluminium sheet precoated with Merck 
kieselgel 60 F254 or Merck aluminium oxide 60 F254 neutral
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(type E) of 0.25 mm thickness. Preparative thin layer 
chromatography was performed on glass plate precoated with 
Merck aluminium oxide 60 F254 (type E) of 1.5 mm thickness. 
Columns for chromatography were packed using Merck 
aluminium oxide 90 active neutral (0.063-0.2 mm, 70-230 
mesh ASTM).
v) Ethereal diazomethane was prepared from
p p nnitrosomethylurea
vi) Reaction temperatures refer to external or bath 
temperatures, unless otherwise indicated.
vii) Where full experimental details are not recorded, 
percentage yields are given in brackets from the 6- 
substituted pyridazin-3-amine and the 6-substituted 
imidazo[1,2-b]pyridazine, as appropriate.
viii) The light petroleum used as a solvent had b.p. 60- 
80° unless specified otherwise.
II-5.2 Synthetic work
The starting materials which were not available from 
commercial sources but which were required for the 
syntheses in this work were prepared according to 
literature procedures as indicated below.
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6-Methylthio-2-phenylimidazo[1,2-b]pyridazine (II.3e)
A mixture of 6-methylthiopyridazin-3-amine x (1.15 g) 
and a-bromoacetophenone (1.63 g) in ethanol (16 ml) was 
refluxed for 2 h. Sodium hydrogen carbonate (0.688 g) was 
then added and the mixture was refluxed for 4 h. After 
chilling, the solid was filtered off and washed with water. 
The solid (1.532 g) was recrystallised from ethanol to give 
the title compound, m.p. 149-151°. (Found, for a sample 
dried at 60°/0.1 mmHg for 15 h: C, 64.9; H, 4.6; N, 17.4. 
C13H11N3S required C, 64.7; H 4.6; N, 17.4%). 1H n.m.r. 6 
2.62, s, SMe; 6.87, d, J 9Hz, H7; 7.77, d, J 9Hz, H8; 7.37- 
7.48 and 7.89-8.00, complex, Ph; 8.17, s, H3 .
6-Chloro-2-(3',4'-methylenedioxyphenyl)imidazo- 
[1,2-b]pyridazine (II.3d)
A mixture of 6-chloropyridazin-3-amine (0.491 g) and
2 2 8a-bromo-3,4-methylenedioxyacetophenone^0 (0.937 g) in 
ethanol (10 ml) was refluxed for 2 h, sodium hydrogen 
carbonate (0.44 g) then added and the reflux continued for 
2 h. After cooling, the yellow solid (0.88 g) was filtered 
off and the residue from the filtrate after t.l.c.
(alumina; benzene) gave a further quantity (0.037 g) of 
product. It was recrystallised from ethanol to give the 
title compound, m.p. 232-234°. (Found: C, 57.2; H, 2.8; N, 
15.1. C13H8C1N302 requires C, 57.0, H, 2.9; N, 15.3%).
^H n.m.r.: 6 6.02, s, OCH2O; 6.89, d, J 8.0 Hz, H5'; 7.04, 
d, J 9.5 Hz, H7; 7.43, bs, H2' ; 7.47, dd, J5'/6' 6 Hz/ 
J2//6/ 1.5 Hz, H6'; 7.87, d, J 9.5 Hz, H8; 8.10, bs, H3.
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In a similar manner from 6-fluoropyridazin-3-amine,120
n p q6-chloropyridazin-3-amine, 6-methylthiopyridazin-3 -
amine,118 6-methoxypyridazin-3-amine,230'231 6- 
phenylthiopyridazin-3-amine,161 6-(2'-
methoxyphenoxy)pyridazin-3-amine,163 6-benzylthiopyridazin- 
3-amine,164 6-(3'-methoxybenzylthio)pyridazin-3-amine163 
and 6-benzyloxypyridazin-3-amine166 with a-
? 3 ?bromoacetophenone, a-bromo-4'-methylacetophenone, a-
n  n Qbromo-3',4'-methylenedioxyacetophenone, or a-bromo-4'-
p O pchloroacetophenone^ were prepared the following 
compounds.
6-Fluoro-2-phenylimidazo[l,2-b]pyridazine (II.3a) (90%),
m.p. 192-194° (from ethanol) (Found: c, 66.1; H, 4.2; N, 
19.8%. C13H8FN3 . 0.25 H20 requires C, 66.2; H, 3.9; N, 
19.4%). XH n.m.r.: 5 6.87, d, J 9.5 Hz, H7; 7.30-7.60 and 
7.80-8.25, complex, Ph and H3,8.
6-Fluoro-2-(4'-tolyl)imidazo[l,2-b]pyridazine (II.3b)
(68%), m.p. 211-213° (from toluene) (Found: C, 68.9; H,
4.3; N, 18.4. C13H 10FN3 requires C, 68.7; H, 4.4; N,
18.5%). XH n.m.r. (CD3SOCD3): & 2.33, s, Me; 7.23, d, J7/8 
9 Hz, H 7 ; 7.25, d, 7.90, d, J2 /,3/ 8 Hz, H2',3',5',6'; 
8.29, dd, J7/8 9 Hz, JH8F 10 Hz, H 8 ; 8.74, s, H 3 . In CDC13 
6 2.40, s, Me; 6.85, d, J 9 Hz, H7; 7.27, d, 7.84, d,
J2 /^3/ 8 Hz, H2',3',5',6'; 7.89-8.03, complex, H8; 8.11, s
H3 .
82
6-Chloro-2-phenylimidazo[1,2-b]pyridazine (II,.3o) was
prepared according to literature procedures.120 It had 
m.p. 200-201° (lit.103 200°) 1H n.m.r.: 6 7.02, d, J 9.5
Hz, H7; 7.78, d, J 9.5 Hz, H8; 7.26-7.57 and 7.84-8.01, 
complex, Ph; 8.20, s, H3.
6-Chloro-2-(4'-tolyl)imidazo[l,2-b]pyridazine (II.3c)
(81%), m.p. 218-220° (from ethanol) (Found: C, 64.2; H,
4.1; N, 17.4 C13H]_oc 1n3 requires: C, 64.1; H, 4.1; N, 
17.2%). XH n.m.r.: 6 2.41, s, Me; 7.03, d, J 9.5 Hz, H7; 
7.28, d, 7.86, d, J 8 Hz, H2',3',5',6'; 7.89, d, J 9.5 Hz, 
H8; 8.18, s, H3.
6-Methylthio-2-(4'-tolyl)imidazo[1,2-b]pyridazine (II.3f)
(61%), m.p. 125-127° (from ethanol) (Found, for a sample 
dried at 60°/0.1 mmHg for 15 h: C, 66.1; H, 5.2; N, 16.4. 
c 14h 13n 3s requires C, 65.9; H, 5.1, N, 16.5%). 1 H  n.m.r.: S 
2.39, s, Me; 2.61, s, MeS; 6.74, d, J 9.5 Hz, H7; 7.25, d, 
7.71, d, J 8 Hz, H2',3',5',6'; 7.83, d, J 9.5 Hz, H8; 8.12, 
s, H3 .
2-(3',4'-Methylenedioxyphenyl)-6-methylthioimidazo- 
[l,2-b]pyridazine (II.3g) (43%), m.p. 162-163° (from
ethanol) (Found, for a sample dried at 95°/710 mmHg for 20 
h: C, 59.0; H, 4.0; N, 14.7 C14H11N302S requires C, 58.9,
H, 3.9; N, 14.7%). 1H n.m.r.: 6 2.61, s, MeS; 6.00, s,
OCH20; 6.85, d, J 9.5 Hz, H7; 6.88, d, J 8 Hz, H5'; 7.41,
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s, H2' ; 7.46, dd, ,6' ® Hz, ^2',6' 1*5 Hz, H6'; 7.69, d,
J 9.5 Hz, H8 ; 8.05, bs, H3.
6-Methoxy-2-phenylimidazo[1,2-b]pyridazine (II.3h) (51%),
m.p. 135-137° (from ethanol). (Found, for a sample dried at 
60°/0.1 mmHg for 15 h: C, 69.7; H, 5.1; N, 18.9. C13H11N30 
requires C, 69.3; H, 4.9; N, 18.7%). 1H n.m.r.: S 4.00, s, 
MeO; 6.70, d, J 9.5 Hz, H7; 7.38-7.46 and 7.87-7.99, 
complex, Ph; 7.81, d, J 9.5 Hz, H8; 8.06, s, H3.
6-Methoxy-2-(4'-tolyl)imidazo[1,2-b]pyridazine (II.3i)
(66%), m.p. 139-140° (from light petroleum), (Found: C,
70.2; H, 5.6, N, 17.6. C14H13N30 requires C, 70.3; H, 5.5; 
N, 17.6%). 1H n.m.r.: 6 2.39, s, Me; 4.00, s, MeO; 6.67, d, 
J 9.5 Hz, H7; 7.25, d, 7.81, d, J 8 Hz, H2' ,3' ,5 ' , 6 ' ; 7.80, 
d, J 9.5 Hz, H8 ; 8.01, s, H3 .
2-Phenyl-6-phenylthioimidazo[1,2-b]pyridazine (II. 3j)
(91%), m.p. 127-129° (from ethanol) (Found, for a sample 
dried at 100°/710 mmHg for 20 h: C, 71.3; H, 4.3; N, 13.9. 
C18H13N3S requires C, 71.3; H, 4.3; N, 13.9%). ^H n.m.r.: 5 
6.77, d, J 9.5 Hz, H7; 7.38-7.99, complex, 2xPh and H8 ; 
7.81, s, H3.
6-Phenylthio-2-(4'-tolyl)imidazo[1,2-b]pyridazine (II.3k)
(85%), m.p. 162-164° (from ethanol) (Found, for a sample 
dried at 100°/710 mm Hg for 15 h: C, 71.7; H, 4.9; N, 13.4. 
C19H15N3S requires C, 71.9; H, 4.8; N, 13.2%). 1H n.m.r.: 6
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6.76, d, J 9.5 Hz, H7; 7.21-7.88, complex, 2xPh and H8;
8.10, s, H3.
6-(2'-Methoxyphenoxy)-2-phenylimidazo[1,2-b]pyridazine 
(11.31) (63%), m.p. 132-134° (from toluene) (Found: C,
71.6; H, 4.5; N, 13.2. C19H15N3O2 requires C, 71.9; H, 4.8; 
N, 13.2%). 1H n.m.r.: 5 3.73, s, MeO; 6.86, d, J7;8 9 Hz/
H7; 6.88-7.91, complex, H3',4',5',6' and Ph; 7.86, d, J7 8^ 
9 Hz, H8; 7.90, s, H3.
6 - (3'-Methoxybenzylthio)-2-(4"-tolyl)imidazo[1,2-b]- 
pyridazine (II.3m) (64%), m.p. 104-105° (from light
petroleum) (Found: C, 69.8; H, 5.2; N, 11.5. C2iHigN30S 
requires C, 69.8; H, 5.3; N, 11.6%). ^H n.m.r.: S 2.37, s, 
Me; 3.77, s, MeO; 4.38, s, CH2 ,* 6.77, d, J 9.5 Hz, H7 ; 
6.72-7.87, complex, H2',4',5',6',2",3",5",6" and H8; 8.11, 
s, H3 .
6-Benzyloxy-2-phenylimidazo[l,2-b]pyridazine (II.3a) (75%),
m.p. 148-149° (from ethanol) (Found, for a sample dried at 
100°/710 mm Hg for 12 h: C, 75.9; H, 5.0; N, 14.0.
C19H15N3° requires C, 75.7; H, 5.0; N, 13.9%). XH n.m.r.: 6 
5.38, s, CH2; 6.75, d, Jg.5 Hz, H7; 7.37-8.00, complex,
2xPh and H8; 8.07, s, H3.
6-Chloro-3-dimethylaminomethy1-2-phenylimidazo- 
[1,2-b]pyridazine (II.4a)
6-Chloro-2-phenylimidazo[1,2-b]pyridazine (0.117 g)
n 1 cwas added to a solution of bis(dimethylamino)methane^
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(0.12 ml) and phosphoric acid (0.2 ml) in glacial acetic 
acid (2.0 ml) and the mixture stirred at 120° for 14 h. The 
acetic acid was evaporated under reduced pressure, the 
residue diluted with water, the mixture adjusted to pH 10 
with aqueous ammonia and extracted with chloroform. The 
extract was washed with water, dried (Na2S04) and solvent 
evaporated and the white solid (0.109 g) was subjected to 
t.l.c. (alumina; chloroform/light petroleum, 2:1) and 
recrystallised from ethanol to give the title compound , 
m.p. 142-143° (Found: C, 62.5; H, 5.3; N, 19.3. C15H15C1N4 
requires C, 62.8; H, 5.3; N, 19.5%). 1H n.m.r.: 6 2.32, s, 
2xMe; 3.97, s, CH2; 7.05, d, J 9.5 Hz, H7; 7.43-7.50 and 
8.05-8.15, complex, Ph; 7.89, d, J 9.5 Hz, H8.
3-Dimethylaminomethyl-6-(2'-methoxyphenoxy)-2-phenyl- 
imidazo[l,2-b]pyridazine (II.4f)
6-(2'-Methoxyphenoxy)-2-phenylimidazo[1,2-b]pyridazine 
(0.15 g), bis(dimethylamino)methane215 (0.2 ml), phosphoric 
acid (0.2 ml) and acetic acid (2.0 ml) as above gave the 
title compound (0.124 g), m.p. 140-142° [after t.l.c. 
(alumina; chloroform)] (Found, for a sample dried at 
100°/710 mm for 5 h: C, 70.9; H, 5.6; N, 15.0. C22H22N402 
requires C, 70.6; H, 5.9; N, 15.0%). -^H n.m.r.: 5 2.09, s, 
Me2N; 3.64, s, CH2; 3.73, s, MeO; 6.92, d, J 9.5 Hz, H7; 
7.00-7.46 and 7.96-8.08, complex, H3',4',5',6' and Ph;
7.90, d, J 9.5 Hz, H8.
In a similar manner the following compounds were
prepared.
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6-Chloro-3-dimethylaminomethyl-2-(3', 4'-methy1- 
enedioxyphenyl)imidazo[1,2-b]pyridazine (II.4b) (28%), m.p.
154-155° after t.l.c. (alumina; chloroform, light 
petroleum, 1:1) and recrystallisation from a mixture of 
ethanol and benzene, and benzene and light petroleum.
(Found, for a sample dried at 50°/0.1 mmHg for 15 h: C,
58.0; H, 4.5; N, 16.7. C16H15C1N402 requires C, 58.1; H,
4.6; N, 16.9%). 1 K  n.m.r.: 5 2.32, s, Me2N ; 3.94, s, CH2N;
6.02, s, 0CH20 ; 6.92, d, J 8 Hz, H5'; 7.03, d, J 9.5 Hz,
H7; 7.63, dd, J5//6, 8 Hz, J2//6, 1-5 Hz > H6' > 7.69, bs,
H2; 7.87, d, J 9.5 Hz, H8.
3-Dimethylaminomethy1-6-methylthio-2-phenylimidazo 
[1,2-b]pyridazine (II.4c) (66%) as light yellow crystals,
m.p. 131-133° after t.l.c. (alumina; chloroform, light 
petroleum, 3:1) and recrystallisation from light petroleum. 
(Found, for a sample dried at 60°/0.1 mmHg for 15 h: C, 
64.6; H, 6.2; N, 18.6. C16H18N4S requires C, 64.4; H, 6.1; 
N, 18.8%). 1H n.m.r.: 5 2.32, s, Me2N ; 2.64, s, MeS; 3.95, 
s, CH2N; 6.85, d, J 9.5 Hz, H7; 7.30-7.60 and 8.02-8.14, 
complex, Ph; 7.72, d, J 9.5 Hz, H8.
3-Dimethylaminomethy1-6-methoxy-2-phenylimidazo- 
[1,2-b]pyridazine (II.4d) (58%), as yellow crystals m.p.
120-122° after t.l.c. (alumina; chloroform, light 
petroleum, 2:1) and recrystallisation from light petroleum. 
(Found: C, 68.1; H, 6.7; N, 20.0. C16H18N40 requires C, 
68.1; H, 6.4; N, 19.85). 1 H n.m.r.: 5 2.32, s, Me2N ; 3.92,
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s, CH2N; 4.03, s, MeO; 6.67, d, J 9.5 Hz, H7; 7.30-7.50 and 
8.0-8.12, complex, Ph; 7.79, d, J 9.5 Hz, H8.
3-Dimethylaminomethy1-2-phenyl-6-phenylthioimidazo- 
[I,2-b]pyridazine (II.4e) (38%), as yellow crystals, m.p.
126-127° after t.l.c. (alumina; chloroform, light 
petroleum, 2:1) and recrystallisation from a mixture of 
ethanol and light petroleum (Found, for a sample dried at 
100°/710 mmHg for 20 h: C, 67.7; H, 5.5; N, 14.9.
C21H20N4S- °-6 h2° requires C, 67.9; H, 5.8; N, 15.1%).
XH n.m.r.: 6 2.14, s, Me2N; 3.77, s, CH2N; 6.82, d, J 9.5 
Hz, H7; 7.38-7.65 and 8.00-8.12, complex, 2xPh, 7.75, d, J 
9.5 Hz, H8.
6-Benzyloxy-3-dimethylaminomethyl-2-phenylimidazo- 
[I,2-b]pyridazine (II.4g) (63%), as white crystals, m.p.
115-117° after t.l.c. (alumina; chloroform, light 
petroleum, 2:1) and recrystallisation from light petroleum. 
(Found, for a sample dried at 100°/710 mmHg for 3 h: C, 
74.0; H, 5.9; N, 15.9. C22H22N40 requires C, 73.7; H, 6.2; 
N, 15.6%). 1H n.m.r.: 5 2.32, s, Me2N; 3.93, s, CH2N; 5.43, 
s, CH20; 6.70, d, J 9.5 Hz, H7; 7.37-7.50 and 7.98-8.11, 
complex, 2xPh; 7.83, d, J 9.5 Hz, H8.
3-Acetamidomethyl-6-methylthio-2-phenylimidazo[l,2-b]- 
pridazine (II.5d)
6-Methylthio-2-phenylimidazo[1,2,- b ]pyridazine (0.18 
g) was added to a solution of N-(hydroxymethyl)acetamide24, 
glacial acetic acid (3.0 ml) and concentrated sulphuric
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acid (0.2 ml) and the mixture refluxed with stirring in an 
oil bath at 120° for 14 h. The acetic acid was evaporated 
under reduced pressure and the residue diluted with water 
and adjusted with ammonium hydroxide to pH 10. This 
mixture was extracted with chloroform, the solvent 
evaporated, and the product subjected to t.l.c. (alumina; 
chloroform, light petroleum, 3:1) to give the title 
compound (0.11 g), m.p. 247-249° (from ethanol) (Found, for 
a sample dried at 60°/0.1 mmHg for 15 h: C, 61.8; H, 5.3;
N, 17.9. C16H16N4OS requires C, 61.5; H, 5.2; N, 17.9%)'
1H n.m.r: 6 2.03, s, MeCO; 2.61, s, MeS; 4.98, d, J 5 Hz, 
CH2; 6.43, bs, NH; 6.86, d, J 9.5 Hz, H7; 7.35-7.60, 
complex, 7.69-7.84, complex, Ph; 7.64, d, J 9.5 Hz, H8.
In a similar manner the following compounds were 
prepared.
3-Acetamidomethyl-6-fluoro-2-phenylimidazo[1,2-b]- 
pryridazine (II.5a) (65%), m.p. 227-229° after t.l.c.
(alumina; chloroform) and recrystallised from toluene and 
also ethanol (Found: C, 62.6; H, 4.6; N, 19.4. Ci5H]_2FN40.
O. 3 H20 requires C, 62.4; H, 4.4; N, 19.4%)* XH n.m.r: 6 
2.02, s, MeCO; 4.99, d, J 5.5 Hz, CH2N; 6.38, bs, NH; 6.93, 
d, J 9.5 Hz, H7; 7.42-7.54 and 7.87-8.15 complex, Ph and
H8 .
3-Acetamidomethyl-6-chloro-2-phenylimidazo[ 1,2-b]pyridazine 
(II.5b) (90%), m.p. 257-259° (from toluene) (Found: C,
60.2; H, 4.4; N, 18.5. C15H13C1N40 requires C, 59.9; H,
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4.4; N, 18.6%). n.m.r: 6 2.03, s, Me; 5.02, d, J 5.5 Hz,
CH2; 7.09, d, J7 f q 9Hz, H7; 7.39-8.02, complex, Ph; 7.92, 
d, J7 ^ g 9 Hz, H8. Mass spectrum m/z 300 (M+) (30%), 257
(100%) , 223 (44%) , 103 (6%) .
3-Acetamidomethyl-6-chloro-2-(3',4'-methylenedioxyphenyl)- 
imidazo[l,2-b]pyridazine (II.5c) (80%), as yellow crystals,
m.p. 237-240° after t.l.c. (alumina; chloroform, light 
petroleum, 2:1) and recrystallisation from methanol (Found: 
C, 55.5; H, 3.6; N, 16.0. C16H13C1N403 requires C, 55.7;
H, 3.8; N, 16.3%). 1 H n.m.r: S 2.04, s, MeCO; 4.97, d, J 
5.5 Hz, CH2N; 6.01, s, 0CH20; 6.92, d, J 8 Hz, H5'; 7.07, 
d, J 9.5 Hz, H7; 7.40-7.52, complex, H2',6'; 7.88, d, J 9.5 
Hz, H8.
3-Acetamidomethyl-6-raethoxy-2-phenylmidazo[1,2-b]- 
pyridazine (II.5e) (52%), as white crystals, m.p. 229-230°
after t.l.c. (alumina; chloroform, light petroleum, 2:1) 
and recrystallisation from ethanol (Found: C, 64.5; H,
5.6; N, 18.6 C16H16N402 requires C, 64.8; H, 5.4; N,
18.9%). XH n.m.r: 5 2.02, s, MeCO; 4.02, s, MeO; 4.97, d, J 
5 Hz, CH2N; 6.25, bs., NH.; 6.70, d, J 9.5 Hz, H7; 7.35- 
7.50, complex, 7.70-7.86, complex, Ph; 7.76, d, J 9.5 Hz,
H8 .
3-Acetamidomethy1-2-phenyl-6-phenylthioimidazo- 
[1,2-b]pyridazine (II.5f) (42%), as white crystals, m.p.
213-215° after t.l.c. (alumina; chloroform) and 
recrystallisation from toluene. (Found: C, 65.8; H, 4.9;
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N, 14.7. C2iH18N4OS. 0.5 H20 requires C, 65.8; H, 5.0; N, 
14.6%)* 1H n.m.r: 5 1.85, s, MeCO; 4.79, d, J 5.5 Hz, CH2N; 
6.03, bs, NH; 6.87, d, J 9.5 Hz, H7; 7.40-8.00, complex,
2xPh; 7.86, d, J 9.5 Hz, H8.
3-Acetamidomethyl-6-phenylthio-2-(4'-tolyl)imidazo- 
[1,2-b]pyridazine (II.5g) (80%), as white crystals, m.p.
191-193° after t.l.c. (alumina; chloroform, light 
petroleum, 3:1) and recrystallisation from toluene (Found: 
C, 67.8; H, 5.2; N, 14.3. C22H20N4OS requires C, 68.0; H, 
5.2; N, 14.4%). 1H n.m.r.: 5 1.85, s, MeCO; 2.38, s, Me;
4.78, d, J 5.5 Hz, CH2N; 6.05, bs, NH, 6.86, d, J 9.5 Hz,
H 7; 7.21-7.86, complex, 2 x Ph and H 8.
3-Acetamidomethyl-6-(2'-methoxyphenoxy)-2-phenylimidazo-
[1,2-b]pyridazine (II.5h)
was
This compound^prepared similarly but with less 
sulphuric acid (0.05 ml) and the mixture was refluxed for 5 
h only. The product was purified by t.l.c. (alumina; 
chloroform) and recrystallisation from toluene to give the 
title compound (50%), as a yellow solid, m.p. 174-175° 
(Found, for a sample dried at 100°/710 mmHg for 20 h: C, 
68.1; H, 5.2; N, 14.2. C22H20N4O3 requires C, 68.0; H,
5.2; N, 14.4%)* 1H n.m.r: S 1.81, s, MeCO; 3.82, s, MeO; 
4.77, d, J 5.5 Hz, CH2N; 6.09, bs, NH; 7.00, d, J 9.5 Hz,
H7; 7.12-7.50, complex, 7.80-8.00, complex, H 3', 4',5',6' 
and Ph; 7.97, d, J 9.5 Hz, H8.
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3-Acetamidomethy1-6-benzyloxy-2-phenylimidazo- 
[1,2-b]pyridazine (II.5i) (22%), m.p. 195-196° after t.l.c.
(alumina; chloroform) and recrystallisation from toluene 
(Found, for a sample dried at 100°/710 mmHg for 7h: C,
70.7; H, 5.3; N, 15.1. C22H20N4°2 requires C, 70.9; H,
5.4; N, 15.0%)- 1H n.m.r: 6 1.97, s, MeCO; 4.88, d, J 5.5 
Hz, CH2NH; 5.38, CH20; 6.66, d, J 9.5 Hz, H7; 7.27-7.50, 
complex, 7.70-7.80, complex, 2xPh; 7.57, d, J 9.5 Hz, H8.
3-Benzamidomethy1-6-fluoro-2-phenylimidazo[1,2-b]pyridazine 
(II.6a) A solution of N-(hydroxymethyl)benzamide216 (0.114 
g) in glacial acetic acid (2 ml) with concentrated 
sulphuric acid (0.2 ml) was heated at 50° for 15 min. 6- 
Fluoro-2-phenylimidazo[1,2-b]pyridazine (0.12 g) was added 
and the reaction mixture was refluxed for 20 h; evaporated 
under reduced pressure and the oily residue diluted with 
water and adjusted with aqueous ammonia to pH 10. The 
solution was extracted with chloroform, the extract was 
washed with water, dried (Na2SC>4) and the solvent 
evaporated. The product was recrystallised from toluene 
and gave the title compound (0.070 g), m.p. 185-187°
(Found: C, 69.2; H, 4.15; N, 15.9. C20H15FN4O requires C, 
69.4; H, 4.4; N, 16.2%). 1H n.m.r.: 6 5.20, d, J 5.5 Hz, 
CH2NH; 6.91, d, J 9.5 Hz, H7, 7.40-8.19, complex, 2xPh and 
H8 .
3-Benzamidomethyl-6-chloro-2-(4'-tolyl)imidazo- 
[l,2-b]pyridazine (II.6b) (84%), m.p. 251-252° after t.l.c.
(alumina; chloroform) and recrystallisaton from toluene
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(Found: C, 66.7; H, 4.8; N, 14.9. C21H17CIN4O requires C, 
66.9; H, 4.5; N, 14.9%). XH n.m.r.: 6 2.39, s, Me; 5.19, d,
J 5.5 Hz, CH2N; 7.01, d, J 9.5 Hz, H7; 7.22-7.86, complex,
H2 ' , 3',5',6 ' , Ph and H8 .
3-Benzamidomethyl-6-chloro-2-(3',4'-methylene- 
dioxyphenyl)imidazo[l,2-b]pyridazine (II.6c) (10%), m.p.
212-214° after t.l.c. (alumina; chloroform) and 
recrystallisation from a mixture of methanol and light 
petroleum, (Found, for a sample dried at 105°/0.1 mmHg for 
5 h: C, 62.0; H, 4.0; N, 13.5. C2iH15ClN4C>3 requires C,
62.0; H, 3.7; N, 13.8%). XH n.m.r.: <5 5.21, d, J 5.5 Hz,
CH2N; 6.02, s, OCH20; 6.95, d, J 9.5 Hz, H7; 7.00-7.97, 
complex, H2",5",6" and Ph and H8.
3-Benzamidomethyl-6-methylthio-2-(4/-tolyl)imidazo- 
[1/2-b]pyridazine (II.6d) (60%), m.p. 222-224° after t.l.c.
(alumina; chloroform, light petroleum, 2:1) and 
recrystallisation from toluene (Found, for a sample dried 
at 60°/0.1 mmHg for 15 h: C, 68.4; H, 5.3; N, 14.5. 
C22H20N4OS requires C, 68.0; H, 5.2; N, 14.1%). 1H n.m.r.:
5 2.40, s, MeC; 2.61, s, MeS; 5.25, d, J 5.5 Hz, CH2N;
6.92, d, J 9.5 Hz, H7; 7.30-7.85, complex, H2",3",5" and 
6", Ph and H8 .
3-Benzamidomethyl-2-(3 ', 4 '-methylenedioxyphenyl)-6- 
methylthioimidazo[1,2-b]pyridazine (II.6e) (64%), as yellow
crystals, m.p. 200-202° after t.l.c. (alumina, chloroform) 
and recrystallisation from toluene (Found: C, 63.2; H,
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4.5; N, 13.2. C22H18N403S requires C, 63.1; H, 4.3; N,
13.4%). 1H n.m.r.: 6 2 .56, s, MeS; 5.14, d, J 5.5 Hz, CH2N;
5.98, s, OCH20; 6.78, d, J 9.5 Hz, H7; 7.21-7.51 and 7.35-
7.98, complex, H2",5",6", Ph and H8 .
3-Benzamidomethyl-6-methoxy-2-(4'-tolyl)imidazo- 
[I,2-b]pyridazine (II.6f) (64%), as white crystals m.p.
215-217° after t.l.c. (alumina; chloroform, light 
petroleum, 2:1) and recrystallisation from toluene (Found, 
for a sample dried at 100°/710 mmHg for 12 h: C, 71.2; H, 
5.5; N, 15.2. C22H20N4°2 requires C, 70.9; H, 5.4; N,
15.0%). 1H n.m.r.: 5 2.36, s, MeC; 3.94, s, MeO; 5.13, d, J 
5.5 Hz, CH2N; 6.57, d, J 9.5 Hz, H7; 7.30-7.94, complex,
H2", 3 ", 5", 6" , Ph and H8.
3-Benzamidomethy1-2-phenyl-6-phenylthioimidazo­
l 1, 2-b]pyridazine (II.6g) (70%), m.p. 177-179° after t.l.c.
(alumina; chloroform) and recrystallisation from toluene 
(Found: C, 71.7; H, 4.8; N, 12.9. C26H20N4OS requires C, 
71.5; H, 4.6; N, 12.8%). XH n.m.r.: 6 5.00, d, J 5.5 Hz, 
CH2N; 6.82, d, J 5.5 Hz, H7; 7.27-8.01, complex, 2xPh and 
H8 .
3-Benzamidomethy1-6-benzyloxy-2-phenylimidazo- 
[1,2-b]pyridazine (II.6h) (26%), as white crystals, m.p.
193-195° after t.l.c. [alumina; chloroform then alumina, 
chloroform, light petroleum] and recrystallisation from 
toluene. (Found: C, 74.7; H, 5.3; N, 13.0. C27H22N402
requires C, 74.6; H, 5.1; N, 12.9%). 1H n.m.r. (CDC13): 6
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5.19, d, J 5.5 Hz, CH2NH; 5.38, s, CH20; 6.74, d, J 9.5 Hz, 
H7; 7.20-7.90, complex, 3 x Ph.
II-5.3 [3H]Diazepam binding assay
Young adult Spargue-Dawley rats were decapitated and 
their brains removed and then placed on ice. Washed 
synaptosmal membranes were prepared from the Mp2" 
mitochondrial pellet according to a previously published 
procedure and stored frozen until used. On the day of 
assay, membrane preparations were thawed, washed once by 
centrifugation and resuspended on ice-cold distilled water, 
then resuspended in 50 mM Tris-HCl buffer, pH 7.4, at 2°C. 
For the receptor binding assays, aliguots of the membrane 
suspension (approximately 0.8 mg protein) were incubated 
with tritiated diazepam (86.6 Ci/mmol, 0.70 ± 0.05 nM final 
concentration) in a final volume of 50 mM Tris-HCl buffer 
containing various concentrations of the test compounds and 
100 /xM GABA (to stimulate the binding of the ligand to the 
benzodiazepine receptors in the plasma membranes). Four 
separate concentrations of test compounds were always used 
in tests on each compound. Assays were conducted on ice 
for an incubation period of 35 min. Nonspecific binding 
was determined in separated tubes by the addition of a 
large excess (100 /xM) of unlabelled diazepam. Membranes 
were collected by filtration under vacuum on glass-fibre 
filters (Whatman GF/B, 2.5 cm) and washed with 12 ml of 
ice-cold buffer. Filters were placed in scintillation 
vials with 1 ml of water and 8 ml toluene/triton X-100
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scintillation fluid; bound radioactivity was determined by 
conventional techniques. The imidazo[1,2-b]pyridazines 
were routinely tested at four different concentrations of 
30, 100, 300 and 1000 nM; and within each experiment all
assays were performed in triplicate. For each 
concentration of the test compounds, results were 
calculated as the per cent displacement of specific 
binding. Where specific binding was taken as the amount of 
radioactive diazepam bound in control tubes (no inhibitor) 
less the amount bound in the presence of excess unlabelled 
diazepam. IC5 0 values (the concentration of the drug 
causing 50% displacement of radioactive diazepam bound to 
the brain membranes, and standard assay conditions) were 
calculated for each test compound by using computer- 
assisted log-logit analysis. If the correlation 
coefficient of the lines of best-fit to log-logit curves 
was less than 0.95 for a test compound, the experiment was 
repeated.
Compounds were initially dissolved in dimethyl 
sulphoxide (DMSO) to give 4 mM stock solutions which were 
then serially diluted with buffer (or DMSO/buffer) and 
immediately added to the assay tubes. DMSO was also added 
to control and blank tubes so that all tubes contained the 
same final concentration of DMSO (0.25%).
CHAPTER III
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CHAPTER III Syntheses and binding studies of some 3- 
(substituted benzamidomethyl)-6-fluoro (and chloro)-2- 
phenyl (and 4'-tolyl)imidazo[1,2-b]pyridazines
III-I Introduction
In Chapter II the synthesis of 6-(variously 
substituted)-3-benzamidomethyl-2-phenyl (and substituted 
phenyl)imidazo[1,2-b]pyridazines and studies of their 
activity in displacing [ HJdiazepam from its specific 
binding sites in rat brain were reported.
In this chapter, syntheses are described for 6- 
fluoro- and 6-chloro-3-(substituted benzamidomethyl)-2 - 
phenyl (and 4'-tolyl)imidazo[1,2-b]pyridazines and the 
results of tests to determine their ability to displace 
[3H]diazepam from rat brain membrane preparations, are 
given and discussed. The aim of this investigation was 
to determine the structure-activity relationships for 
this series of compounds with the hope of identifying 
potent and selective inhibitors of [3H]diazepam binding.
Thus the effect of introducing various substituents 
into the 3-benzamidomethyl group in the 2-aryl-6-(fluoro 
and chloro)-3-benzamidomethylimidazo[1,2-b]pyridazines
has been studied.
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III-2 Syntheses
The starting materials required for the preparation 
of the title compounds (III.3 and III.4, Scheme III-2) 
were the substituted (N-hydroxymethyl)benzamides (III.l, 
Scheme III-l) which were prepared from the corresponding 
amides by stirring with formaldehyde in aqueous potassium 
carbonate, and the 3-unsubstituted-6-chloro (and 6- 
fluoro)-2-phenyl (and 4 '-tolyl) imidazo [ 1,2-jb] pyridazines 
(III.2, X = Cl or F) which have been described in Chapter 
II.
A mixture of an N-(hydroxymethyl)benzamide (III.l) 
and compounds (III.2, Scheme III-2) in acetic acid 
containing sulphuric acid were heated at 120°C for ca 14 
h to give compounds (III.3 or III. 4), respectively, 
obtained in yields which varied from 9 to 88%.
The nitro compounds (III.4a-d) were reduced 
catalytically with hydrogen over Raney nickel in ethanol 
to the corresponding amino compounds (III.4e,t-v, Scheme 
III-3), respectively.
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Scheme III-1
III. 1
Scheme III-2
III. l R2
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99
Scheine III-3
HI. 4 a-d HI. 4 e,t-v.
III-3 n.m.r. spectra
The 1H n.m.r. spectra of the 3-unsubstituted 
compounds (III. 2) employed in this work have been 
described in Chapter II; those of compounds (III.l) are 
recorded in the Experimental section and the methylene 
and methyl protons are recorded in Table III-l. The 
signal for protons of each methylene group in compounds 
(III.l), adjacent to the NH group of the carbamoyl group, 
appeared as a doublet with a coupling constant of 6.5 - 
7.0 Hz and a chemical shift mostly in the range 54.93- 
4.97. The exceptions were the 2-fluoro compound (III.lb) 
and the nitro compounds (III.lh-j) in which the methylene 
protons appeared as a triplet with chemical shifts of 
54.99 (III.lb) and 54.66-4.74 (in CD3SOCD3), respectively. 
On addition of deuterium oxide, each of these doublets 
and triplets collapsed to a singlet.
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The spectra of the title compounds (III.3 and III.4) 
are not recorded in the Experimental section because the 
signals due to the aromatic groups at the 2- and 3- 
positions overlap to give spectra which were not readily 
assigned. The chemical shifts of the methylene protons 
(64.94-5.23) are, however, recorded in Table III-2.
Table III-l Some 1H n.m.r. spectral dataA for some 
N-(hydroxymethyl)benzamides
III. 1 R1 Me of R^ ch2b
a NMe2”/n 2.99 4.95
b F-o 4.99C
c F-m 4.97
d F-p 4.95
e Cl-o 4.96
f Cl-m 4.96
g Cl-p 4.97
h NO2-0 4.66C
i NC»2-/n 4.74C
j no2-p 4.74C
k Me-o 2.46 4.93
1 Me-m 2.40 4.97
m Me-p 2.39 4.93
n OMe-p 3.86 4.95
AReported as parts per million (6) downfield from 
tetramethylsilane as internal standard in 
deuterochloroform except for compounds (III.lh-j) which 
were examined in CD3SOCD3
U Doublet unless specified otherwise 
cTriplet
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Table III-2 Some n.m.r. spectral dataA for 6-fluoro 
(and 6-chloro)-3-(substituted benzamidomethyl)-2-phenyl- 
(and 4'-tolyl)-imidazo[1,2-b]pyridazines
III. 3 R1 and 5 R2 and 8 c h 2b
a H NO2 -o 5.22
b H N02-/n 5.22
c Me-p 2.41 NO 2 ~o 5.17
d H F-o 5.23
e H F-m 5.17
f H F-p 5.17
g Me-p 2.41 F-o 5.23
h Me-p 2.40 F - m 5 . 16
i Me-p 2.40 F-p 5 . 15
j H Cl-o 5 . 17
k H C1 —721 5 . 18
1 H Cl-p 5.20
m Me-o 2.41 Cl-o 5.20
n Me-m 2.41 Cl- m 5 . 18
o Me-p 2.41 Cl-p 5 . 19
P H Me-o 2.42 5 . 18
q H Me-m 2.36 5 . 17r H Me-p 2.38 5 . 19
III.4 
a H NO 2 ~ o 5.22
b H N02”.m 5.22
c H N02-p 5.23
d Me-p 2.41 61CMO2; 5.25
e Me-p 2.41 NH2-/n 5 . 16
f Me-p 2.40 C5H4N-£C 5.23
g H F-o 5.27
h H F - m 5.20
i H F - p 5.23
j Me-p 2.41 F - o 5.24
k Me-p 2.40 F - m 5.18
1 Me-p 2.40 F - p 5.18
m H Cl-o 5.25
n H Cl - m 5.22
o H Cl-p 5.23
P H Me-o 2.44 5.24
q H Me-m 2.37 5 . 19
Table III-2 Continued
III.4 R1 and S R2 and 6 c h 2b
r H Me-p 2 .37 5.21
s H OMe-p 3.84 5.22
t H NH2-o 5.21
u H NH2 -m 4.94
V H NH 2-p 5.22
w H NMe2-m 2.99 5.24
AReported as parts per million (6) downfield from
tetramethylsilane as internal standard in 
deuterochloroform.
BDoublet
pPyridinyl (not substituted phenyl)
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III-4 In vitro binding studies
The series of compounds prepared in this chapter 
were screened for their ability to bind at specific 
benzodiazepine receptors in the rat brain preparations 
using the [ HJdiazepam binding assay as outlined in 
Chapter II-5.3.
II- 4.1 Results of [3H]diazepam binding assays
The in vitro competitive binding results are shown 
in Table III-3 as IC50 values or per cent displacement at 
the specified concentration.
III- 4.2 Discussion of results
An examination of the data in Table III-3 for the 6- 
fluoro compounds (III.3) and the 6-chloro compounds 
(III.4) revealed a wide range of activity.
The 6-fluoro compounds (III.3) generally bound more 
strongly than their 6-chloro analogues. Exceptions were 
the 6-fluoro-3-(nitrobenzamidomethyl) compounds (III.3a, 
IC50 1743 nM and III.3b, IC50 384 nM) and the 6-fluoro-3- 
(2'-toluamidomethyl compound (III.3p, 4% displacement at 
1000 nM) as compared to the 6-chloro analogues (III.4a, 
IC50 657 nM; and III.4b, IC50 354 nM) and the 6-chloro-3- 
(2'-toluamidomethyl) analogue (III.4p, IC5Q 623 nM) .
Compounds which contained the 2-(4'-tolyl) group 
bound more strongly than their analogues which contained 
the 2-phenyl group; comparison of the IC50 values in
104
Table III-3 Results for the displacement of [3H]diazepam 
from its specific binding sites in rat brain preparations 
by some 3-(substituted benzamidomethyl)- 
imidazo[1,2-b]pyridazines
Formula Imidazo[1,2-b] IC50(nM)A
number pyridazine (or % displ.)B
II. 6 a 6-F-3-CH2NHC0Ph-2-Ph 68
II.7 6-F-3-CH2NHC0Ph-2-C6H4Me-p 8
III.3 a 6-F-3-CH2NHC0C6H4N02-o-Ph 1743
b 6-F-3-CH2NHC0C6H4N02-m-Ph 384
c 6-F-3-CH2NHC0C6H4N02-o-2-C6H4Me-p (25%)
d 6-F-3-CH2NHC0CgH4 F-o-2-Ph 114
e 6-F-3-CH2NHC0C6H4 F-m-2-Ph 57
f 6-F-3-CH2NHC0C6H4 F-p-2-Ph 77
g 6-F-3-CH2NHC0C6H4F-O-2-C6H4Me-p 7h 6-F-3-CH2NHC0C6H4F-m-2-C6H4Me-p 8
i 6-F-3-CH2NHC0C6H4F-p-2-C6H4Me-p 8
j 6-F-3-CH2NHC0C6H4Cl-o-2-Ph 460k 6-F-3-CH2NHC0C6H4Cl-m-2-Ph 155
1 6-F-3-CH2NHC0C6H4Cl-p-2-Ph 190
m 6-F-3-CH2NHC0C6H4Cl-o-2-C6H4Me-p 60
n 6-F-3-CH2NHC0C6H4Cl-m-2-C6H4Me-p 18
o 6-F-3-CH2NHC0C6H4Cl-p-2-C6H4Me-p 18
P 6-F-3-CH2NHC0C6H4Me-o-2-Ph (4%)
q 6-F-3-CH2NHC0C6H4Me-m-2-Ph 235r 6-F-3-CH2NHC0C6H4Me-p-2-Ph 94
11.12 6-C1-3-CH2NHC0Ph-2-Ph 140
II. 6 b 6-Cl-3-CH2NHC0Ph-2-C6H4Me-p 18
III.4 a 6-Cl-3-CH2NHC0C6H4NO2-o-Ph 657
b 6-C1-3-CH2NHC0C6H4NO2-m-Ph 354
c 6-Cl-3-CH2NHC0C6H4NO2-p-Ph (9%)
d 6-Cl-3-CH2NHC0C6H4NO2-m-2-C6H4Me-■p 23
e 6-Cl-3-CH2NHC0C6H4NH2-m-2-C6H4Me-■P 17
f 6-Cl-3-CH2NHC0C5H4N-^-2-C6H4Me-p 34
g 6-Cl-3-CH2NHC0C6H4F-o-2-Ph 145h 6-C1-3 -CH2NHC0C6H4F-/n-2 - Ph 66
i 6-Cl-3-CH2NHC0C6H4F-p-2-Ph 97
105
Table III-3 Continued
Formula
number
Imidazo[1,2-b]
pyridazine (or
IC50 (nM)A 
% displ.)0
j 6-C1-3-CH2NHC0C6H4F-o-2-C6H4Me-p 22k 6-Cl-3-CH2NHC0C6H4F-m-2-C6H4Me-p 10
1 6-Cl-3-CH2NHC0C6H4F-p-2-C6H4Me-p 24
m 6-Cl-3-CH2NHC0C6H4Cl-o-2-Ph (24%)n 6-Cl-3-CH2NHC0C6H4Cl-m-2-Ph 203
0 6-Cl-3-CH2NHC0C6H4Cl-p-2-Ph 1961
P 6-C1-3-CH2NHC0C6H4Me-o-2-Ph 623
q 6-Cl-3-CH2NHC0C6H4Me-m-2-Ph 303r 6-Cl-3-CH2NHC0C6H4Me-p-2-Ph 348
s 6-Cl-3-CH2NHCOC6H4OMe-p-2-Ph 185
t 6-C1-3-CH2NHC0C6H4NH2-0-2-Ph 145u 6-Cl-3-CH2NHC0C6H4NH2-7n-2-Ph 140
V 6-Cl-3-CH2NHC0C6H4NH2-p-2-Ph 81
w 6-Cl-3-CH2NHC0C6H4NMe2-/n-2-Ph 87
IC50 values are the concentrations required to displace 
50% of specific [3H]diazepam binding to rat brain 
membrane preparations 
B Percentage displacement at 1000 nM
Table III-3 revealed that this enhanced binding varied 
from 4- to 16-fold.
An examination of the 6-fluoro compounds revealed 
that 6-fluoro-3-(2'-fluorobenzamidomethyl)-2-(4"-tolyl)- 
imidazo[1,2-b]pyridazine (111.3g, IC50 7 nM) bound most 
strongly: it was slightly stronger than the 3'- and 4'- 
fluoro isomers (III.3h and 111.31), respectively, (IC50 
values 8 nM) and also slightly stronger than the 
unsubstituted analogue, 6-fluoro-3-benzamidomethyl-2-(4'- 
tolyl)imidazo[1,2-b]pyridazine (II.7, IC50 8 nM). The
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2'-, 3'- and 4'-fluoro substituents have only a small 
effect on binding ability.
The 6-fluoro-3-(2'-, 3'- and 4'-chlorobenzamido- 
methyl) compounds (III.3j-o, IC50 values 460, 150, 190,
60, 18 and 18 nM, respectively) all bound less strongly 
than the corresponding 6-fluoro-3-(unsubstituted 
benzamidomethyl) compounds (II.6a, IC50 68 nM; and II.7, 
IC50 8 nM), respectively. A similar situation also 
applied to 6-fluoro-3-(substituted benzamidomethyl) 
compounds containing nitro and methyl substituents.
An examination of the 6-chloro compounds revealed a 
pattern of behaviour similar to that of the 6-fluoro 
analogues but with some variations. Thus 6-chloro-3-(3'- 
fluorobenzamidomethyl)-2-(4"-tolyl)imidazo[1,2-b]- 
pyridazine (III.4k, IC50 10 nM) bound more strongly than 
the 3-(unsubstituted benzamidomethyl) analogue (II.6b, 
IC50 18 nM) or its 2'- and 4'-fluoro isomers (III.4j and 
III.41, IC50 values 22 and 24 nM, respectively). The 6- 
chloro-3-(3'-fluorobenzamidomethyl) compound (III.4h,
IC50 66 nM) also bound more strongly than its 2'- and 4'- 
fluoro isomers (111.4g, IC50 145; and III.4i, IC50 97 
nM), respectively. The 6-chloro-3-(4'- 
methoxybenzamidomethyl) compound (III.4s, IC50 185 nM) 
bound more strongly than its 4'-methyl analogue (III.4r, 
IC50 348 nM).
Whereas the 3-(nitrobenzamidomethyl) compounds 
(III.4a-c, IC50 657, 354 nM and 9% displacement at 1000
nM, respectively) possessed only weak binding ability, 
reduction to the corresponding amino compounds (III.4t-v,
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IC50 values 145, 140 and 81 nM, respectively) increased 
binding properties.
N , N -Dimethylation of the 6-chloro-3-(3'-amino- 
benzamidomethyl) compound (III.4U, IC50/ 140 nM) to give
the 3-(3 7- N ,N-dimethylaminobenzamidomethy1) analogue 
(III.4w, IC50 87 nM) increased binding significantly. 6- 
Chloro-3-(3'-nitro- and 3'-amino-benzamidomethy1)-2-(4"- 
tolyl)imidazo[1,2-b]pyridazines (III.4d and III.4e) were 
outstanding with IC50 values of 23 and 17 nM, 
respectively. The 3-nicotinamidomethyl compound (III.4f, 
IC50 34 nM) was less active than the corresponding 3-(3'- 
aminobenzamidomethyl) compound (III.4e, IC50 17 nM).
The effect of a 2'-nitro group in 3-(substituted 
benzamidomethyl) compounds, e.g. (III.3a), (III.3c) and 
III.4a) was to markedly decrease activity relative to the 
3'- and 4'-nitro isomers and to the corresponding 
unsubstituted 3-benzamidomethyl compounds. Similar 
reduced activity was found in compounds (III.3j, 111.3m, 
III.3p, III.4m and III.4p) which each contained a 2'- 
chloro- or 2'-methyl group. Steric effects of relatively 
large groups at the 2'-positions may be responsible for 
the diminished binding ability observed. It has been 
proposed234 that lipophilicity may be an important factor 
affecting the binding of benzodiazepine-like compounds.
In the present work the 3'-dimethylamino compound (IV.4w, 
IC50 87 nM) bound more strongly than its 3'-amino 
analogue (IIIa.4u, IC50 140 nM) and the dimethylamino 
group would be expected to be more lipophilic than the 
amino group.235
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III-5 Experimental
The general procedures and also experimental details 
for [3H]diazepam binding assay have been recorded in 
Chapter 11-5.1 and II-5.3.
3-Dimethylamino-N-(hydroxymethyl)benzamide (III. la)
A mixture of 3-dimethylaminobenzamide236 (1.0 g) , 
potassium carbonate (0.107 g) and water (15 ml) was 
warmed to dissolve the solid, aqueous formaldehyde 
(0.6 ml; 37% solution) added and the mixture stirred at 
room temperature for 2 h. The solid (0.645 g) was 
filtered off, washed with water and recrystallised from 
water to give yellow crysatals of 3-dimethylamino-N- 
(hydroxymethyl)benzamide, m.p. 138-140° (Found: C,
62.1; H, 7.2; N, 14.4. requires C, 61.8; H,
7.3; N, 14.4%). 1H.n.m.r.: 5 2.99, s, Me2N; 4.95, d, J
6.5 Hz, CH2N; 6.83-7.37, complex, ArH.
3-Fluoro-N-(hydroxymethyl)benzamide (III.lc)
A mixture of 3-fluorobenzamide237 (0.5 g), potassium 
carbonate (0.022 g) and water (5 ml) was warmed to 
dissolve the solid. Aqueous formaldehyde (0.42 g) was 
added and the mixture stirred in an oil bath at 100° for 
3h. After cooling, the solid (0.264 g) was filtered off 
and washed with water. It was recrystallised from 
benzene to give colourless crystals of the title 
compound, m.p. 103-105°. (Found, for a sample dried at 
20°/0.1 mmHg for 6 h: C, 56.8; H, 4.7; N, 8.1. CgHgFNC^
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requires C, 56.8; H, 4.8; N, 8.3%). 1H.n.m.r.: 6 4.97,
d, J 6.5Hz, CH2N; 7.13-7.58, complex, ArH.
2-Fluoro-N-(hydroxymethyl)benzamide (III.lb)
This compound was prepared in a similar manner from 
2-fluorobenzamide but the reaction mixture was heated
for 6 h. The product was collected by filtration and 
extraction with chloroform and recrystallised from 
benzene to give colourless crystals of the title compound 
(61%) m.p.. 94-95°. (Found, for a sample dried at 
20°/0.1 mmHg for 15 h: C, 57.0; H, 4.8; N, 8.0.
C8H8FN02 requires C, 56.8; H, 4.8; N, 8.3%. 1H.n.m.r.:
6 3.69, t, J 7.5Hz, CH2Otf; 4.99, t, J 6.5Hz, CH2N; 7.03- 
8.20, complex, ArH.
2- Chloro-N-(hydroxymethyl)benzamide (III.le)
This compound was prepared as described by 
Schönenberger et al.238 It was recrystallised from 
water, subjected to t.l.c. (alumina; chloroform) and 
recrystallised from benzene to give the title compound, 
m.p. 117-119° (lit.238 106-108°) (Found: C, 52.3; H,
4.0; N, 7.5. Calc, for C8H8C1N02. 0.03 C6H6: C, 52.3;
H, 4.4; N, 7.5%). 1H .n .m.r.: 5 4.96, d, J 6.5Hz, CH2N;
7.26-7.76, complex ArH.
3- Chloro-N-(hydroxymethyl)benzamide (III.If)
This compound was prepared as described by 
Schönenberger et al.238 It was recrystallised from 
aqueous ethanol, subjected to t.l.c. (alumina;
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Chloroform) and recrystallised from benzene to give the 
title compound, m.p. 125-127° (lit.238 116-118°) (Found:
C, 52.1; H, 4.1; N, 7.5. Calc, for C8H8C1N02: C, 51.3;
H, 4.3; N, 7.5%) 1H.n.m.r.: S 4.96, d, J 6.5Hz, CH2N;
7.29-7.19, complex, ArH.
Preparation and 1H.n.m.r. of other N-(hydroxymethyl)- 
benzamides
The following N-(hydroxymethyl)benzamides were 
prepared according to literature procedures:
2-, 3- and 4-nitro-;239 4-fluoro-;238 4-chloro-;238 2- 
methyl-;240 3-methyl-;241 4-methyl-;238 and 4-methoxy- 
N-(hydroxymethyl)benzamides.241
Their ^H.n.m.r. data were as follows:
2-N02 (Ill.lh) (CD3SOCD3): S 4.66, t, J 6.5Hz, CH2N;
5.82, t, J 7.5Hz, CH2OH; 7.54-8.07, complex, ArH; 9.25, 
br, NH.
3- N02 (Ill.li) (CD3SOCD3): S 4.74, t, J 6.5Hz, CH2N;
5.80, t, 7.5Hz, CH20H; 7.69-8.69, complex, ArH.; 9.51, 
br, NH.
4- N02 (Ill.lj) (CD3SOCD3): & 4.74, t, J 6.5Hz, Ctf2N;
5.81, t, J 7.5Hz, CH2OH; 8.11, d, J 8Hz, 8.34, d, J 8Hz, 
ArH, 9.04, br, NH.
4-F (III.Id): 5 4.95, d, J 6.5Hz, CH2N; 7.11, t, JHH =
Jpjp = 8Hz, 7.81, g, JhH ® Hz, JhF 5.5Hz, ArH.
Ill
4-Cl (III.lg): S 4.97, d, J 6.5Hz, CH2N; 7.42, d, 7.76,
d, J 8Hz, H 2,3,5,6.
2-Me (III.Ik): 8 2.46, s, Me; 4.93, d, J 6.5Hz, CH2N;
6.80, br, NH; 7.19-7.46, complex, ArH.
3-Me (III.11): 8 2.40, s, Me; 4.97, d, J 6.5Hz, CH2N;
7.27-7.63, complex, ArH.
4-Me (Ill.lm) (CDC13 + D20): 8 2.39, s, Me; 4.93, s,
CH2N ; 7.21, d, J 9Hz, 7.69, d, J 9Hz, ArH.
4-OMe (III.in): 8 3.86, s, MeO; 4.95, d, J 7Hz, CH2N;
6.93, d, J 9Hz, H 3,5; 7.77, dd, J2f3 9Hz, J2 ^5 1.5Hz, H
2 ,6 .
6-Fluoro-3-(4'-fluorobenzamidomethyl)-2-phenyl- 
imidazo[l,2-b]pyridazine (III. 3f)
A mixture of 4-fluoro-N-(hydroxymethyl)benzamide 
(0.11 g), glacial acetic acid (3.0 ml) and concentrated 
sulphuric acid (10 drops) was stirred in an oil bath at 
50° for 15 minutes until a solution was obtained. Then 
6-fluoro-2-phenylimidazo[1,2-b]pyridazine (0.110 g) was 
added and the mixture refluxed with stirring in an oil 
bath at 120° for 15 h. The acetic acid was evaporated 
under reduced pressure, the residue diluted with water, 
adjusted with aqueous ammonia to pH 10, and extracted
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with chloroform. The extract was dried (Na2SC>4), the 
solvent evaporated and the solid obtained was subjected 
to t.l.c. (alumina; chloroform, light petroleum; 2:1) and 
recrystallised from toluene to give the title compound 
(0.068g), m.p. 225-227°. (Found, for a sample dried at 
70°/710 mmHg for 24 h: C, 64.4, H, 3.9; N, 14.8. 
c20H14F2N4°• 0.5 H20 requires C, 64.3; H, 4.0; N, 15.0%)
6-Fluoro-3-(2'-nitrobenzamidomethyl)-2-phenylimidazo- 
[1,2-b]pyridazine (III.3a)
A mixture of N-hydroxymethyl-2-nitrobenzamide 
(0.21 g), glacial acetic acid (4.0 ml) and concentrated 
sulphuric acid (0.5 ml) was stirred in an oil bath at 50° 
for 15 min. 6-Fluoro-2-phenylimidazo[1,2-b]pyridazine 
(0.213 g) was added and the mixture refluxed with 
stirring in an oil bath at 120° for 15 h. The acetic 
acid was evaporated under reduced pressure, the residue 
diluted with water and adjusted to pH 10 and extracted 
with chloroform. The extract was washed with water, 
dried (Na2S04) and evaporated, and the product 
recrystallised from toluene to give white crystals of the 
title compound (0.125 g), m.p. 242-245°. (Found, for a 
sample dried at 75°/710 mmHg for 20 h: C, 61.5; H, 3.7;
N, 17.7. C20H14FN5O3 requires, 61.4; H, 3.6; N, 17.7%).
In a similar manner the following compounds were
prepared.
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6-Fluoro-3-(3'-nitrobenzamidomethyl)-2-phenylimidazo- 
[l,2-b]pyridazine (III.3b) (27%), m.p. 206-208° after
t.l.c. (alumina; chloroform, light petroleum, 2:1) and 
recrystallisation from toluene. (Found: C, 61.2; H,
3.8; N, 17.7. C20H14FN5°3 requires, C, 61.4; H, 3.6; N,
17.9%) .
6-Fluoro-3-(2'-nitrobenzamidomethyl)-2-(4''-tolyl)- 
imidazo[l,2-b]pyridazine (III.3c) was obtained as 
colourless crystals (17%), m.p. 262-264° after t.l.c. 
(alumina; chloroform, light petroleum, 3:1) and 
recrystallisation from toluene. (Found: C, 62.4; H,
4.2; N, 17.5. C21H16FN5°3 requires C, 62.2; H, 4.0; N,
17.3%) .
6-Fluoro-3-(2'-fluorobenzamidomethyl)-2-phenyl- 
imidazo[1,2-b]pyridazine (III.3d) (34%), m.p. 181-183°
after t.l.c. (alumina; chloroform, light petroleum, 2:1) 
and recrystallisation from toluene. (Found: C, 65.7; H,
3.7; N, 15.2. C20H14F2N4O requires C, 65.9; H, 3.9; N,
15.4%) .
6-Fluoro-3-(3'-fluorobenzamidomethyl)-2-phenyl- 
imidazo[1,2-b]pyridazine (III.3e) (21%), m.p. 197-199° 
after t.l.c. (alumina; 33% light petroleum in chloroform) 
and recrystallisation from toluene. (Found: C, 65.9; H,
3.9; N, 15.3. C2oHi4F2N40 requires C, 65.9; H, 3.9; N, 
15.4%) .
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6-Fluor0-3-(2'-fluorobenzamidomethyl)-2-(4''-tolyl)- 
imidazo[l/2-b]pyridazine (III.3g) (21%), m.p. 213-214°
after t.l.c. (alumina; chloroform) and recrystallisation 
from toluene. (Found, for a sample dried at 
120°/710 mmHg for 16 h: C, 66.0; H, 4.3; N, 14.5.
c21h 16f2n4° * °*1 h 2° requires C, 66.3; H, 4.3; N, 14.7%).
6-Fluoro-3-(3'-fluorobenzamidomethyl)-2-(4''-tolyl)- 
imidazo[1,2-b]pyridazine (III.3h) (34%), m.p. 240-242° 
after t.l.c. (alumina; chloroform, light petroleum, 3:1) 
and recrystallisation from toluene. (Found, for a sample 
dried at 120°/710 mmHg for 15 h: C, 66.4; H, 4.3; N,
14.7. C2iH16F2N40 requires C, 66.7; H, 4.3; N, 14.8%).
6-Fluoro-3-(4'-fluorobenzamidomethyl)-2-(4''-tolyl)- 
imidazo[l,2-b]pyridazine (III.3i) (81%), m.p. 236-237° 
after t.l.c. (alumina; chloroform) and recrystallisation 
from toluene. (Found, for a sample dried at 
110°/0.1 mmHg for 5 h: C, 66.4; H, 4.4; N, 14.8.
c 21h 16f2n4° requires C, 66.7; H, 4.3; N, 14.8%).
3-(2'-Chlorobenzamidomethyl)-6-fluoro-2-phenyl- 
imidazo[1,2-b]pyridazine (III.3j) was obtained as white 
crystals (24%), m.p. 225-227° after t.l.c. (alumina; 
chloroform, light petroleum, 2:1) and recrystallisation 
from toluene. (Found: C, 63.1; H, 3.6; N, 14.4.
c20h 14c 1fn4° requires C, 63.1; H, 3.7; N, 14.7%).
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3 - (3'-Chlorobenzamidomethy1)-6-fluoro-2-phenyl- 
imidazo[l,2-b]pyridazine (III.3k) (14%), m.p. 196-197°
after t.l.c. (alumina; chloroform, light petroleum, 2:1) 
and recrystallisation from toluene. (Found: C, 63.3; H,
3.7; N, 14.5. C20H14C1FN4° requires C, 63.1; H, 3.7; N,
14.7%).
3 - (4'-Chlorobenzamidomethyl)-6-fluoro-2-phenyl- 
imidazo[l,2-b]pyridazine (III.31) was obtained as a white 
solid (88%), m.p. 255-257° after t.l.c. (alumina; 
chloroform) and recrystallisation from toluene. (Found, 
for a sample dried at 120°/710 mmHg for 16 h: C, 62.6;
H, 3.6; N, 14.4. c20H14CFFN4°• 0.1 H2O requires C, 62.8;
H, 3.7; N, 14.6%).
3-(2'-Chlorobenzamidomethyl)-6-fluoro-2-(4''-tolyl)- 
imidazo[l,2-b]pyridazine (III.3m) (25%), m.p. 235-236°
after t.l.c. (alumina; chloroform) and recrystallisation 
from toluene. (Found, for a sample dried at 105°/0.1mmHg 
for 2h: C, 63.8; H, 4.1; N, 14.0. C21H16C1FN4° requires 
C, 63.9; H, 4.1; N, 14.2%).
3-(3'-Chlorobenzamidomethyl)-6-fluoro-2-(4''-tolyl)- 
imidazo[l,2-b]pyridazine (III.3n) as a colourless solid 
(26%), m.p. 239-241° after t.l.c. (alumina; chloroform, 
light petroleum, 3:1) and recrystallisation from toluene. 
(Found: C, 63.6; H, 4.1; N, 14.0. C21H16C1FN4° requires 
C, 63.9; H, 4.1; N, 14.2%) .
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3 - (4 '-Chlorobenzamidomethyl)-6-fluoro-2-(4''-tolyl)- 
imidazo[1,2-b]pyridazine (III.3o) (31%), m.p. 257- 259°  
after t.l.c. (alumina; chloroform) and recrystallisation 
from toluene. (Found: C, 64.2; H, 4.3; N, 14.2.
c 21h 16c 1f n4° requires C, 63.9; H, 4.1; N, 14.2%).
6-Fluoro-2-phenyl-3-(2'-toluamidomethyl)imidazo[1,2-b]- 
pyridazine (III.3p) (44%), m.p. 226-228° after t.l.c. 
(alumina; chloroform, light petroleum, 2:1) and 
recrystallisation from toluene. (Found, for a sample 
dried at 120°/710 mmHg for 16 h: C, 69.1; H, 4.7; N,
15.3. C2iH17FN40. 0.2 H20 requires C, 69.3; H, 4.8; N,
15.4%) .
6-Fluoro-2-phenyl-3-(3' -toluamidomethyl)imidazo- 
[1,2-b]pyridazine (III.3q) (38%), m.p. 201-203° after 
t.l.c. (alumina; chloroform, light petroleum, 2:1) and 
recrystallisation from toluene. (Found: C, 69.9; H,
4.7; N, 15.3. C21H17FN40 requires C, 70.0; H, 4.8; N,
15.5%).
6-Fluoro-2-phenyl-3-(4'-toluamidomethyl)imidazo- 
[1,2-b]pyridazine (III.3r) (36%), m.p. 211-213° after 
t.l.c. (alumina; chloroform, light petroleum, 2:1) and 
recrystallisation from toluene. (Found: C, 69.9; H,
4.6; N, 15.4. C21H17FN40 requires C, 70.0; H, 4.8; N,
15.5%) .
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6-Chloro-3-(2'-nitrobenzamidomethyl)-2-phenylimidazo- 
[1,2-b]pyridazine (III.4a) (37%), m.p. 268-270° after
recrystallisation from toluene. (Found: C, 59.2; H,
3.6; N, 17.0. C20H14CIN5O3 requires C, 58.9; H, 3.5; N, 
17.2%) .
6-Chloro-3-(3'-nitrobenzamidomethyl)-2-phenylimidazo- 
[1,2-b]pyridazine (III.4b) (28%), m.p. 220-222° after
t.l.c. (alumina; chloroform, light petroleum, 2:1) and 
recrystallisation from toluene. (Found: C, 58.7; H,
3.5; N, 16.9. C20H14CIN5O3 requires C, 58.9; H, 3.5; N, 
17.2%).
6-Chloro-3-(4'-nitrobenzamidomethyl)-2-phenylimidazo- 
[1,2-b]pyridazine (III.4c) (25%), m.p. 256-258° after
recrystallisation from toluene. (Found: C, 59.2; H,
3.6; N, 16.9. C2oh 14c 1n 5°3 requires C, 58.9; H, 3.5; N,
17.2%) .
6-Chloro-3-(3'-nitrobenzamidomethyl)-2-(4''-tolyl)- 
imidazo[l,2-b]pyridazine (III.4d) (51%), m.p. 238-240° 
(from toluene). (Found, for a sample dried at 
100°/710 mmHg for 17 h: C, 59.8; H, 3.8; N, 16.4.
C21H16C1N5°3 requires C, 59.8; H, 3.8; N, 16.6%).
6-Chloro-3-(2' -fluorobenzamidomethyl)-2-phenyl- 
imidazo[1,2-b]pyridazine (III.4g) (46%), m.p. 205-207° 
after t.l.c. (alumina; chloroform, light petroleum, 2:1) 
and recrystallisation from toluene. (Found: C, 63.0; H,
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3.6; N, 14.5. C20H14C1FN4° requires C, 63.1; H, 3.7; N,
14.7%).
6-Chloro-3-(3'-fluorobenzamidomethyl)-2-phenyl- 
imidazo[1,2-b]pyridazine (III.4h) (35%), m.p. 203-205° 
after t.l.c. (alumina; chloroform, light petroleum, 2:1) 
and recrystallisation from toluene. (Found: C, 63.2; H,
3.6; N, 14.7. C20H14CIFN4O requires C, 63.1; H, 3.7; N, 
14.7%).
6-Chloro-3-(4'-fluorobenzamidomethyl)-2-phenyl- 
imidazo[l,2-b]pyridazine (III.4i) (37%), m.p. 226-228° 
after recrystallisation from toluene. (Found: C, 62.9;
H, 3.7; N, 14.4. C20H14CIFN4O requires C, 63.1; H, 3.7; 
N, 14.7%).
6-Chloro-3-(2'-fluorobenzamidomethyl)-3-(4''-tolyl)- 
imidazo[l,2-b]pyridazine (III.4j) (51%), m.p. 222-224° 
after t.l.c. (alumina; chloroform) and recrystallisation 
from toluene. (Found, for a sample dried at 
105°/0.1 mmHg for 6 h: C, 64.2; H, 4.2; N, 14.1.
c 21h 16c 1f n 4° requires C, 63.9; H, 4.1; N, 14.2%).
6-Chloro-3-(3'-fluorobenzamidomethyl)-3-(4''-tolyl)- 
imidazo[l,2-b]pyridazine (III.4k) (28%), m.p. 231-232°
after t.l.c. (alumina; chloroform) and recrystallisation 
from toluene. (Found, for a sample dried at 
105°/0.1 mmHg for 6 h: C, 64.1; H, 4.2; N, 14.1.
c 21h 16c 1f n 4° requires C, 63.9; H, 4.1; N, 14.2%).
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6-Chloro-3-(4'-fluorobenzamidomethyl)-3-(4''-tolyl)- 
imidazo[1,2-b]pyridazine (III.41) (59%), as pale yellow
crystals, m.p. 232-234° after t.l.c. (alumina; 
chloroform) and recrystallisation from toluene. (Found, 
for a sample dried at 110°/0.1 mmHg for 5 h: C, 64.1; H,
4.4; N, 13.9. C21H16C1FN4° requires C, 63.9; H, 4.1; N,
14.2%) .
6-Chloro-3-(2'-chlorobenzamidomethyl)-2-phenyl- 
imidazo[I,2-b]pyridazine (III.4m) (40%), m.p. 247-248°
after t.l.c. (alumina; chloroform) and recrystallisation 
from toluene. (Found: C, 60.7; H, 3.4; N, 13.8.
C20H14C12N4° requires C, 60.5; H, 3.5; N, 14.1%).
6-Chlor0-3-(3'-chlorobenzamidomethyl)-2-phenyl- 
imidazo[l,2-b]pyridazine (III.4n) (25%), m.p. 214-216° 
after t.l.c. (alumina; chloroform) and recrystallisation 
from toluene. (Found: C, 60.2; H, 3.6; N, 13.8.
C20H14C^2N4° requires C, 60.5; H, 3.6; N, 14.1%).
6-Chloro-3-(4'-chlorobenzamidomethyl)-2-phenyl- 
imidazo[l,2-b]pyridazine (III.4o) (27%), m.p. 257-259° 
after t.l.c. (alumina; chloroform) and recrystallisation 
from toluene. (Found: C, 60.8; H, 3.8; N, 14.2.
c20h 14c 12n4° requires C, 60.5; H, 3.6; N, 14.1%).
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6-Chloro-2-phenyl-3-(2'-toluamidomethyl)imidazo- 
[1,2-b]pyridazine (Ill.4p) (36%), m.p. 249-251° after 
t.l.c. (alumina; chloroform, light petroleum, 2:1) and 
recrystallisation from toluene. (Found, for a sample 
dried at 60°/0.1 mmHg for 40 h: C, 66.8; H, 4.7; N,
14.7. C2 ]_H]_7C1N40 requires C, 66.9; H, 4.5; N, 14.9%).
6-Chloro-2-phenyl-3-(3'-toluamidomethyl)imidazo- 
[1/2-b]pyridazine (III.4q) (32%), m.p. 204-206° after 
t.l.c. (alumina; chloroform, light petroleum, 3:1) and 
recrystallisation from toluene. (Found: C, 67.3; H,
4.4; N, 14.8. C2]_H]_7C1N40 requires C, 66.9; H, 4.5; N,
14.9%) .
6-Chloro-2-phenyl-3-(4'-toluamidomethyl)imidazo- 
[l,2-b]pyridazine (III.4r) (53%), m.p. 237-239° after 
t.l.c. (alumina; chloroform, light petroleum, 2:1) and 
recrystallisation from toluene. (Found: C, 67.2; H,
4.5; N, 14.8. C21H17C1N40 requires C, 66.9; H, 4.5; N,
14.9%) .
6-Chloro-3-(4'-methoxybenzamidomethyl)-2-phenyl- 
imidazo[l,2-b]pyridazine (III.4s) (9%), m.p. 227-228°
after t.l.c. (alumina; chloroform, light petroleum, 2:1) 
and recrystallisation from toluene. (Found, for a sample 
dried at 110°/710 mmHg for 2 h: C, 64.3 ; H, 4.4; N,
14.0. C21H17C1N402 requires C, 64.2; H, 4.4; N, 14.3%).
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3-(2'-Aminobenzamidomethyl)-6-chloro-2-phenylimidazo- 
[1,2-b]pyridazine (III.4t)
6-Chlor0-3-(2'-nitrobenzamidomethy1)-2- 
phenylimidazo[ 1,2 - J b ]pyridazine (0.056 g) in ethanol 
(20 ml) with Raney nickel was shaken with hydrogen at 
room temperature and pressure until uptake ceased. The 
catalyst was filtered on kieselguhr and the solvent 
evaporated. The product was recrystallised from toluene 
to give the title compound (0.040 g) (77%), m.p. 210- 
212°. (Found, for a sample dried at 100°/710 mmHg for 
14 h: C, 64.3; H, 4.4; N, 18.2. C20H16C1N5° requires C,
63.6; H, 4.3; N, 18.5%).
3-(3'-Aminobenzamidomethyl)-6-chloro-2-phenylimidazo- 
[1,2-b]pyridazine (III.4u)
6-Chloro-3-(3'-nitrobenzamidomethyl)-2- 
pheny limidazo [ 1,2 — Jb ] pyridazine (0.073 g) in ethanol 
(20 ml) with Raney nickel was shaken with hydrogen at 
room temperature and pressure until uptake ceased. The 
catalyst was filtered off on celite and the solvent 
evaporated. The product was recrystallised from toluene 
to give yellow crystals of the title compound (0.035 g, 
52%), m.p. 211-213°. (Found: C, 64.0; H, 4.3; N, 18.4.
c20h 16c 1n5° requires C, 63.6; H, 4.3; N, 18.5%).
3-(4'-Aminobenzamidomethyl)-6-chloro-2-phenylimidazo- 
[1,2-b]-pyridazine (III.4V) (18%), m.p. 279-281° after 
recrystallisation from ethanol. (Found, for a sample
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dried at 100°/710 mmHg for 10 h: C, 63.4; H, 4.4; N,
18.4. C2oh 16c-*-n5° requires C, 63.6; H, 4.3; N, 18.5%).
6-Chloro-3-(3'-dimethylaminobenzamidomethyl)-2-phenyl- 
imidazo[1,2-b]pyridazine (III.4m) (21%), m.p. 185-187°
after t.l.c. (alumina; chloroform) and recrystallisation 
from a mixture of benzene and cyclohexane. (Found, for a 
sample dried at 110°/0.1 mmHg for 4 h: C, 64.8; H, 5.0;
N, 17.1. C22H20C1N5° requires C, 65.1; H, 5.0; N,
17.3%) .
3-(3'-Aminobenzamidomethyl)-6-chloro-2-(4''-tolyl)- 
imidazo[1,2-b]pyridazine (III.4e) (70%), m.p. 206-208° 
after t.l.c. (alumina; chloroform) and recrystallisation 
from toluene. (Found, for a sample dried at 
105°/710 mmHg for 24 h: C, 66.6; H, 5.1; N, 16.3.
C21H18CIN5O. 0.4 C7H8 requires C, 66.7; H, 5.0; N,
16.3%) .
6-Chloro-3-(nicotinamidomethyl)-2-(4'-tolyl)imidazo- 
[1,2-b]pyridazine (III.4f) (7%) was prepared in a similar 
manner from 6-chloro-2-(4'-tolyl)imidazo[1,2-b]pyridazine 
and N-(hydroxymethyl)nicotinamide.242 It was purified by 
t.l.c. (alumina; chloroform) and recrystallised from 
toluene to give light yellow crystals, m.p. 212-214° 
(Found: C, 63.6; H, 4.4; N, 18.5. C20H16C1N5° requires
C, 63.6; H, 4.3; N, 18.5%).
CHAPTER IV
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CHAPTER IV Syntheses and binding studies of some 
6-(N-benzy1-N-methylamino) and 6-(substituted benzylamino)- 
3-methoxy (and unsubstituted)-2-arylimidazo[1,2-b]- 
pyridazines
IV-1 Introduction
Some 6-benzylamino [and 6-(methoxybenzylamino)]-3 - 
methoxy-2-phenyl (substituted phenyl and pyridinyl)imidazo-
i n i[1,2-b]pyridazines have been prepared previously from 6- 
benzylamino [or 6-(methoxybenzylamino)]pyridazin-3-amine 2- 
oxides. Studies on structure-activity relationships of 
some 2-aryl-3-methoxy-6-(various substituted)imidazo 
[1,2-b]-pyridazines indicated that the 6-(methoxybenzy1- 
amino) compounds were in general more effective in the 
displacement of [3H]diazepam than imidazo[1,2-b]- 
pyridazines with other substituents at the 6-position.
In the work described in this chapter the study has 
been extended to 2-aryl-3-methoxy-6-(3'-methoxy-, 3',4'- 
dimethoxy-, 3',4'-methylenedioxy- and 2'- and 4'- 
chlorobenzylamino)imidazo[1,2-b]pyridazines to examine the 
electronic (and other) effects of substituents in both the 
benzylamino group and the 2-aryl group; and also to the 6- 
(N-benzy1-N-methylamino)-3-methoxy-2-phenyl (substituted 
phenyl or pyridinyl)imidazo[1,2-b]pyridazines to examine 
the steric and electronic effects of N-methylation and of 
substitution in the 2-aryl group. The results from this
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study have been compared with binding activities exhibited
by derivatives of 3-methoxy-6-(methoxybenzyl-
amino)imidazo[l,2-b]pyridazines reported previously.121
In addition, the syntheses and binding affinity of 6- 
( 3 ' , 4 '-methylenedioxybenzylamino)-2-(3 ", 4"-methyl- 
enedioxyphenyl) imidazo[ 1,2-jb]pyridazine and of some 3- 
alkoxy-6-(3'-methoxybenzylamino)-2-phenylimidazo[1,2-b]- 
pyridazines have been investigated.
IV-2 Syntheses
The intermediate required for the synthesis of the 
title compounds in this chapter was 6-chloropyridazin-3 - 
amine 2-oxide which was more reactive towards nucleophilic 
substitution than the 6-chloropyridazin-3-amine.121 In 
1989, Barlin and coworkers reported the preparation of 
6-benzylamino(and methoxybenzylamino)-3-methoxy-2-ary1- 
imidazo[1,2-b]pyridazines from 6-chloropyridazin-3-amine 2- 
oxide (IV.1). Replacement of the 6-chloro substituent in 
compound (IV.1) by the relevant benzylamine gave the 
intermediate 6-benzylaminopyridazin-3-amine 2-oxide which 
when heated with a-bromoacetyl compounds such as a- 
bromoacetophenone in ethanol gave the corresponding 2- 
phenylimidazo[1,2-b]pyridazin-3-ols (such as IV.3). These 
compounds were treated directly with diazomethane and gave 
the corresponding 3-methoxy compounds.
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Scheme IV-1
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IV-2.1 Syntheses of some 6-(N-benzyl-N-methylamino)-3- 
methoxy-2-arylimidazo[1,2-b]pyridazines
6-Chloropyridazin-3-amine 2-oxide was found to react 
with excess N-benzyl-N-methylamine in a sealed reaction 
vessel at 170°C for 16 h to give 6-(N-benzy1-N-methy1- 
araino)pyridazin-3-amine 2-oxide (IV.2) in 50% yield. The 
latter, when heated with a-bromoacetyl compounds such as a- 
bromoacetophenone in ethanol, gave the 6-(N-benzy1-N- 
methylamino)-2-phenylimidazo[1,2-b]pyridazin-3-ols (IV.3). 
Compounds (IV.3) were methylated directly with diazomethane 
and gave corresponding methoxy derivatives (IV.4) in 3-58% 
yield.
The 2-(pyridinyl) compound [IV.4r and s] were prepared 
in low yield by an analogous method.
The nitro compounds (IV.4b and c) were reduced by iron 
powder in aqueous methanolic hydrochloric acid to the 
corresponding amino compounds (IV.4p and q).
IV-2.2 Syntheses of some 6-(substituted benzylamino)-3- 
methoxy-2-(substituted phenyl and pyridinyl)imidazo- 
[1,2-b]pyridazines
The general method for the synthesis of the compounds
1 0  1(IV.5) was described by Barlin and coworkers. *x In an 
analogous manner, 6-chloropyridazin-3-amine 2-oxide was 
heated at 142-145°C for 12-40 h with 2-chlorobenzylamine, 
4-chlorobenzylamine and 3,4-methylenedioxybenzylamine, 
respectively, to give compounds (IV.5). These compounds 
(IV.5), with a-bromoacetyl compounds (as above), underwent 
cyclisation to give the hydroxy compounds (IV.6) which were
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Scheme IV-2
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subsequently methylated with diazomothane to give the 
methoxy compounds (IV.7a-p).
6-(3'-Methoxybenzylamino)-3-(3"-methoxybenzyloxy)-2- 
phenylimidazo[ 1,2-jb]pyridazine (IV.8e) was also prepared 
from 6-(3'-methoxybenzylamino)-2-phenylimidazo[1,2-b]- 
pyridazin-3-ol by heating with 3-methoxybenzyl chloride in 
dimethylformamide at 100°.
IV-2.3 Synthesis of 6-(3',4'-methylenedioxybenzylamino)-2- 
(3",4"-methylenedioxyphenyl)imidazo[l,2-b]pyridazine
6-(Benzylamino)pyridazin-3-amine 2-oxides have 
generally been prepared from 6-chloropyridazin-3-amine 2- 
oxides and the appropriate benzylamine by heating at 160° 
for 16-20 h.121 However, when 6-chloropyridazin-3-amine 2- 
oxide was heated with excess 3,4-methylenedioxybenzylamine 
at 160° for 14 h it gave, as an oil, 6-(3',4'- 
methylenedioxybenzylamino)pyridazin-3-amine (IV.9) by 
replacement of the 6-chloro substituent and removal of the 
N-oxide group, perhaps by intermolecular N-oxidation. This 
product with a-bromo-3,4-methylenedioxyacetophenone gave 6- 
(3',4'-methylenedioxybenzylamino)-2-(3",4"- 
methylenedioxyphenyl)imidazo[1,2-b]pyridazine (IV.10) as 
the hydrobromide.
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IV-3 1H n.m.r. spectra
The 1H n.m.r. spectral data of some 2-aryl-6-(W- 
benzyl-N-methylamino)-3-methoxyimidazo[1,2-b]pyridazines 
(IV.4) and 2-ary1-3-methoxy-6-(substituted benzylamino)- 
imidazo[1,2-b]pyridazines (IV.7) are reported in Tables 
IV-1 and IV-2, respectively, and may be compared with those 
for some 2-aryl-3-methoxy-6-(methoxybenzylamino)imidazo­
le 1 , 2-b ] pyridaz ines reported121 previously. The signal due 
to the 3-methoxy group in compounds (IV.4 and IV.7) 
appeared in the range 64.00-4.15 except for the 2-(2'- 
tolyl) compound (IV.4k, 63.92) and the 2-(2'-chloropheny1) 
compound (IV.7b, 63.98). Generally downfield shifts were 
observed in this signal with increased electron-withdrawing 
power of the substituent in the 2-aryl group (with due 
allowance for positional effects). This is probably due to 
extended conjugation to the C2-C3 double bond.
The chemical shifts for the protons of the N-methyl 
group of compounds (IV.4) occurred in the range 63.13-3.22, 
and the signals for protons of the benzylic methylene group 
in compounds (IV.4) are sharp singlets in the range 64.69- 
4.78. However, those of the benzylic methylene group in 
compounds (IV.7) generally appeared as a doublet with a 
chemical shift in the range 64.50-4.58, except for the 6- 
(2'-chlorobenzylamino) compounds (IV.7i-m) in which the 
signal was in the range 64.70-4.72 possibly due to steric 
effects. The protons of the methylene group in compounds 
(IV.4) were more deshielded than those in compounds (IV.7), 
and the doublet given by compounds (IV.7) collapsed to a
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Table IV-1 Some 1H n.m.r. spectral dataA for 2-aryl-6-(N- 
benzyl-N-methylamino)-3-methoxy imidazo[l,2-b]pyridazines
IV. 4 NMe 3-OMe c h 2 H7 H8
a 3 . 18 4.07 4.74 6.66 7.60
b 3.22 4.15 4.78 6.75 7.65
c 3.22 4.14 4.78 6.78 7.67
d 3.14 4.06 4.71 6.65 7.60
e 3 . 16 4.08 4.72 6.66 7.57
f 3.16 4.06 4.73 6.65 7.57
g 3.18 4.01 4.75 6.68 7.61
h 3 . 19 4.07 4.76 6.69 7.60
i 3.20 4.10 4.76 6.71 7.61
j 3.22 4.11 4.78 6.78 7.73
k 3.18 3.92 4.75 6.67 7.60
1 3 . 18 4.07 4.74 6.66 7.61
m 3 . 13 4.04 4.69 6.60 7.55
n 3 . 17 4.06 4.74 6.64 7.58
0 3 . 16 4.05 4.73 6.64 7.56
P 3 . 15 4.05 4.72 6.63 7.58
3.17 4.05 4.75 6.65 7.62
3.21 4.11 4.77 6.72 7.62
sc 3.20 4.14 4.76 6.75 7.60
A Reported as parts per million (6 downfield from
tetramethylsilane as internal standard in
deuterochloroform
BPyridin-2-yl group (not substituted phenyl) 
c*Pyridin-3-yl group (not substituted phenyl)
singlet on addition of deuterium oxide thus confirming 
coupling between the benzylic methylene and the amino 
proton in compounds (IV.7). In general, the amino proton 
in compounds (IV.7) appeared as a broad triplet, with a 
chemical shift of 64.65-5.24.
The protons on C-7 and C-8 of the compounds (IV.4 and 
IV.7) appeared as an AB quartet with a coupling constant of 
J7 fQ 9.5 Hz. The chemical shifts of these protons in 
compounds (IV.4) are in the range 56.60-6.78 and 7.55-7.67 
and in compounds (IV.7) the signals for H7 and H8 were in
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the range 66.20-6.47 and 7.49-7.64, respectively. The 
signal due to H-7 in compounds (IV.4) was downfield of that 
in compounds (IV.7). The downfield shift of H-7 in 
compounds (IV.4) is probably due to decreased conjugation 
of the lone pair on nitrogen across the pyridazine ring due 
to the steric effects in the N-methyl compounds.
The aromatic protons of the phenyl substituents on C-2 
and C-6 of the imidazo[1,2-b]pyridazine ring usually 
appeared complex. However, the assignments for these 
protons in para-substituted phenyl groups at the 2-position 
in the compounds (IV.4) were readily carried out.
Table IV-2 Some 1H n.m.r. spectral dataA for 2-aryl-3- 
methoxy-6-(substituted benzylamino)imidazo[1,2-b]- 
pyridazines
IV. 7 3-OMe c h 2b NHC H7 H8
a 4.04 4.58 4.73 6.36 7.55
b 3.98 4.58 4.88 6.20 7.58
c 4.08 4.58 5.03 6.47 7.64
d 4.04 4.56 4.91 6.39 7.52
e 4.04 4.57 4.86 6.43 D
f 4.08 4.55 - 6.37 7.58
g 4.08 4.55 - 6.36 7.56h 4.07 4.50 4.65 6.36 7.54
i 4.05 4.70 4.83 6.40 7.60
j 4.05 4.70 4.92 6.42 7.57k 4.10 4.70 5.24 6.47 7.53
1 4.13 4.72 5.01 6.47 7.57_Em 4.08 4.72 5.11 6.44 7.56
n 4.01 4.53 5.09 6.36 7.49
o 4.00 4.56 4.91 6.36 7.52
P 4.00 4.57 4.80 6.36 7.53
AReported as parts per million (6) downfield from
tetramethylsilane as internal standard in 
deuterochloroform
BDoublet DH8 complex
cBroad triplet EPyridin-3-yl
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IV-4 In vitro binding studies
The binding studies on the compounds prepared in this 
chapter were carried out using the [3H]diazepam binding 
assay as outlined in Chapter II-5.3.
IV-4.1 Results of [3H]diazepam assay
The results for the in vitro displacement studies by 
the compounds (IV.4 and IV.7) are shown in Table IV-3 as 
IC50 values (or per cent displacement) at the concentration 
specified in the presence of 100 /jM 7-aminobutyric acid 
(GABA).
IV-4.2 Discussion of results
The results are recorded (in Table IV-3) from 
investigations of the displacement of [3H]diazepam from rat 
brain membranes by the 6-(N-benzyl-N-methylamino)- 
imidazo[1,2-b]pyridazines (IV.4a-s), the 6-(substituted 
benzylamino)imidazo[1,2-b]pyridazines (IV.7a-p) and 6- 
(3',4'-methylenedioxybenzylamino)-2-(3",4"- 
methylenedioxyphenyl)imidazo[l,2-b]pyridazine (IV.10) 
prepared in this chapter.
Data for some 6-(benzylamino and methoxybenzylamino)-
19 13-alkoxy-2-phenylimidazo[1,2-b]pyridazines reported 
previously are also given in Table IV-3 for comparison.
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Table IV-3 Results for the displacement of [3H]diazepam 
from its specific binding sites in rat brain preparation by 
some 6-(N-benzyl-N-methylamino) and 6-(substituted benzyl- 
amino) imidazo [ 1, 2-b]pyridazines and some reference 
compounds
Formula Substituted
number imidazo[1,2-b]pyridazine
IC50 (nM)A 
(or % 
displ.)B
6-NHCH2Ph-3-OMe-2-Ph 9C
IV. 4a 6-NMeCH2Ph-3-0Me-2-Ph 18.9
b 6-NMeCH2Ph-3-OMe-2-C6H4N02-m 166
c 6-NMeCH2Ph-3-OMe-2-C6H4N02-p >>300
d 6-NMeCH2Ph-3-OMe-2-C6H4F-o 9.8
e 6-NMeCH2Ph-3-OMe-2-C6H4F-m 20.7
f 6-NMeCH2Ph-3-OMe-2-C6H4F-p 33
g 6-NMeCH2Ph-3-OMe-2-C6H4Cl-o (74%)h 6-NMeCH2Ph-3-OMe-2-C6H4Cl-p 329
i 6-NMeCH2Ph-3-OMe-2-C6H4CF3-m 683
j 6-NMeCH2Ph-3-OMe-2-C6H4CF3-p (30%)
k 6-NMeCH2Ph-3-OMe-2-C6H4Me-o (57%)
1 6-NMeCH2Ph-3-OMe-2-C6H4Me-m 111
m 6-NMeCH2Ph-3-OMe-2-C6H4Me-p 266
n 6-NMeCH2Ph-3-OMe-2-C6H4OMe-p 152
o 6-NMeCH2Ph-3-OMe-2-C6H3(3',4'-OCH20-) 46
P 6-NMeCH2Ph-3-OMe-2-C6H4NH2-m 11.3
q 6-NMeCH2Ph-3-OMe-2-C6H4NH2-p 187
r 6-NMeCH2Ph-3-OMe-2-C5H4N-0 69
s 6-NMeCH2Ph-3-OMe-2-C6H4N-7 (15.8%)
IV.7a 6-NHCH2C6H4OMe-m-3-OMe-2-C6H4OMe-p 8
b 6-NHCH2C6H4OMe-m-3-OMe-2-C6H4Cl-o 37
c 6-NHCH2C6H4OMe-m-3-OMe-2-C6H4Cl-m 17
d 6-NHCH2C6H4OMe-m-3-OMe-2-C6H4Cl-p 9
e 6-NHCH2C6H4OMe-m-3-OMe-2-C6H3(3",4"-0CH20--) 1.5
f 6-NHCH2C6H3(OMe)2”3',4'-3-OMe-2-C6H4Me-p 5
g 6-NHCH2C6H3(OMe)2-3'/4'-3-OMe-2-C6H3-( 3",4"-OCH20-) 2
h 6-NHCH2C6H3(3',4'-OCH20-)-3-OMe-2-C6H3-
(3" , 4"-OCH20-) 1
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Table IV-3 Continued
Formula Substituted IC50 (nM)A
number imidazo[1,2-b]pyridazine (or %
displ.)B
i 6-NHCH2C6H4Cl-o-3-OMe-2-C6H4Me-p 120
j 6-NHCH2C6H4Cl-o-3-OMe-2-C6H4Cl-p 114
k 6-NHCH2C6H4Cl-o-3-OMe-2-C6H4N02-m 1121 6-NHCH2C6H4Cl-o-3-0Me-2-C6H4N02-p (25%)Um 6-NHCH2C6H4Cl-o-3-OMe-2-C6H4N-| 20
n 6-NHCH2C6H4Cl-p-3-OMe-2-Ph
0 6-NHCH2C6H4Cl-p-3-OMe-2-C6H4Me-p 38
P 6-NHCH2C6H4Cl-p-3-OMe-2-C6H3 (3M,4"-OCH20-) 10
IV. 10 6-NHCH2C6H3 (3' ,4'-OCH2 0-)-3-H-2-C6H3-
(3",4"-OCH20-) 8
IV. 8a 6-NHCH2C6H4OMe-m-3-OMe-2-Ph 2.9C
b 6-NHCH2C6H4OMe-m-3-OEt-2-Ph 5E
c 6-NHCH2C6H4OMe-m-3-OPr-2-Ph 120l *
d 6-NHCH2C6H4OMe-m-3-OCH2Ph-2-Ph (8%) E
e 6-NHCH2C6H4OMe-m-3-OCH2C6H4OMe-m-2-Ph (0%)
a IC5q values are the concentrations required to displace 
50% of specific [3H]diazepam binding to rat brain 
membrane preparations 
BAt 1000 nM unless specified otherwise 
cRef. 121
°At 30 nMPKindly prepared by Mr S.J. Ireland
i Discussion of binding results for the 2-aryl-6-(N-
benzyl-N-methylamino)-3-methoxyimidazo[1,2-b]pyridazines
An examination of the results for the 6- (N-benzy 1-iV- 
methylamino)imidazo[1,2-b]pyridazines reveals that 6-(N- 
benzyl-N-methylamino)-3-methoxy-2-phenylimidazo[1,2-b]- 
pyridazine (IV.4a; IC50 18.9 nM) was ca half as active as 
its N-demethyl analogue, 6-benzylamino-3-methoxy-2-pheny1- 
imidazo[l,2-b]pyridazine (IC5Q 9 nM).121 The lower potency 
for the 6- (N-benzy1-N-methylamino) derivative may be due to
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the steric hindrance by the W-methyl substituent which 
limits interaction of the compound (IV.4a) with the 
benzodiazepine receptor relative to the corresponding 6- 
benzylamino analogue; or it may indicate that the N-H group 
of the 6-benzylamino compounds interacts with the receptor, 
for example by forming hydrogen bonds. In both of these 
circumstances the 6-benzylamino compounds would be expected 
to bind more strongly than their N-methyl derivatives. 
However, it should be noted that 3-methoxy-6-phenethy1- 
amino-2-phenylimidazo[1,2-b]pyridazine121 (IC50 800 nM) 
binds much less strongly than its N-methyl derivative.
The effects of substitution in the 2-phenyl 
substituent of 6-(N-benzyl-N-methylamino)-3-methoxy-2- 
phenylimidazo[1,2-b]pyridazine (IV.4a; IC50 18.9 nM) with 
electron-donating or electron-withdrawing groups have been 
examined. Strong electron-withdrawing groups such as para- 
nitro (Opara = 0.78) and para-trifluoromethy1 decreased 
binding activity. For example, a comparison of 6-(N- 
benzyl-N-methylamino)-3-methoxy-2-(4'-nitropheny1)imidazo- 
[1,2-b]pyridazine (IV.4c; IC50 >>300 nM) with the parent 
compound (IV.4a; IC5 0  18.9 nM) reveals that the para-nitro 
compound is significantly less active. This effect is 
greater than in 6-(3'-methoxybenzylamino)-3-methoxy-2- 
phenylimidazo[1,2-b]pyridazine (IV.8 a; IC50 2.9 nM) and its
1para-nitro derivative, 6-(3'-methoxybenzylamino)-3 -
methoxy-2-(4"-nitrophenyl)imidazo[1,2-b]pyridazine (IC50 13 
nM), but less than in 6-(2'-methoxybenzylamino)-3-methoxy- 
2-phenylimidazo[1,2-b]pyridazine (IC50 1.8 nM)121 and its
1 p 1para-nitro derivative (20.6% displacement at 10 nM).
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The receptor site appears to tolerate the small 
electron-withdrawing fluoro substituent at 2'-position in 
the 2-phenyl ring. For example, the effect of a fluoro 
substituent in the 6-(N-benzyl-N-methylamino)-2-(2'-,3'- 
and 4 ' -f luoropheny 1) -3-methoxyimidazo [ 1,2-jb] pyridaz ines 
(IV.4d-f; IC50 values 9.8, 20.7 and 33 nM, respectively) 
was to increase activity in the 2-(2'-fluorophenyl) 
compound relative to the parent 2-phenyl compound (IV.4a; 
IC50 18.9 nM) but to decrease activity slightly in the 2- 
(3'- and 4'-fluorophenyl) isomers. In a comparison of the 
6-(3'-methoxybenzylamino)-3-methoxy-2-(2"-,3"- and 4"- 
fluorophenyl)imidazo[1,2-b]pyridazines121 with their parent 
compounds, the 2"- and 4"-fluoro-substituents enhanced 
activity by ca two-fold but the 3M-fluoro-substituent
i n idecreased activity by ca five-fold. The 2-(4'-
fluorophenyl) compound (IV.4f; IC50 33 nM) bound more 
strongly than the 2-(4'-chlorophenyl) analogue (IV.4h, IC5Q 
329 nM).
The 2'- and 4'-chloro substituent in compounds (IV.4g,
74% displacement at 1000 nM; and IV.4h, IC50 329 nM)
decreased binding significantly relative to the 2-phenyl
compound (IV.4a; IC50 18.9 nM). A similar situation
prevailed with 2-(4'-chlorophenyl)-3-methoxy-6-(2'-
methoxybenzylamino)imidazo[1,2-b]pyridazine (IC50 16 nM)
19 1relative to its 2-phenyl analogue (IC50 1.8 nM), and 
likewise the 3'- and 4'-trifluoromethyl compounds (IV.4i; 
IC50 683 nM and IV.4j; 30% displacement at 1000 nM 
respectively) exerted considerable deactivating effects
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which were greater than in the 6-(3'-methoxybenzylamino) 
compounds (IC50 values 55 and 24 nM).121
Electron-donating groups present in the 2-phenyl 
substituent of 6-(N-benzyl-N-methylamino)-3-methoxy-2-(2'- 
3'- and 4'-tolyl), 2-(4'-methoxyphenyl) and 2-(3',4'- 
methylenedioxyphenyl)imidazo[1,2-b]pyridazines (IV.4k-o) 
decreased binding ability relative to the 2-(unsubstituted 
phenyl) compound (IV.4a), but the 3',4'-methylenedioxy 
group in compound (IV.4o; IC50 46 nM) was less deactivating 
than a 4'-methyl or 4'-methoxy group as in compound (IV.4m; 
IC50 266 nM or IV.4n; IC50 152 nM).
2-(3'-Aminophenyl)-6-(N-benzyl-N-methylamino)-3- 
methoxyimidazo[1,2-b]pyridazine (IV.4p; IC50 11.3 nM) was 
ca twice as active as the parent 2-phenyl analogue (IV.4a; 
IC50 18.9 nM) but in the 2-(4'-aminophenyl) isomer (IV.4q; 
IC50 187 nM) , the binding ability was decreased ten-fold. 
However, the 6-(3'-methoxybenzylamino)-3-methoxy-2-(3"- and 
4"-aminophenyl) imidazo[l, 2-jb]pyridazines (IC50 values 1.8 
and 1.0 nM respectively) were both more active than the 2- 
(unsubstituted phenyl) analogue (IC50 2.9 nM).121
The 2 — (3'— and 4'-aminophenyl) compounds (IV.4p; IC50 
11.3 nM and IV.4q; IC50 187 nM) were significantly more 
active than the corresponding nitro compounds (IV.4b; IC50 
166 nM and IV.4c; IC50 »300 nM).
Replacement of the 2-phenyl group of 6-(N-benzyl-N- 
methylamino)-3-methoxy-2-phenylimidazo[1,2-b]pyridazine 
(IV.4a) with a pyridin-3-yl or pyridin-4-yl group resulted 
in a reduction in binding potency [as with the 2-(3'- and
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4'-nitro or 3'- and 4'-trifluoromethyl) analogues] and 
these compounds (IV.4r; IC50 69 nM and IV.4s; 15.8% 
displacement at 1000 nM) were less active than the 2-(3'- 
and 4'-aminophenyl) analogues (IV.4p; IC50 11.3 nM and 
IV.4q; IC50 187 nM), respectively. In the 6-(2'- and 3'- 
methoxybenzylamino)-3-methoxy-2-[pyridin-3"-(and 4"-)yl] 
imidazo[1,2-b]pyridazines121 the 2-(pyridin-3n-yl) 
compounds (IC50 values 3 and 2.1 nM, respectively) had 
approximately the same activity as the 2-phenyl analogues 
(IC50 values 1.8 and 2.9 nM, respectively) but the 3- 
methoxy-6-(3'-methoxybenzylamino)-2-(pyridin-4"-yl) 
compound (GBLD 258; IC50 5.8 nM) was less active.121
In the series of 6-(N-benzyl-N-methylamino) compounds 
reported here it was found that the effect of para- 
substituents in the 2-phenyl group was a lower binding 
affinity for benzodazepine receptors than that for the 
corresponding meta-substituted isomers.
ii Discussion of binding results for the 3-(alkoxy and 
unsubstituted)-2-aryl-6-(substituted benzylamino)- 
imidazo[l,2-b]pyridazines
The effect of substitution by methoxy groups in the 6- 
benzylamino substituent of 2-aryl-6-benzylamino-3-methoxy- 
imidazo[1,2-b]pyridazines has been investigated 
previously121 and we have now examined the effect of some 
substituents in the 2-aryl group. The activity of 3- 
methoxy-6-(3'-methoxybenzylamino)-2-(4"-methoxyphenyl)- 
imidazo[1,2-b]pyridazine (IV.7a; IC50 8 nM) was ca half 
that of 3-methoxy-6-(3'-methoxybenzylamino)-2-phenyl-
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imidazo[1,2-6]pyridazine (IV.8a; IC50 2.9 nM).121 A 
similar situation existed with the 6-benzylthio164 (and 6- 
benzyloxy) -3-methoxy-2-phenylimidazo[ 1,2-b]pyridazines
and their 2-(4'-methoxyphenyl) analogues, but in the 6-(3'- 
methoxybenzylthio) analogues165 the 2-phenyl and 2-(4'- 
methoxyphenyl) compounds (GBLD 190 and GBLD 205) both had 
IC50 11 nM. A comparison of 2-(4'-methoxyphenyl) with 2- 
(4'-tolyl) groups revealed that compound (IV.7a; IC50 8 nM) 
was ca 2.5 fold less active than 3-methoxy-6-(3'- 
methoxybenzylamino)-2-(4"-tolyl)imidazo[1,2-b]pyridazine 
(GBLD 308; IC50 3.2 nM)121 whereas in the 6-(N-benzyl-iV- 
methylamino) compounds described above, compound (IV.4n;
IC50 152 nM) was twice as active as its 2-(4'-tolyl) 
analogue (IV.4m; IC50 266).
An examination of the activity of the 2-(chloropheny1) 
compounds (IV.7b,c,d; IC50 values 37, 17 and 9 nM,
respectively), revealed the 2-(4'-chloropheny1) isomer to 
be the more active [as with the 6-(benzylthio)-2-(2'- and 
4'-chlorophenyl)-3-methoxyimidazo[1,2-b]pyridazines164 
(GBLD 148 and 147; IC50 values 198 and 48 nM, 
respectively)].
The 6-(3'-methoxybenzylamino) compound (IV.7d; IC50 
9 nM) was also more active than 2-(4'-chlorophenyl)-3- 
methoxy-6-(2'-methoxybenzylamino)imidazo[1,2-b]pyridazine 
(GBLD 309; IC50 16 nM).121
The results for the chloro compounds differ from those 
for the fluoro analogues, 2-(2'-,3'- and 4'-fluoropheny1)- 
3-methoxy-6-(3"-methoxybenzylamino)imidazo[1,2-b]- 
pyridazines (GBLD 283, 216 and 274; IC50 values 1.5, 15 and
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1.5 nM respectively), in which the 2'- and 4'-fluoro 
isomers were equally active. In all cases the 2- 
(chlorophenyl) compounds were significantly less active 
than the 2-(fluorophenyl) analogues. Amongst the 6-[N- 
benzyl-N-methylamino)-3-methoxy-2-(2'-,3'- and 4'- 
fluorophenyl)imidazo[1,2-b]pyridazines (IV.4d-f; IC50 
values 9.8, 20.7 and 33 nM, respectively), the 2-(2'- 
fluorophenyl) isomer was the most active. The 3', 4'- 
methylenedioxy group in the aromatic substituent at the 2- 
position has been observed previously122 to engender 
significant activation. Similarly 3-methoxy-6-(3'- 
methoxybenzylamino)-2-(3",4"-methylenedioxyphenyl)- 
imidazo[1,2-b]pyridazine (IV.7e; IC50 1.5 nM) was found to 
be ca twice as active as its 2-phenyl or 2-(4'-tolyl) 
analogues (GBLD 231 and 308; IC50 values 2.9 and 3.2 nM)121 
and it was ca five-fold more active than its 2 — (4' — 
methoxyphenyl) analogue (IV.7a). A similar situation 
exists in the corresponding 6-(2 '-methoxyphenyl) 
compounds but its effect was slightly greater in the 
foregoing example. However, in the 6-(N-benzy1-N- 
methylamino) compounds (IV.4a, m-o; IC50 values 18.9, 266, 
152 and 46 nM, respectively), the effect of inserting a 4'- 
methyl, 4'-methoxy, or 3',4'-methylenedioxy group in the 2- 
phenyl substituent was deactivating.
In the 6 - (3',4'-dimethoxybenzylamino)-3-methoxy-2- 
(substituted phenyl) imidazo[ 1,2-jb] pyridazines , a 2-(4"- 
tolyl)substituent as in compound (IV.7f; IC50 5 nM) was 
deactivating relative to its 2-phenyl analogue (GBLD 253; 
IC50 3.4 nM); a similar situation applied between 3-
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methoxy-6-(3'-methoxybenzylamino)-2-phenylimidazo[1,2-b]- 
pyridazine and its 2-(4"-tolyl) analogue.121 The activity 
of 6- (3 ' ,4'-dimethoxybenzylamino)-3-methoxy-2-(3",4M- 
methylenedioxyphenyl)imidazo[l,2-b]pyridazine (IV.7g; IC50 
2 nM) was found to be greater than that of the 2-(4'-tolyl) 
analogue (IV.7f; IC50 5 nM).
Comparison of the 6-(3',4'-dimethoxybenzylamino) 
substituent in compound (IV.7g; IC50 2 nM) with a 6-(3',4'- 
methylenedioxybenzylamino) group in compound (IV.7h; IC50
1 nM) revealed that the methylenedioxy compound bound more 
strongly.
Whereas the effect of an electron-donating methoxy 
group in 6-(2'- or 3'-methoxybenzylamino) compounds 
increased binding ability,121 an electron-withdrawing 
chloro substituent in the 6-(2'- or 4'-chlorobenzylamino) 
analogues (IV.7) was to decrease binding ability. 6-(4'- 
Chlorobenzylamino)-3-methoxy-2-(4M-tolyl)imidazo- 
[ 1,2-jb]pyridazine (IV.7o; IC50 38 nM) was more active than 
the 6-(2'-chlorobenzylamino) isomer (IV.7i; IC5q 120 nM) by 
ca three-fold. In the 6-(4'-chlorobenzylamino) compounds 
(IV.7o and p; IC50 values 38 and 10 nM respectively), 6- 
(4'-chlorobenzylamino)-3-methoxy-2-(3",4"-methyl- 
enedioxyphenyl) imidazo[ 1,2-jb]pyridazine (IV. 7p) bound more 
strongly by ca four-fold. There was little difference in 
the activity of the 2-(4'-tolyl), 2-(4'-chlorophenyl) and
2 - (3 '-nitropheny1) compounds (IV.7i-k; IC50 values 120, 114 
and 112 nM, respectively), but the 2-(pyridin-3'-y1) 
compound (IV.7m; IC50 20 nM) was significantly more active 
in binding.
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The effect of replacing the 3-methoxy group of 3- 
methoxy-6-(3'-methoxybenzylamino)-2-phenylimidazo[1,2-b]- 
pyridazine121 (IV.8 a; IC5 0 2.9 nM) with other alkoxy 
substituents was also examined. The results of in vitro 
displacement by compounds (IV.8 a-e; IC5Q values 2.9, 5, 120 
nM and 8% and 0% displacements at 1000 nM, respectively) 
showed that stronger binding occurred with the smaller 3- 
methoxy group.
Comparison of 6-(3',4'-methylenedioxybenzylamino)-2 - 
(3",4M-methylenedioxyphenyl)imidazo[1,2-b]pyridazine 
(IV.10; IC5Q 8 nM) with its 3-methoxy analogue (IV.7h; IC5 0  
1 nM) revealed that the 3-unsubstituted compound (IV.10) 
was less active by eight-fold but compound (IV.10) was 
significantly more active than the 3-unsubstituted 
compounds described in Chapter II.
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IV-5 Experimental
The general procedure, and experimental details for 
the [ Hjdiazepam binding assay, are recorded in Chapter 
III-5.3, except that analytical samples were dried at 60- 
90°0/0.1 mmHg for 5-20 h unless otherwise specified.
6-(N-Benzy1-N-methylamino)pyridazin-3-amine 2-oxide (IV.2)
6-Chloropyridazin-3-amine 2-oxide243 (0.4 g) and N- 
benzyl-N-methylamine (4.0 ml) were heated in a screw-top 
Teflon-lined stainless steel reaction vessel at 170° for 
16 h. After cooling the reaction mixture was diluted with 
ether and the ether solution decanted from the thick oil 
which was washed with more ether. The oil was dissolved in 
chloroform and chromatographed over a column of alumina.
It was eluted firstly with chloroform and then with a 
mixture of methanol in chloroform (1:9). The yellow band 
which was eluted in the latter gave a solid which was 
recrystallised from acetone to give yellow crystals of the 
title compound (0.316 g), m.p. 171-172° (Found: C, 62.3;
H, 6.3; N, 24.2. C12H14N40 requires C, 62.6; H, 6.1; N,
24.3%). 1H n.m.r.: S 3.06, s, MeN; 4.64, s, CH2N; 6.52,
d, 7.10, d, J 9 Hz, H 4,5; 7.23, complex, Ph.
6-(N-Benzyl-N-methylamino)-3-methoxy-2-phenylimidazo- 
[l,2-b]pyridazine (IV.4a)
A mixture of 6-(N-benzyl-N-methylamino)pyridazin-3- 
amine 2-oxide (0.189 g), phenacyl bromide (0.205 g) and
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ethanol (9.0 ml) was refluxed with stirring for 4 h. The 
solvent was evaporated and the solid residue stirred with 
an ethereal solution of diazomethane (from 2.5 g 
nitrosomethylurea) at 0° and then at room temperature 
overnight. The mixture was evaporated to dryness and the 
residue subjected to t.l.c. (alumina; chloroform) and the 
product (0.015 g) recrystallised from a mixture of ethanol 
and light petroleum to give the title compound, m.p. 146- 
147° (Found: C, 72.8; H, 6.1; N, 16.1. C21H20N4O
requires C, 73.2; H, 5.9; N, 16.3%). 1H n.m.r.: 5 3.18,
s, MeN; 4.08, s, MeO; 4.74, s, CH2N; 6.72, d, J 9.5 Hz, H 
7; 7.30-8.14, complex, 2 x Ph; 7.65, d, J 9 Hz, H 8.
In a similar manner the following compounds were 
prepared from 6-(N-benzyl-N-methylamino)pyridazin-3-amine 
2-oxide21+3 and a-bromo-2-fluoroacetophenone,165 a-bromo- 
3(and 4)-fluoroacetophenone,121'244 a-bromo-2(and 4)- 
chloroacetophenone,244 a-bromo-3(and 4)-trifluoromethy1- 
acetophenone,165 a-bromo-2(3 and 4)-methylacetophenone 
(prepared from the corresponding methylacetophenones by 
bromination in ether232'245) a-bromo-4-methoxyaceto- 
phenone,244 a-bromo-3,4-methylenedioxyacetophenone,228 
3(and 4)-bromoacetylpyridine (hydrobromides),165 and a-
inibromo-3(and 4)-nitroacetophenone.
6-(N-Benzyl-N-methylamino)-2-(2'-fluorophenyl)-3-methoxy- 
imidazo[l,2-b]pyridazine (IV.4d) (53%),as a thick oil after
t. l.c. (alumina; chloroform, light petroleum, 3:1) (Found: 
C, 68.5; H, 5.4; N, 15.7. C21H19FN4O 0.2 H2O requires C,
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68.7; H, 5.3; N, 15.3%). 1H n.m.r.: 5 3.14, s, MeN; 4.06,
s, MeO; 4.71, s, CH2N; 6.65, d, J 9 Hz, H 7; 7.25-7.83, 
complex, ArH; 7.60, d, J 9 Hz, H 8.
6-(N-Benzyl-N-methylamino)-2-(3 '-fluorophenyl)-3-methoxy- 
imidazo[1,2-b]pyridazine (IV.4e) (46%),as an oil after
t. l.c. (alumina; chloroform, light petroleum, 3:1) (Found:
C, 69.1; H, 5.5; N, 15.7. C21H19FN4° requires C, 69.6; H,
5.3; N, 15.5%). 1H n.m.r.: 6 3.16, s, MeN; 4.08, s, MeO;
4.72, s, CH2N; 6.66, d, J 9 Hz, H 7; 6.96-7.87, complex, H 
2',4',5',6' and Ph; 7.57, d, J 9 Hz, H 8.
6-(N-Benzyl-N-methylamino)-2-(4'-fluorophenyl)-3-methoxy- 
imidazo[l,2-b]pyridazine (IV.4f) (10%), m.p. 108-109° after
t.l.c. (alumina; chloroform, light petroleum, 3:1) and 
recrystallisation from light petroleum (Found: C, 69.9;
H, 5.5; N, 15.6. C21H19FN4° requires C, 69.6; H, 5.3; N,
15.5%). XH n.m.r.: S 3.17, s, MeN; 4.07, s, MeO; 4.73, s,
CH2N; 6.66, d, J 9 Hz, H 7; 7.00-8.14, complex, H 
2',3',5',6' and Ph; 7.57, d, J 9 Hz, H 8.
6-(N-Benzyl-N-methylamino)-2-(2'-chlorophenyl)-3-methoxy- 
imidazo[l,2-b]pyridazine (IV.4g) (49%), after t.l.c.
(alumina; chloroform, light petroleum, 1:2) (Found: C,
66.9; H, 5.3; N, 14.8. C21H19C1N40 requires C, 66.6; H,
5.1; N, 14.8%). XH n.m.r.: 5 3.18, s, MeN; 4.01, s, MeO;
4.75, s, CH2N ; 6.68, d, J 9 Hz, H 7; 7.30-7.60, complex, H 
3',4',5',6' and Ph; 7.61, d, J 9 Hz, H 8.
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6-(N-Benzyl-N-methylamino)-2-(4'-chlorophenyl)-3 - 
methoxyimidazo[1,2-b]pyridazine (IV.4h) (31%), m.p. 115-
117° after t.l.c. (alumina; chloroform, light petroleum, 
1:3) and recrystallisation from light petroleum (Found:
C, 66.9; H, 5.0; N, 14.6. C21H19C1N4° requires C, 66.6; H,
5.1; N, 14.8%). 1H n.m.r.: 6 3.16, s, MeN; 4.31, s, MeO;
4.73, s, CH2N; 6.66, d, J 9 Hz, H 7; 7.29, s, Ph; 7.37, d, 
J2',3' 9 Hz, H2/,6'; 7.57, d, J 9 Hz, H 8; 8.03, d, J 2',3' 
9 Hz, H3',5' .
6-(N-Benzyl-N-methylamino)-3-methoxy-2-(3 '-trifluoro- 
methyl)imidazo[1,2-b]pyridazine (IV.4i) (58%) as an oil
after t.l.c. (alumina; chloroform) (Found: C, 64.2; H,
4.6; N, 14.0. C22H19F3N4° requires C, 64.1; H, 4.6; N,
14.0%). 1H n.m.r.: S 3.20, s, MeN; 4.10, s, MeO; 4.76, s,
CH2N; 6.71, d, J 9 Hz, H 7; 7.31-8.38, complex, H 
2', 4',5',6' and Ph; 7.62, d, J 9 Hz, H 8.
6-(N-Benzyl-N-methylamino)-3-methoxy-2-(4'-trifluoro- 
methylphenyl)imidazo[l,2-b]pyridazine (IV.4j) (18%), m.p.
105-107° after t.l.c. (alumina; chloroform, benzene, 2:1) 
(Found, for a sample dried at 80°/0.1 mmHg for 40 h: C,
64.4; H, 4.7; N, 13.5. C22H19F3N4° requires C, 64.1; H,
4.6; N, 13.6%). 1H n.m.r.: 5 3.22, s, MeN; 4.11, s, MeO;
4.78, s, CH2N; 6.78, d, J 9 Hz, H 7; 7.32, s, 7.74, d, J 9 
Hz, H 8; 7.68, d, Ph; 8.23, d, J 2',3' 9 Hz, H 2',3',5',6'
148
6-(N-Benzyl-N-methylamino)-3-methoxy-2-(2 '- tolyl)imidazo- 
[1,2-b]pyridazine (IV.4k) (38%) after t.l.c. (alumina;
Chloroform, light petroleum, 1:1) (Found: C, 74.0; H,
6.5; N, 15.8. C22H22N4° requires C, 73.7; H, 6.2; N,
15.6%). 1H n.m.r.: 5 2.45, s, Me; 3.19, s, MeN; 3.92, s,
MeO; 4.76, s, CH2N; 6.67, d, J 9 Hz, H 7; 7.30-7.87, 
complex, H 3',4',5',6' and Ph; 7.60, d, J 9 Hz, H 8.
6-(N-Benzyl-N-methylamino)-3-methoxy-2-(3'-tolyl)imidazo- 
[I,2-b]pyridazine (IV.41) (39%) after t.l.c. (alumina;
chloroform, light petroleum, 1:1) (Found: C, 73.5; H,
5.9; N, 15.6. C22H22N40 requires C, 73.7; H, 6.2; N, 
15.6%). 1 H n.m.r.: 6 2.42, s, MeC; 3.18, s, MeN; 4.07, s,
MeO; 4.74, s, CH2N; 6.66, d, J 9 Hz, H 7; 7.06-7.95, 
complex, H 2',4',5',6' and Ph; 7.61, d, J 9 Hz, H 8.
6-(N-Benzyl-N-methylamino)-3-methoxy-2-(4'-tolyl)imidazo- 
[1,2-b]pyridazine (IV.4m) (44%) as an oil after t.l.c.
(alumina; chloroform, light petroleum, 3:1 and alumina; 
chloroform, benzene, 1:1) (Found, for a sample dried at 
80°/0.1 mmHg for 48 h: C, 73.7; H, 6.4. C22H22N4°
requires C, 73.7; H, 6.2%). ^H n.m.r.: 6 2.38, s, MeC; 
3.17, s, MeN; 4.06, s, MeO; 4.74, s, CH2N; 6.65, d, J 9 Hz, 
H 7; 7.29, s, Ph; 7.24, d, 7.99, d, J2',3' 8 Hz, H 
2',3',5',6'; 7.61, d, J 9 Hz, H 8.
6-(N-Benzyl-N-methylamino)-3-methoxy-2-(4'-methoxy- 
phenyl)imidazo[1,2-b]pyridazine (IV.4p) (24%) as a thick
oil after t.l.c. (alumina; chloroform, light petroleum,
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2:1) (Found: C, 69.7; H, 5.9, N, 14.7. C22H22N402. °-2
H20 requires C, 69.9; H, 6.0; N, 14.8%). -^H n.m.r.: 5
3.17, s, MeN; 3.84, s, 4'-0Me; 4.06, s, 3-OMe; 4.74, s,
CH2N; 6.64, d, J 9 Hz, H 7; 6.98, d, 8.03, d, J2/ 3/ 7 Hz,
H 2', 3',5',6'; 7.30, s, Ph; 7.57, d, J 9 Hz, H 8.
6-(N-Benzyl-N-methylamino)-3-methoxy-2-(3',4'-methylene- 
dioxyphenyl)imidazo[1,2-b]pyridazine (IV.4q) (59%) after
t.l.c. (alumina; chloroform, light petroleum, 1:2) (Found: 
C, 67.7; H, 5.3, N, 14.4. C22H20N4°3 requires C, 68.0; H,
5.2; N, 14.4%). 1H n.m.r.: 5 3.16, s, MeN; 4.05, s, MeO;
4.73, s, CH2N; 5.96,s, 0CH20; 6.63, d, J 9 Hz, H 7; 7.55, 
d, J 9 Hz, H 8; 6.83-7.66, complex, H 2',5',6' and Ph.
6-(N-Benzyl-N-methylamino)-3-methoxy-2-(pyridin-4'-yl)- 
imidazo[1,2-b]pyridazine (IV.4s)
A solution of 6-(N-benzyl-N-methylamino)pyridazine-3- 
amine 2-oxide (0.2 g) in ethanol (5.0 ml) was added to a 
mixture of 4-bromoacetylpyridine hydrobromide165 and sodium 
hydrogen carbonate (0.08 g) in ethanol (5.0 ml) and the 
mixture refluxed with stirring in an oil bath for 7.5 h.
The ethanol was evaporated under reduced pressure and the 
oily residue stirred with excess ethereal diazomethane in 
ice and then at room temperature overnight. After 
evaporation of the solvent the product was subjected to 
t.l.c. (alumina; chloroform, carbon tetrachloride, 3:10; 
developed three times) to give the title compound (0.008 g) 
m.p. 135-137° (Found, for a sample dried at 70°/0.1 mmHg 
for 48 h: C, 66.6; H, 6.0, N, 19.5. C2QH]_gN50. 1.0 H20
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requires C, 66.1; H, 5.8; N, 19.3%). n.m.r.: 6 3.20,
s, MeN; 4.14, s, MeO; 4.76, s, CH2N; 6.75, d, J 9 Hz, H 7; 
7.29-8.76, complex, H 2',3',5',6' and Ph; 7.60, d, J 9 Hz, 
H 8.
6-(N-Benzyl-N-methylamino)-3-methoxy-2-pyridin-3'-yl- 
imidazo[1,2-b]pyridazine (IV.4r) was prepared similarly; 
after t.l.c. (alumina; chloroform) it was obtained as a 
thick oil (10%) (Found, for a sample dried at 
100°/0.1 mmHg for 12 h: C, 68.1; H, 5.8, N, 19.4.
C20H19N5°- °*7 CHC13 requires C, 68.1; H, 5.4; N, 19.8%).
1H n.m.r.: 5 3.21, s, MeN; 4.11, s, MeO; 4.77, s, CH2N;
6.72, d, J 9 Hz, H 7; 7.61, d, J 9 Hz, H 8; 6.31-9.33, 
complex, H 2',4',5',6' and Ph.
6-(N-Benzyl-N-methylamino)-3-methoxy-2-(3'-nitrophenyl)- 
imidazo[1,2-b]pyridazine (IV.4b)
A solution of a-bromo-3-nitroacetophenone (0.42 g) in 
ethanol (5.0 ml) was added to a hot solution of 6-(N- 
benzyl-N-methylamino)pyridazin-3-amine 2-oxide (0.350 g) in 
ethanol (10 ml) and the mixture refluxed with stirring in 
an oil bath for 0.5 h. Sodium hydrogen carbonate (0.064 g) 
was then added and the reflux continued for 4 h. It was 
chilled, diluted with water (10 ml), adjusted to pH 7, and 
the red-brown precipitate (0.442 g) filtered off and washed 
with water and ether and dried.
This product (0.202 g) was suspended in a little 
methanol and stirred with excess ethereal diazomethane in 
ice and then at room temperature overnight. The solvent
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was evaporated and the product subjected to t.l.c.
(alumina; chloroform, light petroleum, 3:1) and 
recrystallised from methanol to give yellow crystals of the 
title compound (0.137 g), m.p. 128-130° (Found: C, 64.8;
H, 5.0, N, 18.0. C21H19N5°3 requires C, 64.8; H, 4.9; N,
18.0%). 1H n.m.r.: 6 3.22, s, MeN; 4.15, s, MeO; 4.78, s, 
CH2N; 6.75, d, J 9 Hz, H 7; 7.32-8.95, complex, Ph and H 
2',3',5',6'; 7.65, d, J 9 Hz, H 8.
6-(N-Benzyl-N-methylamino)-3-methoxy-2-(4'-nitrophenyl)- 
imidazo[1,2-b]pyridazine (IV.4c)
To a warm solution of 6-(N-benzyl-N-methylamino)- 
pyridazin-3-amine 2-oxide (0.349 g) in ethanol (10 ml) was 
added a solution of 4-nitrophenacyl bromide (0.42 g) in 
ethanol (5.0 ml) and the mixture refluxed in an oil bath at 
90° for 5.5 h. It was then chilled, diluted with water 
(10 ml) and the red-brown precipitate (0.206 g) filtered 
off, washed with water followed by ether, and dried.
This product in a little methanol was stirred with 
excess ethereal diazomethane cooled in ice overnight. The 
solvent was evaporated and the product recrystallised from 
methanol to give yellow crystals of the title compound 
(0.062 g), m.p. 184-185° (Found: C, 64.4; H, 4.9, N,
17.8. 0,21H19N5O3 requires C, 64.8; H, 4.9; N, 18.0%).
^H n.m.r.: 6 3.22, s, MeN; 4.14, s, MeO; 4.78, s, CH2N;
6.78, d, J 9 Hz, H 7; 7.32, s, Ph; 7.67, d, J 9 Hz, H 8; 
8.27, s, H 2',3 ' ,5',6'.
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2-(3'-Aminophenyl)-6-(N-benzyl-N-methylamino)-3-methoxy- 
imidazo[1,2-b]pyridazine (IV.4n)
A solution of 6-(N-benzyl-W-methylamino)-3-methoxy-2- 
( 3 ' -nitropheny 1) imidazo [ 1,2-jb ] pyridaz ine (0.361 g) in 
methanol (65 ml) was added over 5 minutes to a rapidly 
stirred mixture of reduced iron powder (0.56 g), methanol 
(35 ml), water (7.0 ml) and concentrated hydrochloric acid 
(2.8 ml) at 85-90° and the stirring continued at this 
temperature for 3 h. The mixture was filtered through 
celite, which was then washed with hot methanol. The 
filtrate was evaporated and the residue diluted with water, 
adjusted to pH 7 and extracted with chloroform. The 
extract was washed with water and evaporated and the 
product subjected to t.l.c. (alumina; chloroform, light 
petroleum, 1:1) to give the title compound (0.203 g)
(Found: C, 70.0; H, 6.2, N, 19.3. C21H21N5° requires C,
70.2; H, 5.9; N, 19.5%). 1H n.m.r.: 6 3.16, s, MeN; 3.44,
s, NH2; 4.06, s, MeO; 4.72, s, CH2N; 6.64, d, J 9 Hz, H 7; 
7.29-7.49, complex, H 2',4',5',6' and Ph; 7.56, d, J 9 Hz,
H 8.
2-(4'-Aminophenyl)-6-(N-benzyl-N-methylamino)-3-methoxy- 
imidazo[l,2-b]pyridazine (IV.4o) (30%) as a thick oil after
t. l.c. (alumina; chloroform) (Found: C, 63.2; H, 5.3, N,
17.1. C2iH2iN50. 0.4 CHCI3 requires C, 63.1; H, 5.3; N, 
17.2%). XH n.m.r.: 6 3.17, s, MeN; 3.50, br, NH2; 4.05,
s, MeO; 4.75, s, CH2N; 6.65, d, J 9 Hz, H 7; 6.75, d, 7.90, 
d, J 7 Hz, H 2 ',3',5',6'; 7.30, s, Ph; 7.62, d, J 9 Hz,
H 8.
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6-(3',4'-Methylenedioxybenzylamino)pyridazin-3-amine 2- 
oxide (IV.5)
A mixture of 6-chloropyridazin-3-amine 2-oxide (0.5 g) 
and 3,4-methylenedioxybenzylamine (2.018 g) was heated in a 
Teflon lined screw-top reaction vessel at 145° for 12 h.
The mixture was dissolved in ethanol and added to a column 
of alumina and developed with chloroform to remove excess 
methylenedioxybenzylamine. It was then eluted with ethanol 
and the product (0.277 g) recrystallised from ethanol to 
give the title compound, m.p. 160-162° (Found: C, 55.6; H, 
4.6; N, 21.7. C12H12N4°3 requires C, 55.4; H, 4.6; N,
21.5%). 1H n.m.r. (CD3SOCD3). 4.21, d, J 5.5 Hz, CH2; 5.86, 
br, NH; 5.97, s, OCH20; 6.50, d, J 9.5 Hz, H7; 7.07, d, J 
9.5 Hz, H8; 6.82-6.89, complex, H2',5',6'.
3-Methoxy-6-(3'-methoxybenzylamino)-2-(4"-methoxyphenyl)- 
imidazo[1 ,2-b]pyridazine (IV.7a)
A mixture of 6-(3'-methoxybenzylamino)pyridazin-3 - 
amine 2-oxide121 (0.1 g) and 4-methoxyphenacy1 bromide 
(0.11 g) in ethanol (2.0 ml) was refluxed with stirring in 
an oil bath for 4 h. The solvent was evaporated and the 
residue stirred with ethereal diazomethane in ice and at 
room temperature overnight. The crude product was subjected 
to t.l.c. (alumina; chloroform, light petroleum, 2:1) and 
gave the title compound as an oil (0.039 g) (Found: C,
67.5; H, 5.7; N, 14.2. C22H22N403 requires C, 67.7; H, 5.7; 
N, 14.4). 1H n.m.r.: <5 3.81, s, 3.85, s, 3'-OMe 4"-OIVIe;
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4.04, s, 3-OMe; 4.58, d, CH2 ; 6.36, d, J 9.5 Hz, H7 ; 6.80- 
8.06, complex, H2',4',5',6',2",3",5",6" and 8 .
2-(2'-Chlorophenyl)-3-methoxy-6-(3"-methoxybenzylamino)- 
imidazo[l,2-b]pyridazine (IV.7b) (40%) as an oil after
t.l.c. (alumina; chloroform, light petroleum, 1:1) and the 
product extracted with chloroform (Found: C, 62.7; H, 5.2; 
C21H19CIN4O2 . 0.1 CHCI3 requires C, 62.3; H, 4.7.
XH n.m.r.: 6 3.81, s, 3"-0Me; 3.98, s, 3-OMe; 4.58, d, J
5.5 Hz, CH2; 4.88, br, NH; 6.42, d, J 9.5 Hz, H7; 6.80- 
7.63, complex, H3',4',5',6',2",4",5”,6" and 8 .
3 - (3 '-Chlorophenyl)-3-methoxy-6-(3"-methoxybenzylamino)- 
imidazo[l,2-b]pyridazine (IV.7c) (28%), m.p. 191-193° after
t.l.c. (alumina, chloroform) and recrystallisation from 
ethanol (Found: C, 64.0; H, 5.0; N, 13.9. C2 iH]_9C1N402 
requires C, 63.9; H 4.9; N, 14.2%). 1H n.m.r.: S 3.81, s,
3"-OMe; 4.08, s, MeO; 4.58, d, J 5.5 Hz, CH2; 6.47, d, J
9.5 Hz, H7; 6.79-8.08, complex, H2',4',5',6',2",4",5",6" 
and 8 .
2-(4'-Chlorophenyl)-3-methoxy-6-(6"-methoxybenzylamino)- 
imidazo[1,2-b]pyridazine (IV.7d) (58%), m.p. 162-163°
after t.l.c. (alumina; chloroform) and recrystallisation 
from a mixture of toluene and cyclohexane (Found: C, 63.6; 
H, 5.1; N, 13.9. C21H19C1N402 requires C, 63.9; H, 4.9; N, 
14.2%). ^H n.m.r.: S 3.79, s, 3'-OMe; 4.04, s, 3-OMe; 5.55, 
d, J 5.5 Hz, CH2; 4.91, t, NH; 6.39, d, J 9.5 Hz, H7; 6.78- 
8.06, complex, H2',3',5',6',2",4",5",6" and 8 .
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3-Methoxy-6- (3 ' -methoxybenzylami.no) -2-(3"/4"- 
methylenedioxyphenyl)imidazo[1,2-b]pyridazine (IV.7e) (25%)
as an oil after t.l.c. (alumina; chloroform, developed 
twice) (Found, for a sample dried at 25° and 0.6 mmHg for 
10 h: C, 62.1; H, 5.3; N, 12.8. C22H20H404. 1 - ° H2° 
requires C, 62.5; H, 5.2; N, 13.3%). -^H n.m.r.: S 3.80, s,
3' -OMe; 4.03, s, 3-0Me; 4.56, d, J 5.5 Hz, CH2 ,* 4.81, t,
NH; 5.98, s, OCH20; 6.37, d, J 9.5 Hz, H7, 6.78-7.66,
complex, H2',4',5',6',2",5",6" and 8.
3-Methoxy-6-(3',4'-dimethoxybenzylamino)-2-(4"-tolyl)- 
imidazo[1,2-b]pyridazine (IV.7f) (49%), as yellow
crystals, m.p. 150-152° after t.l.c. (alumina, chloroform) 
and recrystallisation from a mixture of acetone and 
cyclohexane (Found: C, 68.5; H, 6.3; N, 14.0. C23H24N4°3 
requires C, 68.3; H, 6.0; N, 13.9%). 1H n.m.r.: 6 2.38, s, 
MeC; 3.88, s, 3.89, s, 3',4'-(OMe)2; 4.08, s, 3-OMe; 4.55, 
bs, CH2N; 6.37, d, J 9.5 Hz, H7; 6.78-8.03, complex,
H2',5',6',2",3",5",6" and 8.
3-Methoxy-6-(3', 4'-dimethoxybenzylamino)-2-(3",4"- 
methylenedioxyphenyl)imidazo[l,2-b]pyridazine (IV.7g)
A mixture of 6-(3',4'-dimethoxybenzylamino)pyridazin- 
3-amine 2-oxide121 (0.1 g) and 3',4'-methylenedioxyphenacyl 
bromide228 (0.1 g) in ethanol (2.0 ml) was refluxed with 
stirring in an oil bath for 5 h. The solvent was 
evaporated, the residue suspended in methanol (2.0 ml) and 
stirred with excess ethereal diazomethane in ice and at
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room temperature overnight. The solvent was then evaporated 
and the resulting oil subjected to t.l.c. (alumina; 
chloroform). The product (0.084 g) obtained was 
recrystallised from ethanol to give the title compound 
(0.047 g) as yellow crystals, m.p. 182-184° (Found: C,
63.9; H, 5.2; N, 13.0. C23H22N4O5 requires C, 63.6; H, 5.1; 
N, 12.9%). 1H n.m.r.: 6 3.88, s, 3.89, s, 3',4'-(OMe)2;
4.08, s, 3-OMe; 4.55, bs, CH2; 5.98, s, OCH20; 6.37, d, J
9.5 Hz, H7; 6.78-7.67, complex, H2',5',6',2",5",6" and 8.
3-Methoxy-6-(3',4'-methylenedioxybenzylamino)-2-(3",4"- 
methylenedioxyphenyl)imidazo[1,2-b]pyridazine (IV.7h) (6%)
as an oil after t.l.c. (alumina; chloroform, twice) (Found, 
for a sample dried at 20° and 0.1 mmHg for 16 h: C, 59.4;
H, 3.7; N, 12.4. C22H3.8N4O5. 0.25 CHCl3 requires C, 59.6;
H, 4.1; N, 12.5%). 1H n.m.r.: 5 4.07, s, MeO; 4.50, d, J
5.5 Hz, CH2N; 4.68, bs, NH; 5.95, s, 5.98, s, 2xOCH20;
6.35, d, J 9.5 Hz, H7; 6.72-7.67, complex,
H2',5',6',2",5",6" and 8.
6-(2'-And 4'-chlorobenzylamino)pyridazin-3-amine 2- 
oxides were prepared by Mr S.J. Ireland.
6-(2'-Chlorobenzylamino)-3-methoxy-2-(4"-tolyl)imidazo- 
[1,2-b]pyridazine (IV.7i) (21%) as an oil after t.l.c.
(alumina; chloroform, light petroleum, 1:1) (Found: C,
66.4; H, 5.2; N, 14.6. C2iH19ClN40 requires C, 66.6; H,
5.1; N, 14.8%). It crystallised from cyclohexane as yellow 
crystals, m.p. 97-98° with some solvent included.
1H n.m.r.: 5 2.38, s, MeC; 4.04, s, MeO; 4.71, d, J 5.5 Hz,
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CH2N ; 6.38, d, J 9.5 Hz, H7; 7.17-8.01, complex,
H3',4',5',6',2",3",5",6" and 8.
6- (2'-Chlorobenzylamino)-2-(4"-chlorophenyl)-3-methoxy- 
imidazo[1,2-b]pyridazine (IV.7j) (30%) as an oil from
t.l.c. (alumina; chloroform, light petroleum, 1:1) (Found:
C, 60.3; H, 3.9; N, 14.3. C20H16cl2N4° requires C, 60.2; H, 
4.0; N, 14.0%). It crystallised from cyclohexane as yellow 
crystals, m.p. 87-88° but even after drying at 65° and 0.1 
mmHg for 20 h it analysed for 0.15 molecules of included 
cyclohexane. 1H n.m.r.: 6 4.05, s, Me; 4.70, d, J 5.5 Hz,
CH2N; 4.92, bs, NH; 6.40, d, J 9.5 Hz, H7; 7.17-8.06, 
complex, H3',4',5',6',2",3",5",6" and 8.
6-(2'-Chlorobenzylamino)-3-methoxy-2-(3"-nitrophenyl)- 
imidazo[1,2-b]pyridazine (IV.7k) (20%) as an oil from
t.l.c. (alumina; chloroform), which on standing gave yellow 
crystals, m.p. 184-186° (Found: C, 58.6; H, 4.2; N, 16.9. 
c 20h 16c 1n 5°3 requires C, 58.6; H,, 3.9; N, 17.1%).
1H n.m.r.: <5 4.10, s, MeO; 4.69, d, J 5.5 Hz, CH2; 5.24, t, 
NH; 6.46, d, J 9.5 Hz, H7; 7.15-8.91, complex,
H3',4',5',6',2",4",5",6" and 8.
6-(2'-Chlorobenzylamino)-3-methoxy-2-(4"-nitrophenyl)- 
imidazo[l,2-b]pyridazine (IV.71) (15%), m.p. 226-228° after
t.l.c. (alumina; chloroform) and recrystallisation from 
ethanol (Found: C, 58.9; H, 3.9; N, 16.8. C22Hi6c -^5°3 
requires C, 58.6; H, 3.9; N, 17.1%). 1H n.m.r.: 5 4.11, s,
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MeO; 4.72, d, J 5.5 Hz, CH2; 5.01, t, NH; 6.47, d, J 9.5 
Hz, H7 ; 7.19-8.25, complex, H3',4',5',6',2",3",5",6" and 8.
6 - (2'-Chlorobenzylamino)-3-methoxy-2-(pyridin-3"-yl)- 
imidazo[l,2-b]pyridazine (IV.7m) (9%) as a crystalline
solid, m.p. 148-150° after t.l.c. (alumina; chloroform) and 
recrystallisation from a mixture of acetone and light 
petroleum (Found: C, 62.1; H, 4.5; N, 19.1. C^gH^gClgO 
requires C, 62.4; H, 4.4; N, 19.1%). ^H n.m.r.: 6 4.08, s, 
MeO; 4.71, d, J 5.5 Hz, CH2N; 5.10, bs, NH; 6.45, d, J 9.5 
Hz, H7; 7.18-9.28, complex, H3',4',5',6',8 and pyridinyl.
6 - (4'-Chlorobenzylamino)-3-methoxy-2-phenylimidazo- 
[1,2-b]pyridazine (IV.7n) (43%), m.p. 158-160° after
t.l.c. (alumina; chloroform, light petroleum, 3:1) and 
recrystallisation from ethanol (Found: C, 66.0; H, 4.8; N, 
15.2. C2QH17CIN40 requires C, 65.8; H, 4.7; N, 15.4).
•^H n.m.r.: 5 4.00, s, Me; 4.53, d, J 5.5 Hz, CH2; 5.09, t, 
NH; 6.35, d, J 9.5 Hz, H7; 7.29-8.12, complex,
H2',3',5',6',8 and Ph.
6-(4'-Chlorobenzylamino)-3-methoxy-2-(4'-tolyl)imidazo- 
[1,2-b]pyridazine (IV.7o) (25%) as a yellow solid m.p.
143-145° after t.l.c. (alumina, chloroform) and 
recrystallisation from a mixture of acetone and cyclohexane 
(Found: C, 66.7; H, 5.1; N, 14.6. C21H19C1N40 requires C, 
66.6; H, 5.1; N, 14.8%). 1H n.m.r.: 5 2.38, s, MeC; 4.00, 
s, MeO; 4.55, d, J 5.5 Hz, CH2; 4.91, t, NH; 6.35, d, J 9.5 
Hz, H7; 7.19-8.01, complex, H29 ,3',5',6',2",3",5",6" and 8.
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6-(4'-Chlorobenzylamino)-3-methoxy-2-(3",4"-methyl- 
enedioxyphenyl)imidazo[1,2-b]pyridazine (IV.7p) (20%), as
yellow crystals m.p. 124-126° after t.l.c. (alumina, 
chloroform) and recrystallisation from a mixture of ethanol 
and cyclohexane (Found: C, 61.7; H, 4.5; N, 13.4. 
c 21h 17c 1n 4°3 requires C, 61.7; H, 4.2; N, 13.7%).
1H n.m.r.: 5 4.00, s, MeO; 4.57, d, J 5.5 Hz, CH2; 4.80, t, 
NH; 5.98, s, OCH20; 6.37, d, J 9.5 Hz, H7; 6.83-7.66, 
complex, H2',3',5#,6',2",5",6" and 8.
6-(3',4'-Methylenedioxybenzylamino)-2-(3",4"-methylene- 
dioxyphenyl)imidazo[1,2-b]pyridazine (IV.10)
A mixture of 6-chloropyridazin-3-amine 2-oxide (1.0 g) 
and 3,4-methylenedioxybenzylamine (5.0 g) was heated at 
160° for 16 h. The reaction mixture was dissolved in 
ethanol and then added to a column of alumina (in 
chloroform) and then eluted with chloroform and then 
ethanol. The ethanol eluate gave an oil (0.110 g) (Found:
C, 58.7; H, 5.0. Ci2H12N4°2 requires C, 59.0; H, 5.0)
XH n.m.r. (CD3SOCD3). 6 4.33, d, 5.5 Hz, CH2; 5.35, br,
NH2; 5.96, s, OCH20; 6.35, br, NH; 6.67-6.90 complex, ArH.
A mixture of this product (0.106 g) and 3,4- 
methylenedioxyphenacyl bromide1 (0.100 g) in ethanol (2.0 
ml) was refluxed in an oil bath with stirring from 5 h. 
After cooling, the precipitate was filtered off and washed 
with ethanol to give a solid (0.1 g), m.p. 237-239° (Found 
C, 53.2; H, 3.5; N, 11.6. C21H16N404 .HBr requires C, 53.7; 
H, 3.7; N, 11.9%).
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This solid was suspended in water and neutralised, the 
solvent evaporated and the residue subjected to t.l.c. 
(alumina; chloroform). The product (0.062 g) was 
recrystalled from ethanol to give the title compound 
(0.043 g), m.p. 224-226° (Found: C, 65.3; H, 4.1; N, 14.2. 
c21h 16n 4°4 requires C, 64.9; H, 4.2; N, 14.4%). 1H n.m.r.:
5 4.47, br, CH2; 5.96, s, 5.99, s, 2xOCH20; 6.42, d, J 9.5 
Hz, H7 ; 6.81-7.70, complex, H2',5',6',2",5",6" and H8;
7.86, s, H3.
6-(3'-Methoxybenzylamino)-3-(3"-methoxybenzyloxy)-2-phenyl- 
imidazo[1,2-b]pyridazine (IV.8e)
A mixture of 6-(3'-methoxybenzylamino)pyridazin-3- 
amine 2-oxide (0.664 g) and phenacyl bromide (0.537 g) in 
ethanol (6.0 ml) was refluxed with stirring for 7 h. The 
solvent was then evaporated,'the residue diluted with 
acetone (3 ml) and the solid (0.627 g) filtered off and 
washed with acetone.
Part of this solid (0.1 g) with 3-methoxybenzyl 
chloride (0.71 g) and potassium carbonate (0.1 g) in 
dimethylformamide (2.0 ml) was stirred in an oil at 100° 
for 4 h. It was then diluted with water (20 ml) and 
extracted with ether and the product subjected to t.l.c. 
(alumina; chloroform) (three times) to give as an oil the 
title compound (0.021 g) (Found: C, 70.7; H, 5.9; N, 11.4. 
c28h26n4°3 0,5 h2° requires C, 70.7; H, 5.9; N, 11.8%.
1H n.m.r.: 6 3.42, s, CH20; 3.70, s, 3"-0Me; 3.76, s, 3'-
OMe; 4.39, d, J 5 Hz, CH2; 4.49, br, NH; 6.32, d, J 9.5 Hz, 
H7 ; 6.65-7.84, complex, H2',4',5',6',2",4",5",6" and H8.
CHAPTER V
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CHAPTER V Syntheses and binding studies of some 2- 
benzyl(phenethyl, biphenyl-4'-yl, 6'-methylnaphthalen-2'- 
yl, t-butyl and cyclohexyl)-3-methoxy(acylaminomethyl and 
dimethylaminomethyl)-6-(variously substituted)imidazo- 
[1,2-b]pyridazines
V-l Introduction
In this chapter a large number of 6-(variously 
substituted)-3-methoxy (unsubstituted, dimethyl­
aminomethyl, acetamidomethyl and benzamidomethyl)-2- 
benzyl (phenethyl, biphenyl-4'-yl, 6'-methylnaphthalen- 
2'-yl, t-butyl and cyclohexyl)imidazo[1,2-b]pyridazines 
have been prepared and their ability to displace 
[3H]diazepam from its specific binding sites in rat brain 
membrane has been examined. In imidazo[1,2-b]pyridazine 
derivatives, it has been shown that a 2-aryl substituent 
is a requirement for significant binding. This 2-aryl
group may correspond to the "A" ring in the Fryer model 
(see Chapter 1-3) .
The aim of the present investigation was to examine 
structure-binding activity relationships in 2,3,6- 
trisubstituted imidazo[1,2-b]pyridazines in which the 
potential "A" to tt^  distance was varied by inserting 
benzyl, phenethyl, biphenyl, 6'-methylnaphthalen-2'-yl 
(and cyclohexyl and t-butyl) groups at the 2-position, 
and to compare their activity with analogous compounds 
which contained 2-phenyl (substituted phenyl and 
pyridinyl) groups.
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V-2 Syntheses
The general methods for syntheses of 6-(variously 
substituted)-3-methoxy-2-benzyl(phenethyl, biphenyl-4'- 
yl, substituted biphenyl-4'-yl, 6'-methylnaphthalen-2'- 
yl, cyclohexyl and t-butyl)imidazo[1,2-b]pyridazines 
(V.3-8, Scheme V-l) and 6-(variously substituted)-3- 
unsubstituted (and dimethylaminomethyl, acetamidomethy1, 
and benzamidomethyl)-2-benzyl(phenethyl, biphenyl-4'-yl, 
cyclohexyl and t-butyl)imidazo[1,2-b]pyridazines (V.9-11) 
are as outlined in Scheme V-l.
The compounds (V.3-8) were prepared generally from 
the relevant 6-substituted pyridazin-3-
amine161'163-165,229'230 with the appropriate glyoxals 
followed by methylation with diazomethane or from the 
relevant 6-substituted pyridazin-3-amine 2-oxides, such 
as 6-(2'-methoxyphenoxy)pyridazin-3-amine 2-oxide, with 
the appropriate bromoacetyl compound followed by 
methylation.
Benzylglyoxal246 was prepared from mandelic acid, 
phenethylglyoxal247 from hydrocinnamic acid, biphenyl-4- 
ylglyoxal248 from 4-acetylbiphenyl, 4'-nitrobiphenyl-4- 
ylglyoxal from 4-nitrobiphenyl through 4-acetyl-4'- 
nitrobiphenyl,249 t-butylglyoxal250 from pinacolone, 
cyclohexylglyoxal251 from cyclohexyl chloride through 
cyclohexyl methyl ketone, l-bromo-3-phenylpropanone 
from phenylacetyl chloride, l-bromo-4-phenylbutan-2- 
one254 from 3-phenylpropionic acid, a-bromo-4- 
phenylacetophenone255 from 4-phenylacetophenone, 1-bromo-
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Scheme V-l
V.10
CHoNHCOR
V . l l
V.3-8
V. 3 n,o
V R2
3a-u CH2Ph
4a-r CH2CH2Ph
5a-i C6H4Pb-p»or CgH^CgfyNOj-p’l-p
6a, b (C10HsMe-6' H3
7a-e Bul
8a-d C6H xx-cyclo
9a-s CH2Ph, CH2CH2Ph, C ^ P h -p , Bul or C6Hu -c y c lo
lOa-n CH2Ph, CH2CH2Ph, C6H4Ph-p( Bul or C6Hn - c y c lo
l l a - j CH2Ph, CH2CH2Ph, C6H4Ph-p, Bul or C6Hn -cy c lo
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o  c  /:3, 3-dimethylbutan-2-one from pinacolone, and a-
n  c nbromomethyl cyclohexyl ketone by bromination of 
cyclohexyl methyl ketone.
The compounds (V.9) were prepared from the relevant 
pyridazin-3-amine and bromoacetyl compounds; and when 
compounds (V.9) were heated with bis(dimethylamino)- 
methane and phosphoric acid in acetic acid at 120°, the 
3-dimethylaminomethyl compounds (V.10) were obtained.
The 3-acetamidomethyl and 3-benzamidomethyl 
compounds (V.ll) were prepared from compounds (V.9) by 
heating with N-(hydroxymethyl)acetamide or N- 
(hydroxymethyl)benzamide in acetic acid containing a 
catalytic amount of concentrated sulphuric acid.
2-Benzyl (and phenethyl)-3-methoxy-6- 
(nitrobenzylthio)imidazo[1,2-b]pyridazines (V.31,m and 
V.41, m) were reduced with iron in aqueous hydrochloric 
acid to the corresponding 6-(aminobenzylthio) compounds 
(V.3n,o and V.4n,o; in Scheme V-l) respectively.
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V-3 1H n.m.r. spectra
The n.m.r. spectra of the compounds reported in 
this chapter are recorded in the Experimental section.
In deuterochloroform, the signal due to the protons of 
the 3-methoxy group in the 2-benzyl compounds (V.3a-r) 
was at 63.80-3.96, and that in the 2-phenethyl compounds 
(V.4a-o) at 63.75-3.87; these were upfield of the signals 
for some corresponding 2-phenyl and 2-(biphenyl-4'-yl) 
compounds at 64.01-4.17 and 4.02-4.19, respectively. The 
signals due to the methylene of the 2-benzyl group and 
the ethylene of the 2-phenethyl group in the above 
compounds were at 64.09-4.11 and 3.06-3.07 respectively.
The protons H7 and H8 in compounds (V.3a-r and 
V.4a-o) appeared as an AB quartet within the small 
chemical shift ranges of 66.68-6.76 for H7 and 67.53-7.61 
for H8, with coupling constants of 9.0-9.5 Hz.
The 1H n.m.r. spectra of compounds (V.7-11) revealed 
the signal due to the 2-t-butyl group in the range 61.41- 
1.55; that for the 2-cyclohexyl group at 51.26-2.90; the 
3-H of 3-unsubstituted imidazo[1,2 - b ]pyridazines (V.9) 
was at 67.55-7.72; and for substituents at 3-position the 
dimethyl and the methylene of the 3-dimethylaminomethyl 
group at 62.07-3.35 and 3.55-4.01, respectively; the 
methylene of the 3-acetamidomethyl group as a doublet at 
64.39-4.99, acetyl at 61.75-1.99; and the methylene of the 
3-benzamidomethyl group as a doublet at 64.60-5.26.
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V-4 In vitro binding studies
The compounds prepared in this work were examined in 
the [ HJdiazepam binding assay outlines in Chapter 
II-5.3.
V-4.1 Results of [ H]diazepam binding assay
The results of the above in vitro displacement 
studies from rat brain membrane by the compounds 
described in this chapter are shown in Table V-l for the 
3-methyoxyimidazo[ 1,2-jb]pyridazines and in Table V-2 for 
3-benzamidomethyl (acetamidomethyl, dimethylaminomethy1 
and unsubstituted)imidazo[1,2-b]-pyridazines provided the 
activity of these compounds generally exceded 5% 
displacement of [HJdiazepam at 1000 nM. Some literature 
data for some 2-phenyl analogues are also included at the 
beginning of Table V-l for comparison.
V-4.2 Discussion of binding results
An examination of the data in Table V-l for the 
series of the 2-benzylimidazo[1,2-b]pyridazines, revealed 
that 2-benzyl-3-methoxy-6-(3'-methylbenzylthio)imidazo- 
[1,2-b]pyridazine (V.3f, IC50 93 nM) was the most active 
compound.
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Table V-l Results for the displacement of [ H]diazepam 
from rat brain membranes by some 2-benzyl(phenethyl, 
biphenyl-4'-yl, 6'-methylnaphthalen-2'-yl, t-butyl and 
cyclohexyl)-3-methoxy-6-(variously substituted)imidazo- 
[1,2-b]pyridazines (V.3-8)
Formula Imidazo[1,2-b]pyridazine IC50 (nM)A
number (or % displ.)B
6-Benzylthio-3-methoxy-2-phenyl-compounds
6-SCH2Ph-3-0Me-2-Ph 25C
6-SCH2C6H4OMe-o-3-OMe-2-Ph 9°
6-SCH2C6H4OMe-m-3-OMe-2-Ph 11°
6-SCH2C6H4OMe-p-3-OMe-2-Ph 55°
6-Variously substituted-3-methoxy-2-phenyl 
compounds
6-Cl-3-OMe-2-Ph 7 7 2 E
6-OC6H4OMe-p-3-OMe-2-Ph 998°
6-SPh-3-OMe-2-Ph 117 F
6-Benzylthio-3-methoxy-2-benzyl compounds
a 6-SCH2Ph-3-OMe-2-CH2Ph 197G
b 6-SCH2C6H4OMe-o-3-OMe-2-CH2Ph 208
c 6-SCH2C6H4OMe-m-3-OMe-2-CH2Ph 114
d 6-SCH2C6H4OMe-p-3-OMe-2-CH2Ph 499
e 6-SCH2C6H4Me-o-3-OMe-2-CH2Ph 425
f 6-SCH2C6H4Me-jn-3-OMe-2-CH2Ph 93
g 6-SCH2C6H4Cl-o-3-OMe-2-CH2Ph 352h 6-SCH2C6H4Cl-m-3-OMe-2-CH2Ph 277
i 6-SCH2C6H4Cl-p-3-OMe-2-CH2Ph 417
j 6-SCH2C6H3Cl2-o/p-3-OMe-2-CH2Ph (41%)
k 6-SCH2C6H4N02-o-3-0Me-2-CH2Ph 126
1 6-SCH2C6H4N02-jn-3-OMe-2-CH2Ph 193
m 6-SCH2C6H4N02-p-3-OMe-2-CH2Ph 151
n 6-SCH2C6H4NH2-m-3-OMe-2-CH2Ph 136
0 6-SCH2C6H4NH2-p-3-OMe-2-CH2Ph 181
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Table V-l Continued
6-Picolylthio-3-methoxy-2-benzyl compounds
p 6-SCH2C5H4N-CÜ-3 -OMe-2 -CH2Ph 363q 6-SCH2C5H4N-^-3-OMe-2-CH2Ph 372
r 6-SCH2C5H4N-7-3-OMe-2-CH2Ph 390
6-Variously substituted 3-methoxy-2-benzyl compounds
s 6-OC6H4OMe-p-3-OMe-2-CH2Ph (51%)
t 6-OC6H4Cl-p-3-OMe-2-CH2Ph (27%)
u 6-SPh-3-OMe-2-CH2Ph 203
6-Benzylthio-3-methoxy-2-phenethy1 compounds
V .4 a 6-SCH2C6H4OMe-o-3-OMe-2-CH2CH2Ph (45%)
b 6-SCH2C6H4OMe-m-3-OMe-2-CH2CH2Ph >>1000
c 6-SCH2C6H4OMe-p-3-OMe-2-CH2CH2Ph (5.9%)
d 6-SCH2C6H4Me-o-3-OMe-2-CH2CH2Ph (24%)
e 6-SCH2C6H4Me-m-3-OMe-2-CH2CH2Ph (3.8%)
f 6-SCH2C6H4Me-p-3-OMe-2-CH2CH2Ph (2.2%)
g 6-SCH2C6H4Cl-o-3-OMe-2-CH2CH2Ph (6.3%)
h 6-SCH2C6H4Cl-m-3-OMe-2-CH2CH2Ph (29%)
i 6-SCH2C6H4Cl-p-3-OMe-2-CH2CH2Ph (4.3%)
j 6-SCH2C6H3Cl2-o,p-3-OMe-2-CH2CH2Ph >>1000
k 6-SCH2C6H4N02-o-3-0Me-2-CH2CH2Ph (32%)
1 6-SCH2C6H4N02-m-3-0Me-2-CH2CH2Ph (31%)
m 6-SCH2C6H4N02-p-3-0Me-2-CH2CH2Ph (13%)
n 6-SCH2C6H4NH2-m-3-OMe-2-CH2CH2Ph (43%)
o 6-SCH2C6H4NH2-p-3-OMe-2-CH2CH2Ph (31%)
6-Variously substituted-3-methoxy-3-phenethyl 
compounds
p 6-OC6H4OMe-p-3-OMe-2-CH2CH2Ph (9.2%)
q 6-OC6H4Cl-p-3-OMe-2-CH2CH2Ph (2.2%)
r 6-SPh-3-OMe-2-CH2CH2Ph >>1000
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Table V-l Continued
Formula Imidazo [ 1,2 — Jb ] pyridazine I C s n ( n M ) A
number (or % displ.)B
6-Variously substituted 3-methoxy 
biphenyl), t-butyl or cyclohexyl -2-(4'- compounds
V. 5 b
c 6-SCH2C6H4OMe-o-3-OMe-2-C6H4Ph-p 6-SCH2C6H4OMe-7n-3-OMe-2-C6H4Ph-p
(4%)
(4%)
e 6-Cl-3-OMe-2-C6H4Ph-p (8.9%)
V. 7 a 6-SCH2Ph-3-OMe-2-But (5%)
b 6-C1-3-OMe-2-But (12%)
V. 8 c 6-OC6H4OMe-o-3-OMe-2-C6H11 (8%)
AIC5q values are the concentrations required to displace 
50% of specific [3H]diazepam binding to rat brain 
membrane preparations 
BAt 1000 nM 
CRef. 164
°Ref. 165 
ERef. 162
FRef. 167
GKindly prepared by Mr S.J. Ireland
A comparison of the 2-benzyl compounds (V.3) with 
their 2-phenyl analogues revealed that 2-benzyl-3- 
methoxy-6-(4'-methoxyphenoxy)imidazo[1,2-b]pyridazine 
(V.3s, 51% displacement at 1000 nM) was approximately as 
active as 3-methoxy-6-(4'-methoxyphenoxy)-2-phenyl- 
imidazo[1,2-b]-pyridazine165 (IC50 988 nM; see Table V-l) 
and 2-benzyl-3-methoxy-6-phenylthioimidazo [1,2- jb]  -  
pyridazine (V.3u, IC50 203 nM) was ca half as active as 
3-methoxy-2-phenyl-6-phenylthioimidazo [ 1,2-Jb] pyridazine 
(IC50 117 nM; see Table V-l). However the 2-benzyl 
compounds generally were significantly less active. This
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lower activity varied from ca 10 to 20-fold for the 2- 
benzyl-3-methoxy-6-(2',3' and 4'-methoxybenzyl- 
thio)imidazo[1,2-b]pyridazines (in comparison to their 2- 
phenylimidazo[1, 2-b]pyridazine analogues). It was ca 8- 
fold for 2-benzyl-6-benzylthio-3-methoxyimidazo[1,2-b]- 
pyridazine (V.3a; IC50 197 nM) in comparison to its 2- 
phenyl analogue (IC50 25 nM; see Table V-l).164
Amongst 3-unsubstituted 2-benzyl-6-(2',3'- and 4'- 
methoxybenzylthio)imidazo[1,2-b]pyridazines (V.9b-d; 34%, 
27% and 12% displacement at 1000 nM; in Table V-2) the 6- 
(2'-methoxybenzylthio) compound (V.9b) was the most 
active; and 2-benzyl-6-(3'-methoxybenzylthio)imidazo­
le 1 , 2-b] pyridazine (V.9c; 27% displacement at 1000 nM) was 
markedly less active than its 2-phenyl analogue (II.3g; 
IC50 330 nM); see Chapter II). 2-Benzyl-6-phenylthio- 
imidazo[1,2-b]pyridazine (V.9h; 24% displacement at 1000 
nM) was half as active as 2-phenyl-6-phenylthioimidazo- 
[1,2-b]pyridazine (II.3j; 43% displacement at 1000 nM, 
see Chapter II).
Similar lower activities were also noted for the 3- 
dimethylaminomethyl (and 3-benzamidomethyl)-2-benzyl- 
imidazo[1,2-b]pyridazines as compared to their 2-phenyl 
analogues. For example, 2-benzyl-3-dimethylaminomethy1- 
6-(2'-methoxyphenoxy)imidazo[1,2-b]pyridazine (V.lOd;
6.7% displacement at 1000 nM) was much less active than 
3-dimethylaminomethyl-6-(2'-methoxyphenoxy)-2-phenyl- 
imidazo[1,2-b]pyridazine (II.4f; IC50 333 nM, see Chapter 
II) .
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Table V-2 . Results for the displacement of [3H]diazepam
from rat brain membranes by some 3-benzamidomethyl 
(acetamidomethyl, dimethylaminomethyl and 
unsubstituted)imidazo[1,2-b]pyridazines (V.9-11).
Formula Imidazo[1,2-b]pyridazine IC5o(nM)A (or %
number displ.)B
2-Benzyl compounds
. 9b 
10a
6-SCH2C6H4OMe-o-3-H-2-CH2Ph
6-SCH2C6H4OMe-o-3-CH2NMe2-2-CH2Ph
(34%)
(19%)
9c
10b
6-SCH2C6H4OMe-m-3-H-2-CH2Ph
6-SCH2C6H4OMe-m-3-CH2NMe2-2-CH2Ph
(27%)
(31.5%)
9d
10c
6-SCH2C6H4OMe-p-3-H-2-CH2Ph
6-SCH2C6H4OMe-p-3-CH2NMe2-2-CH2Ph
(12%)
(3.8%)
9e
11a
6-C1-3-H-2-CH2Ph 
6-Cl-3-CH2NHBz-2-CH2Ph
(1%)
>>1000
lOd 6-OC6H4OMe-o-3-CH2NMe2-2-CH2Ph (6.7%)
9 f 
lOe
6-OC6H4OMe-p-3-H-2-CH2Ph
6-OC6H4OMe-p-3-CH2NMe2-2-CH2Ph
C15%)
(17%)
9glOf
6-OC6H4Cl-p-3-H-2-CH2Ph
6-OC6H4Cl-p-3-CH2NMe2-2-CH2Ph
(0%)
(19%)
9h
10g
6-SPh-3-H-2-CH2Ph
6-SPh-3-CH2NMe2-2-CH2Ph
(24%)
(33%)
-Phenethyl compounds
9j10h
lib
lie
6-SCH2Ph-3-H-2-CH2CH2Ph
6-SCH2Ph-3-CH2NMe2-2-CH2CH2Ph
6-SCH2Ph-3-CH2NHAc-2-CH2CH2Ph
6-SCH2Ph-3-CH2NHBz-2-CH2CH2Ph
(2%)
(3.1%)
(16%)
(12%)
9k
lOi
6-SCH2C6H4OMe-p-3-H-2-CH2CH2Ph 
6-SCH2C6H4OMe-p-3-CH2NMe2-2-CH2CH2Ph
(8%)
>>1000
91
lOj
lid
lie
6-C1-3-H-2-CH2CH2Ph 
6-C1-3-CH2NMe2-2-CH2CH2Ph 
6-Cl-2-CH2NHAc-2-CH2CH2Ph 
6-Cl-3-CH2NHBz-2-CH2CH2Ph
(3%)
>>1000
(8.7%)
(22%)
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Table V-2 Continued
Formula Imidazo[1,2-b]pyridazine IC50 (nM)A (or %
number displ.)B
9m 6-SPh-3-H-2-CH2CH2Ph (7%)
Ilf 6-SPh-3-CH2NHAc-2-CH2CH2Ph (11%)
a IC5q Values are the concentrations required to displace 
50% of specific [3H]diazepam binding to rat brain 
membrane preparations
BAt 1000 nM
The 2-(phenethyl)imidazo[l,2-b]pyridazines were also 
found to be significantly less active than the 
corresponding 2-benzylimidazo[1,2-b]pyridazines. This 
lower activity of the 2-(phenethyl) compound was ca five­
fold in 3-methoxy-6-(4'-methoxyphenoxy)-2-(phenethyl)- 
imidazo[1,2-b]pyridazine (V.4p; 9.2% displacement at 1000 
nM) and 3-methoxy-6-(2'-methoxybenzylthio)-2-(phenethyl)- 
imidazo[ 1,2-jb]pyridazine (V.4a; 45% displacement at 1000 
nM) relative to their 2-benzyl analogues (V.3s, 51%
displacement at 1000 nM and V.3b; IC50 208 nM); but 
probably the biggest difference was observed between 3- 
methoxy-6-(3'-methylbenzylthio)-2-(phenethyl)imidazo- 
[1,2-b]pyridazine (V.4e; 3.8% displacement at 1000 nM) 
and its 2-benzyl analogue (V.3f; IC50 93 nM). 
Qualitatively, the pattern of activities amongst the 2- 
benzyl (and 2-phenethyl)-3-methoxy-6-(substituted 
benzylthio)imidazo[1,2-b]pyridazines was generally
1 4similar to that observed for their 2-phenyl analogues.
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All 2-(biphenyl-4'-yl), 2-(substituted biphenyl-4'- 
yl) , 2-(6'-methylnaphthalen-2'-yl), 2-t-butyl and 2- 
cyclohexylimidazo[1,2-b]pyridazines showed low binding 
ability. The data for 3-methoxy-6-(2 ' - 
methoxybenzylthio)-2-phenethylimidazo[1,2-b]pyridazine 
(V.4a; 45% displacement at 1000 nM) and for 3-methoxy-6- 
(2'-methoxybenzylthio)-2-(biphenyl-4M-yl)- 
imidazo[1,2-b]pyridazine (V.5b; 4% displacement at 1000 
nM) reveals that the 2-phenethyl compound bound much more 
strongly than the 2-(biphenyl-4"-yl) analogue.
Whereas 3-benzamidomethyl-6-chloro-2-phenethyl- 
imidazo[1,2-b]pyridazine (V.lle; 22% displacement at 1000 
nM) bound more strongly than its 3-unsubstituted analogue 
(V.91; 3% displacement at 1000 nM), both 3- 
benzamidomethy1-2-benzyl-6-chloroimidazo[1,2 — Jb ]pyridazine 
(V.lla; IC50 >>1000 nM) and its 3-unsubstituted analogue 
(V.9e; 1% displacement at 1000 nM) did not show 
significant activity at 1000 nM. Also the 3-dimethyl- 
aminomethyl group did not engender significant activation 
in these 2-benzyl- and 2-phenethyl-imidazo[1,2-b]- 
pyridazines.
In the 3-acetamidomethyl, 3-benzamidomethy1 and 3- 
unsubstituted-6-chloro-2-phenethylimidazo[1,2 — jb ] — 
pyridazines (V.lld,e and 91; 8.7%, 22% and 3% 
displacement at 1000 nM respectively) the order of 
activity was 3-benzamidomethyl > 3-acetamidomethyl > 3- 
hydrogen, consistent with that found in the 2-phenyl 
analogues (II.6j, IC50 140 nM, II.5b, IC50 474 nM and 
II.3o, IC50 >3000 nM respectively, see Chapter II); but
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in the 6-benzylthio-2-phenethylimidazo[1,2-b]pyridazines, 
3-benzamidomethyl-6-benzylthio-2-phenethylimidazo- 
[1,2-b]pyridazine (V.llc; 12% displacement at 1000 nM) 
was slightly weaker than the corresponding 3- 
acetamidomethyl compound (V.llb; 15% displacement at 1000 
nM) .
In summary, it appears that the activity of 
interaction with benzodiazepine receptors by derivatives 
of 2-phenyl(or substituted phenyl)imidazo[1,2-b]- 
pyridazine is effectively destroyed in the 2-t-butyl and 
2-cyclohexyl analogues; and replacement of the 2-phenyl 
group by larger and non-conjugating group such as 2- 
benzyl, 2-phenethyl or by the larger conjugating 2- 
(biphenyl-4'-yl) or (6'-methylnaphthalen-2'-yl) groups 
markedly decreases binding ability which is in the order 
phenyl > benzyl > phenethyl > biphenyl-4'-yl.
Despite the low activity of many of these compounds 
in tests in the central nervous system, some of these 
compounds proved guite active (IC50 values <10 nM) in 
binding to peripheral (mitochondrial) tissue (personal 
communication from Dr L.P. Davies).
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V-5 Experimental
The general procedure and experimental details for 
the [H]diazepam binding assay are recorded in Chapter 
II-5.3 except that samples of compounds prepared in this 
chapter for analysis were dried at 55-90°/0.1 mmHg for 
5-20 h unless otherwise specified.
Benzylglyoxal
P 4This compound was prepared from mandelic acid
n c nthrough acetylmandelic acid, acetylmandelyl chloride 
(1H n.m.r.: 5 2.21, s, MeCO; 6.08, s, CH; 7.47, s, Ph) 
and l-acetoxy-3-diazo-l-phenylacetone.246 (4H n.m.r.: 6 
2.18, s, MeCO; 5.46, s, CHN2; 6.00, s, CH; 7.39, s, Ph) . 
The product was recrystallised from light petroleum and 
had m.p. 116-119° (lit.246 119-121°) XH n.m.r.: 5 6.18, 
s, 6.63, s, CH2 ; 7.36-7.91, complex, Ph, 9.26, s, CHO.
Phenethylglyoxal
This compound was prepared from hydrocinnamic acid 
(3-phenylpropionic acid) through hydrocinnamy1 
chloride,259 diazomethyl phenethyl ketone247 and the a- 
keto-triphenyl phosphazine.247
The product had b.p. 79-80°/l mmHg (lit. 80°/l mmHg) 
1H n.m.r.: 6 2.95-3.05, complex, CH2CH2; 7.21-7.33, 
complex, Ph; 9.75, s, CHO.
Biphenyl-4-ylglyoxal
This compound was prepared from 4-acetylbipheny1 by 
oxidation with selenium dioxide in dioxane. The product
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was recrystallised from water and had m.p. 119-121° 
(lit.248 114-117°) 1H n.m.r.: 6 7.45-8.34, complex,
PhC6H4; 9.70, s, CHO.
4'-Nitrobiphenyl-4-ylglyoxal
This compound was prepared from 4-nitrobipheny1 
through 4-acetyl-4'-nitrobiphenyl249 which was oxidised 
with selenium dioxide in aqueous dioxane. The product 
crystallised from methanol as yellow crystals (38%), m.p. 
174-176° (Found, for a sample dried at 50°/710 mmHg for 5 
h: C, 63.9; H, 4.1; N, 5.5. C14H9N04. 0.5 MeOH requires 
C, 64.2; H, 4.1; N, 5.2%). 1H n.m.r.: 6 3.58, s, MeO, 
7.73-8.40, complex, CgH4C6H4; 9.69, s, CHO.
t-Butylglyoxal
O C AThis compound was prepared by oxidation of 
pinacolone with selenium dioxide in methanol. The product 
was distilled (b.p. 113-118°/710 mmHg, lit.250 114-115°)
mixed with water and the hemihydrate recrystallised from 
benzene. It had m.p. 78-80° with prior softening (lit.250 
91-92° with softening at 85°; lit.260 85°).
Cyclohexylglyoxal
This compound251 was prepared from cyclohexyl 
chloride through cyclohexyl methyl ketone by oxidation 
with selenium dioxide in aqueous dioxane. The product was 
distilled and had b.p. 78-90°/40 mmHg (lit.251 71-72°/17 
mmHg) 1H n.m.r.: S 1.30-2.69, complex, CgH^i; 9.23, s,
CHO.
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l-Bromo-3-phenylpropanone
This compound was prepared from phenylacetyl 
chloride as described by Lohrisch et al. . It had b.p.
100-104°/0.9 mmHg (lit. 65°/0.04 mmHg).
l-Bromo-4-phenylbutan-2-one
This compound was prepared from 3-phenylpropionic 
acid as described by Bestmann et. al.254. It was
distilled (b.p. 102-120°/0.1 mmHg) and had m.p. 32-33°
( n t . 2 5 4 4^ 1 4^ 00 0 . 1H n.m.r.: 6 2.96, s, CH2CH2; 3.83, s,
CH2Br; 7.2 4, s, Ph.
a-Bromo-4-phenylacetophenone
This compound255 was prepared from 4-phenyl- 
acetophenone by bromination in acetic acid. The product 
was filtered off and had 1H n.m.r.: 6 4.48, s, CH2; 7.41- 
8.12, complex, PI1C5H4 .
l-Bromo-3,3-dimethylbutan-2-one
This compound was prepared by bromination of 
pinacolone in anhydrous ether as described by Boyer and 
Straw.256 It had b.p. 46-50°/1.5 mmHg (lit.256 59°/4 
mmHg) ^H n.m.r.: 6 1.20, s, Bu^; 4.16, s, CH2.
a-Bromomethyl cyclohexyl ketone
This compound was prepared by bromination of 
cyclohexylmethyl ketone in methanol as described for 1-
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methyl-3-methyl-2-butanone.257 n.m.r.: S 1.28-2.71,
complex, CßHn; 3.96, s, CH2.
2-Benzyl-3-methoxy-6-(2'-methoxybenzylthio)imidazo- 
[1,2-b]pyridazine (V.3b)
Benzylglyoxal (0.060 g) was added to a solution of 
6-(2'-methoxybenzylthio)pyridazin-3-amine (0.1 g) and 
concentrated hydrochloric acid (0.06 ml) in ethanol (2.0 
ml) and the mixture was refluxed with stirring in an oil 
bath overnight.
After cooling in ice a solution of ethereal 
diazomethane was added and the mixture stirred at 20° 
overnight. The solvents were evaporated and the product 
subjected to t.l.c. (alumina; chloroform-light petroleum, 
1:1) and recrystallised from light petroleum to give the 
title compound (0.020 g), m.p. 131-133° (Found, for a 
sample dried at 60°/0.1 mmHg for 2 h: C, 67.4; H, 5.7; N, 
10.7. C22H21N3O2S requires C, 67.5; H, 5.4; N, 10.7%).
^H n.m.r.: 6 3.87, s, 3.96, s, 2'-0Me, 3-OMe; 4.11, s,
CH2; 4.48, s, CH2S; 6.70, d, J 9 Hz, H7; 6.81-7.54, 
complex, Ph and H3',4',5',6'; 7.53, d, J 9 Hz, H8 .
3-Methoxy-6-(3'-nitrobenzylthio)-2-phenethylimidazo- 
[1,2-b]pyridazine (V.41)
A mixture of 6-(3'-nitrobenzylthio)pyridazin-3-amine 
(0.2 g), phenylethylglyoxal (0.15 g) , hydrochloric acid 
(0.12 ml) and ethanol (4.0 ml) was refluxed with stirring 
overnight, and then cooled in ice. Excess ethereal 
diazomethane solution was then added and stirring
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continued overnight. The solvents were removed and the 
product subjected to t.l.c. (alumina; chloroform) to give 
the title compound (0.112 g) (Found: C, 62.9; H, 5.0; N, 
13.6. C22H20n 403s requires C, 62.8; H, 4.8; N, 13.3%).
1H n.m.r.: 6 3.06, s, CH2CH2; 3.79, s, MeO; 4.49, s,
CH2S; 6.73, d, J 9 Hz, H7; 7.22-8.37, complex, Ph and 
H2',4',5',6'; 7.59, d, J 9 Hz, H8.
6- (3'-Aminobenzylthio)-3-methoxy-2-phenethylimidazo- 
[l,2-b]pyridazine (V.4n)
A solution of 3-methoxy-6-(3'-nitrobenzylthio)-2- 
(phenethyl) imidazo[ 1,2-jb]pyridazine (0.11 g) in methanol 
(10 ml) was added over 5 minutes to a rapidly stirred 
mixture of iron powder (0.4 g), methanol (12 ml), water 
(4.0 ml) and concentrated hydrochloric acid (0.8 ml) at 
80-85° and the mixture maintained at that temperature for 
3 h. The mixture was filtered hot and the residue washed 
with hot methanol. The combined filtrates were evaporated 
to dryness, the residue diluted with water and adjusted 
to pH 7 and extracted with chloroform. The product was 
subjected to t.l.c. (alumina; chloroform) and gave the 
title compound (0.075 g) as an oil. (Found: C, 68.0; H, 
6.0; N, 14.4. C22H22N40S requires C, 67.7; H, 5.7; N, 
14.4%). XH n.m.r.: 6 3.06, s, CH2CH2; 3.80, s, MeO; 4.34, 
s, CH2S; 6.51-7.22, complex, Ph and H2',4',5',6'; 6.71, 
d, J 9 Hz, H7; 7.56, d, J 9 Hz, H8.
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2-(Biphenyl-4'-yl)-6-chloro-3-methoxyimidazo- 
[1,2-b]pyridazine (V.5e)
Biphenyl-4-ylglyoxal (0.18 g) was added to a mixture 
of 6-chloropyridazin-3-amine (0.1 g), ethanol (2.0 ml) 
and concentrated hydrochloric acid (0.2 ml) and the 
mixture refluxed with stirring in an oil bath at 95° for 
5 h. The volatile material was then removed under reduced 
pressure, the residue diluted with methanol (2.0 ml), 
chilled in ice, and stirred with excess ethereal 
diazomethane overnight. The solvents were evaporated and 
the residue subjected to t.l.c. (alumina; chloroform) and 
the product recrystallised from light petroleum to give 
the title compound (0.074 g), m.p. 166-167° (Found: C, 
68.0; H, 4.2; N, 12.5. C19H14C1N30 requires C, 68.0; H, 
4.2; N, 12.5%). 1H n.m.r.: S 4.19, s, MeO; 7.00, d, J 9 
Hz, H7; 7.26-8.27, complex, CgH4Ph and H8.
2-t-Butyl-3-methoxy-6-(2'-methoxyphenoxy)imidazo[l,2-b]- 
pyridazine (V.7d)
l-Bromo-3,3-dimethylbutan-2-one (0.14 g) was added 
to a warm solution of 6-(2'-methoxyphenoxy)pyridazin-3- 
amine 2-oxide (0.1 g) in ethanol (2.0 ml) and the mixture 
refluxed with stirring in an oil bath for 7 h. The 
reaction mixture was evaporated under reduced pressure, 
the residue dissolved in methanol (2 ml), cooled in ice, 
and stirred with excess ethereal diazomethane in ice and 
then at 20° overnight. The volatile material was removed 
under reduced pressure and the residue subjected to 
t.l.c. (alumina; chloroform) to give the title compound
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(0.060 g), m.p. 106-107° (Found: C, 66.1; H, 6.7; N,
13.0. C18H2iN303 requires C, 66.0; H, 6.5; N, 12.8%).
n.m.r.: 6 1.41, s, Bu^; 3.77, s, 3.79, s, 2,-OMe, 3-
OMe; 6.75, d, J 9 Hz, H7; 6.99-7.26, complex,
H3 ' , 4 ' , 5' , 6' ,* 7.77, d, J 9 Hz , H8 .
2-Benzyl-6-benzylthioimidazo[1,2-b]pyridazine (V.9a)
6-Benzylthiopyridazin-3-amine (0.217 g), l-bromo-3- 
phenylpropanone (0.33 g) and ethanol (5.0 ml) were 
refluxed with stirring in an oil bath at 95° overnight.
The solvent was evaporated and the residue subjected to 
t.l.c. (alumina; light petroleum, chloroform, 1:1) to 
give the title compound (0.124 g) (Found: C, 72.3; H,
5.3; N, 12.7. C2 oHi7 N3S requires C, 72.5; H, 5.2; N, 
12.7%). 1H n.m.r.: 6 4.14, s, CH2; 4.37, s, CH2S; 6.77, 
d, J 9 Hz, H7; 7.31, complex, 2xPh; 7.55, s, H3; 7.64, d, 
J 9 Hz, H8.
6- (4'-Methoxybenzylthio)-2-phenethylimidazo[1,2-b]- 
pyridazine (V.9k)
A mixture of 6-(4'-methoxybenzylthio)pyridazin-3 - 
amine (1.0 g), l-bromo-4-phenylbutan-2-one (0.92 g) and 
ethanol (15 ml) was refluxed with stirring for 2 h.
Sodium hydrogen carbonate (0.18 g) was then added and the 
reflux continued overnight. The solvent was evaporated 
and the residue diluted with water and extracted with 
chloroform. The extract was dried (Na2 S0 4 ), the solvent 
evaporated and the product subjected to t.l.c. (alumina; 
chloroform, light petroleum, 7:3) and recrystallised from
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light petroleum to give the title compound (0.058 g) , 
m.p. 93-94° (Found: C, 70.2; H, 5.9; N, 11.3. C22H21N3OS 
reguires C, 70.4; H, 5.6; N, 11.2%). 1H n.m.r.: 5 3.12, 
s, CH2CH2; 3.79, s, MeO; 4.36, s, CH2S; 6.77-7.76, 
complex, ArH.
2- Benzyl-6-(4'-chlorophenoxy)-3-dimethylaminomethyl- 
imidazo[l,2-b]pyridazine (V.lOf)
2-Benzyl-6 - (4 ' -chlorophenoxy) imidazo [ 1,2 — Jb ] — 
pyridazine (0.046 g) was added to a solution of 
bis(dimethylamino)methane (0.1 g),215 phosphoric acid 
(0.2 ml) and acetic acid (2 ml) and the mixture was 
refluxed with stirring in an oil bath at 120° overnight. 
It was cooled, diluted with water, adjusted with aqueous 
sodium hydroxide to pH 12, and extracted with chloroform. 
After drying (Na2S04) the solvent was evaporated and the 
oil was subjected to t.l.c. (alumina; chloroform, light 
petroleum, 7:3) to give the title compound (0.042 g) 
(Found: C, 67.0; H, 5.7; N, 14.2. C22H21CIN4O requires C, 
67.3; H, 5.4; N, 14.3%). XH n.m.r.: 6 2.17, s, Me2N;
3.60, s, CH2N; 4.18, s, CH2; 6.80, d, J 9 Hz, H7; 7.13- 
7.43, complex, Ph and H2',3',5',6'; 7.85, d, J 9 Hz, H8.
3- Acetamidomethyl-2-phenethyl-6-phenylthioimidazo[1,2-b]- 
pyridazine (V.llf)
2-Phenethyl-6-phenylthioimidazo[1,2-b]pyridazine 
(0.6 g) was added to a solution of N-(hydroxymethyl)- 
acetamide (0.3 g), acetic acid (4.0 ml) and 
concentrated sulphuric acid (0.3 ml) and the mixture
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refluxed with stirring in an oil bath at 120° overnight. 
The acetic acid was evaporated under reduced pressure and 
the residue diluted with water, adjusted to pH 11 with 
aqueous ammonia, and the mixture extracted with 
chloroform. The solvent was evaporated and the residue 
was subjected to t.l.c. (alumina, chloroform). The 
product was recrystallised from a mixture of acetone and 
light petroleum and gave the title compound (0.025 g) , 
m.p. 134-136°. (Found: C, 68.4; H, 5.6; N, 14.2. 
c23h22n40S requires C, 68.6; H, 5.5; N, 13.9%).
XH n.rn.r.: 6 1.78, s, MeCO; 3.08, s, CH2CH2; 4.39, d, J 6 
Hz, CH2N; 6.81, d, J 9 Hz, H7; 7.20-7.60, complex, 2xPh, 
7.69, d, J 9 Hz, H8.
3-Benzamidomethyl-2-benzyl-6-chloroimidazo[1,2-b]- 
pyridazine (V.lla)
2-Benzyl-6-chloroimidazo[1,2-b]pyridazine (0.16 g) 
was added to a solution of N-(hydroxymethyl)benzamide 
(0.1 g) in acetic acid (3.0 ml) containing sulphuric acid 
(0.2 ml) and the mixture was refluxed in an oil bath at 
120° overnight. The acetic acid was evaporated under 
reduced pressure and the residue diluted with water, 
adjusted with aqueous sodium hydroxide to pH 11 and 
extracted with chloroform. The solvent was evaporated and 
the product subjected to t.l.c. (alumina; chloroform) and 
recrystallised from acetone/light petroleum to give the 
title compound (0.032 g), m.p. 177-178°. (Found: C, 66.7; 
H, 4.7; N, 14.8. C21H17C1N40 requires C, 66.9; H, 4.5; N, 
14.9%). ^H n.rn.r.: 6 4.33, s, CH2; 4.98, d, J 6 Hz, CH2N;
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6.98, d, J 9 Hz, H7; 7.18-7.72, complex, 2xPh; 7.78, d, J 
9 Hz, H8.
The following compounds were prepared in a similar 
manner.
2-Benzyl-3-methoxy-6-(4'-methoxyphenoxy)imidazo[1,2-b]- 
pyridazine (V.3s) (23%), m.p. 89-90° after t.l.c.
(alumina; chloroform, light petroleum, 1:1) and 
recrystallisation from light petroleum. (Found: C, 70.2; 
H, 5.5; N, 11.6. C21H19N3°3 requires C, 69.8; H, 5.3; N, 
11.6%). 2H n.m.r.: 5 3.79, s, 3.81, s, 4'-0Me, 3-OMe; 
4.07, s, CH2; 6.68, d, J 9 Hz, H7; 6.89, d, 7.12, d, J 9 
H7, H2',3',5',6'; 7.26, bs, Ph; 7.71, d, J 9 Hz, H8.
2-Benzyl-6-(4'-chlorophenoxy)-3-methoxy[1,2-b]pyridazine
(V.3t) (36%), as colourless crystals m.p. 102-103° after
t.l.c. (alumina; chloroform, light petroleum, 2:1) and 
recrystallisation from light petroleum (Found: C, 65.8;
H, 4.3; N, 11.2. C20H16C1N302 requires C, 65.7; H, 4.4;
N, 11.5%). 1H n.m.r.: 5 3.78, s, MeO; 4.07, s, CH2; 6.72, 
d, J 9 Hz, H7; 7.16-7.42, complex, Ph and H2',3',5',6'; 
7.75, d, J 9 Hz, H8.
2-Benzyl-3-methoxy-6-phenylthioimidazo[1,2-b]pyridazine
(V.3u) (34%) after t.l.c. (alumina; chloroform, light
petroleum, 1:1 then alumina; ether/light petroleum (b.p. 
40-60°), 1:1, developed twice). (Found: C, 69.1; H, 5.2; 
N, 12.2. C20H17N30S requires C, 69.1; H, 4.9; N, 12.1%).
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n.m.r.: 8 3.83, s, MeO; 4.09, s, CH2; 6.65, d, J 9 Hz, 
H7; 7.19-7.66, complex, 2xPh; 7.57, d, J 9 Hz, H8 .
2-Benzyl-3-methoxy-6-(2'-methylbenzylthio)imidazo[l,2-b]- 
pyridazine (V.3e) (51%) after t.l.c. (alumina;
chloroform) (Found: C, 70.1; H, 5.9; N, 11.0. C22H21N3OS 
requires C, 70.4; H, 5.6; N, 11.2%). ^H n.m.r.: 6 2.43, 
s, Me; 3.93, s, MeO; 4.11, s, CH2; 4.45, s, CH2S; 6.69, 
d, J 9 Hz, H7; 7.17-7.28, complex, Ph and H3',4',5',6; 
7.54, d, J 9 Hz, H8.
2-Benzyl-3-methoxy-6-(3'-methylbenzylthio)imidazo[l,2-b]- 
pyridazine (V.3f) (36%) after t.l.c. (alumina; chloroform
and alumina; chloroform, light petroleum, 1:1) (Found:
C, 70.0; H, 5.9; N, 11.1. C22H21N30S requires C, 70.4;
H, 5.6; N, 11.2%). XH n.m.r.: 6 2.33, s, Me; 3.92, s, 
MeO; 4.11, s, CH2; 4.41, s, CH2S; 6.73, d, J 9 Hz, H7; 
7.11-7.35, complex, H 2',4',5',6' and Ph; 7.58, d, J 
9 Hz, H8 .
2-Benzyl-3-methoxy-6-(3'-methoxybenzylthio)imidazo- 
[1,2-b]pyridazine (V.3c) (28%) after t.l.c. (alumina;
chloroform, light petroleum, 1:1) (Found: C, 67.4; H,
5.7; N, 10.7. C22H21N3O2S requires C, 67.5; H, 5.4; N, 
10.7%). XH n.m.r.: 8 3.76, s, 3.90, s, 3'-OMe, 3-OMe; 
4.10, s, CH2; 4.40, s, CH2S; 6.69, d, J 9 Hz, H7; 6.84- 
7.28, complex, Ph and H2' , 4' , 5',6'; 7.54, d, J 9 Hz, H8 .
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2-Benzyl-3-methoxy-6-(4'-methoxybenzylthio)imidazo- 
[1,2-b]pyridazine (V.3d) (40%) after t.l.c. (alumina;
chloroform, light petroleum, 1:1) (Found: C, 67.4; H,
5.7; N, 10.5. C22H2iN302S requires C, 67.5; H, 5.4; N, 
10.7%). XH n.m.r.: 6 3.77, s, 3.94, s, 4'-OMe, 3-OMe;
4.10, s, CH2; 4.39, s, CH2S; 6.69, d, J 9 Hz, H7; 6.73, 
d, 7.38, d, J 8.5 Hz, H2 ' , 3 ' , 5 ' , 6 ' ; 7.35, complex, Ph 
7.54, d, J 9 Hz, H8.
2-Benzyl-6-(2'-chlorobenzylthio)-3-methoxyimidazo[1,2-b]- 
pyridazime (V.3g) (22%) after t.l.c. (alumina;
chloroform, light petroleum, 1:1) (Found, for a sample 
dried at 50°/0.1 mmHg for 24 h: C, 63.3; H, 4.8; N, 10.4. 
c21h 18c1n 30S requires C, 63.7; H, 4.6; N, 10.6%).
XH n.m.r.: S 3.92, s, MeO; 4.11, s, CH2; 4.55, s, CH2S; 
6.71, d, J 9 Hz, H7; 7.13-7.67, complex, Ph and 
H3' ,4',5',6'; 7.55, d, J 9 Hz, H8.
2-Benzyl-6-(3'-chlorobenzylthio)-3-methoxyimidazo[1,2-b]- 
pyridazine (V.3h) (29%) as a colourless solid, m.p. 124-
126° after t.l.c. (alumina; chloroform, light petroleum, 
1:1) and recrystallisation from light petroleum. (Found: 
63.8; H, 4.6; N, 10.8. C21H18C1N30S requires C, 63.7; H, 
4.6; N, 10.6%). ^H n.m.r.: 6 3.88, s, MeO; 4.11, s, CH2 ; 
4.40, s, CH2S; 6.74, d, J 9 Hz, H7; 7.15-7.35, complex,
Ph and H2',4',5',6'; 7.61, d, J 9 Hz, H8.
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2-Benzyl-6-(4'-chlorobenzylthio)-3-methoxyimidazo[1,2-b]- 
pyridazine (V.3i) (27%) after t.l.c. (alumina,
chloroform). (Found: 63.3; H, 4.8; N, 10.2. C21H18C1N30S 
requires C, 63.7; H, 4.6; N, 10.6%). n.m.r.: 6 3.90,
s, MeO; 4.10, s, CH2; 4.39, s, CH2S; 6.70, d, J 9 Hz, H7; 
7.21-7.37, complex, Ph and H2',3',5',6'; 7.56, d, J 9 Hz, 
H8 .
2-Benzyl-6-(2',4'-dichlorobenzylthio)-3-methoxyimidazo- 
[1,2-b]pyridazine (V.3j) (10%), m.p. 95-97° after t.l.c.
(alumina; chloroform, light petroleum, 1:1) and 
recrystallisation from light petroleum (Found: C, 58.3;
H, 4.0; N, 9.7. C21H17C12N3OS requires C, 58.6; H, 4.0;
N, 9.8%). -^H n.m.r.: S 3.92, s, MeO; 4.11, s, CH2; 4.51,
s, CH2S; 6.71, d, J 9 Hz, H7; 7.21-7.54, complex, Ph and 
H3',5',6'; 7.56, d, J 9 Hz, H8.
2-Benzyl-3-methoxy-6-(2' -nitrobenzylthio)imidazo- 
[1,2-b]pyridazine (V.3k) (22%), m.p. 118-120° after
t. l.c. (alumina, chloroform) and recrystallisation from 
light petroleum. (Found: C, 62.4;, H, 4.7; N, 13.8. 
C21H18N4°3S requires C, 62.1; H, 4.5; N, 13.8%).
1H n.m.r.: 6 3.91, s, MeO; 4.10, s, CH2; 4.79, s, CH2S; 
6.68, d, J 9 Hz, H7; 7.20-8.10, complex, Ph and 
H3',4',5',6' and 8.
2-Benzyl-3-methoxy-6-(3'-nitrobenzylthio)imidazo[l,2-b]- 
pyridazine (V.31) (44%), m.p. 94-96° after t.l.c.
(alumina; chloroform) and recrystallisation from light
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petroleum. (Found: C, 62.4, H, 4.5; N, 14.0. C21HigN403S 
requires C, 62.0; H, 4.5; N, 13.8%). 1H n.m.r.: 5 3.90, 
s, MeO; 4.10, s, CH2; 4.49, s, CH2S; 6.72, d, J 9 Hz, H7; 
7.28-8.38, complex, Ph and H2',4' ,5',6',8.
2-Benzyl-3-methoxy-6-(4'-nitrobenzylthio)imidazo[1,2-b]- 
pyridazine (V.3m) (12%), m.p. 99-101° after t.l.c.
(alumina, chloroform) and recrystallisation from light 
petroleum. (Found: C, 61.9; H, 4.5; N, 13.7. C21H18N403S 
requires C, 62.1; H, 4.5; N, 13.8%). 1H n.m.r.: 6 3.87,
s, MeO; 4.11, s, CH2; 4.50, s, CH2S; 6.74, d, J 9 Hz, H7;
7.26-8.23, complex, Ph and H2',3',5',6 and 8.
6- (3'-Aminobenzylthio)-2-benzyl-3-methoxyimidazo[1,2-b]- 
pyridazine (V.3n) (77%), m.p. 102-104° after t.l.c.
(alumina; chloroform) and recrystallisation from light 
petroleum (Found: C, 67.4; H, 5.7; N, 14.8. C2^H2qN40S 
requires C, 67.0; H, 5.4; N, 14.9%). ■''H n.m.r.: 6 3.34,
br, NH2; 3.92, s, MeO; 4.09, s, CH2; 4.34, s, CH2S; 6.51-
7.30, complex, Ph and H3',4',5',6' and 7; 7.54, d, J 9 
Hz, H8.
6-(4'-Aminobenzylthio)-2-benzy1-3-methoxyimidazo[1,2-b]- 
pyridazine (V.3o) (95%), m.p. 101-103° after t.l.c.
(alumina, chloroform) and recrystallisation from light 
petroleum (Found, for a sample dried at 55°/0.1mmHg for 
2 h: C, 67.2; H, 5.7; N, 15.0. C21H20N4OS requires C,
67.0; H, 5.4; N, 14.9%). 1H n.m.r.: S 3.95, s, MeO;
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4.10, s, CH2 ; 4.35, s, CH2S; 6.56-7.27, complex, Ph and 
H2',3',5',6 ' and 7; 7.53, d, J 9 Hz, H 8.
2-Benzyl-3-methoxy-6-(pyridin-2'-ylmethylthio)imidazo- 
[1,2-b]pyridazine (V.3p) (18%), after t.l.c. (alumina,
chloroform) (Found: C, 66.0; H, 5.3; N, 15.8. 
C20H18N4OS requires C, 66.3; H, 5.0; N, 15.5%).
■^H n.m.r.: S 3.88, s, MeO; 4.09, s, CH2; 4.58, s, CH2S; 
6.76, d, J 9 Hz, H 7; 7.25-8.59, complex, Ph and 
H3',4,,5',6',8; 7.55, d, J 9 Hz, H8.
2-Benzyl-3-methoxy-6-(pyridin-3'-ylmethylthio)imidazo- 
[1,2-b]pyridazine (V.3q) (10%), after t.l.c. (alumina,
chloroform) (Found: C, 65.9; H, 5.3; N, 15.2. 
C20H18N4OS requires C, 66.3; H, 5.0; N, 15.5%).
XH n.m.r.: 5 3.90, s, MeO; 4.10, s, CH2; 4.42, s, CH2S; 
6.71, d, J 9 Hz, H7; 7.26-7.86, complex, Ph and 
H2 ' ,4',5',6'; 7.57, d, J 9 Hz, H8.
2-Benzyl-3-methoxy-6-(pyridin-4'-ylmethylthio)imidazo- 
[1,2-b]pyridazine (V.3r) (18%), after t.l.c. (alumina,
chloroform) (Found: C, 66.5; H, 5.3; N, 15.7.
C20H18N4OS requires C, 66.3; H, 5.0; N, 15.5%).
■^ H n.m.r.: 6 3.80, s, MeO; 4.09, s, CH2; 4.39, s, CH2S; 
6.73, d, J 9 Hz, H7; 7.27-8.54, complex, Ph and 
H2 ' ,3 ' ,5' , 6 ' ; 7.58, d, J 9 Hz, H8.
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3-Methoxy-6-(4'-methoxyphenoxy)-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4p) (39%), after t.l.c. (alumina;
chloroform, light petroleum, 1:1) and recrystallisation 
from light petroleum. (Found: C, 70.4; H, 5.9; N, 11.4. 
c22h21n3°3 requires C, 70.4; H, 5.6; N, 11.2%).
n.m.r. : 6 3.05, s, CH2CH2,* 3.67, s, 4'-0Me; 3.83, s, 
3-OMe; 6.72, d, J 9 Hz, H7; 6.91, d, 7.09, d, J 9 Hz,
H2',3',5',6'; 7.23, bs, Ph; 7.75, d, J 9 Hz, H8.
6-(4 '-chlorophenoxy)-3-methoxy-2-phenethylimidazo[1,2-b]- 
pyridazine (V.4q) (47%), after t.l.c. (alumina;
chloroform, light petroleum, 1:1) and recrystallisation 
from light petroleum. (Found: C, 66.4; H, 4.8; N, 11.2. 
c21h 18c1n 3°2 requires C, 66.4; H, 4.8; N, 11.1%).
■^H n.m.r.: 8 3.06, s, CH2CH2; 3.66, s, MeO; 6.74, d, J 
9 Hz, H7 ; 7.10-7.44, complex, Ph and H2',3',5',6'; 7.80, 
d, J 9 Hz, H8.
3-Methoxy-6-(2'-methylbenzylthio)-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4d) (46%), after t.l.c. (alumina;
chloroform, light petroleum, 3:2). (Found: C, 70.5; H,
6.3; N, 10.4. C23H23N3OS requires C, 70.9; H, 6.0; N, 
10.8%). 1H n.m.r.: 6 2.44, s, MeC; 3.07, s, CH2CH2;
3.82, s, MeO; 4.45, s, CH2S; 6.72, d, J 9 Hz, H7; 7.19- 
7.43, complex, Ph and H3',4',5',6'; 7.57, d, J 9 Hz, H8.
3-Methoxy-6-(3'-methylbenzylthio)-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4e) (37%), after t.l.c. (alumina;
chloroform, light petroleum, 3:2). (Found: C, 70.9; H,
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6.1; N, 10.7. C23H23N3OS requires C, 70.9; H, 6.0; N, 
10.8%). 1H n.m.r.: 6 2.33, s, MeC; 3.07, s, CH2CH2;
3.81, s, MeO; 4.41, s, CH2S; 6.73, d, J 9 Hz, H7; 7.11- 
7.28, complex, Ph and H2',4',5',6 '; 7.57, d, J 9 Hz, H8 .
3-Methoxy-6-(4'-methylbenzylthio)-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4f) (27%), after t.l.c. (alumina;
chloroform, light petroleum, 3:2). (Found: C, 70.8; H, 
6.2; N, 10.7. C23H23N3OS requires C, 70.9; H, 6.2; N, 
10.7%). 1H n.m.r.: 6 2.31, s, MeC; 3.07, s, CH2CH2;
3.81, s, MeO; 4.40, s, CH2S; 6.72, d, J 9 Hz, H7; 7.07- 
7.40, complex, Ph and H2',3',5',6'; 7.56, d, J 9 Hz, H8 .
3-Methoxy-6-(2'-methoxybenzylthio)-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4a) (23%), after t.l.c. (alumina;
chloroform, light petroleum, 3:2). (Found: C, 67.7; H,
5.8; N, 10.7. C23H23N3O2S requires C, 68.1; H, 5.7; N, 
10.4%). XH n.m.r.: 5 3.07, s, CH2CH2; 3.84, s, 3.87, s, 
2'-OMe, 3-OMe; 4.47, s, CH2S; 6.72, d, J 9 Hz, H7; 6.80-
7.45, complex, Ph and H3',4',5',6'; 7.56, d, J 9 Hz, H8 .
6-(2'-Chlorobenzylthio)-3-methoxy-2-phenethylimidazo- 
[1 , 2-b]pyridazine (V.4g) (35%), after t.l.c. (alumina;
chloroform, light petroleum, 3:2). (Found: C, 64.1; H,
5.1; N, 10.0. C22H18CIN3OS requires C, 64.2; H, 4.5; N, 
10.2%). 1H n.m.r.: S 3.07, s, CH2CH2; 3.80, s, MeO ; 
4.55, s, CH2S; 6.72, d, J 9 Hz, H7; 7.13-7.66, complex, 
Ph and H3',4',5',6'; 7.57, d, J 9 Hz, H8 .
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6 - (3'-Chlorobenzylthio)-3-methoxy-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4h) (37%), after t.l.c. (alumina;
chloroform, light petroleum, 3:2). (Found: C, 65.1; H,
4.8; N, 10.6. C22H18C1N30S requires C, 64.8; H, 4.4; N,
10.3%). 1H n.m.r.: 6 3.07, s, CH2CH2; 3.78, s, MeO;
4.39, s, CH2S; 6.72, d, J 9 Hz, H7; 7.22-7.49, complex,
Ph and H2',4',5',6'; 7.58, d, J 9 Hz, H8.
3-Methoxy-6-(3'-methoxybenzylthio)-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4b) (29%), after t.l.c. (alumina;
chloroform, light petroleum, 3:2). (Found: C, 67.6; H, 
5.9; N, 10.1. C23H23N302S requires C, 68.1; H, 5.7; N, 
10.4%). 1H n.m.r.: 6 3.07, complex, CH2CH2; 3.80, s, 3'- 
OMe, 3-OMe; 4.42, s, CH2S; 6.73, d, J 9 Hz, H8; 6.86- 
7.23, complex, Ph and H2',4',5',6'; 7.58, d, J 9 Hz, H8.
3-Methoxy-6-(4' -methoxybenzylthio)-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4c) (45%), after t.l.c. (alumina;
chloroform, light petroleum, 3:2). (Found: C, 67.6; H,
5.9; N, 10.0. C23H23N302S requires C, 68.1; H, 5.7; N, 
10.4%). -^H n.m.r.: S 3.07, s, CH2CH2; 3.78, s, 3.82, s,
4'-OMe, 3-OMe; 4.39, s, CH2S; 6.72, d, J 9 Hz, H7; 6.79-
7.42, complex, Ph and H2',3',5',6'; 7.56, d, J 9 Hz, H8.
6-(4'-Chlorobenzylthio)-3-methoxy-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4i) (30%), after t.l.c. (alumina;
chloroform, light petroleum, 3:2). (Found: C, 64.2; H,
4.8; N, 10.3. C22H18C1N30S requires C, 64.8; H, 4.5; N,
10.3%). 1H n.m.r.: 6 3.07, s, CH2CH2; 3.79, s, MeO;
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4.39, s, CH2 S; 6.72, d, J 9 Hz, H7; 7.22-7.37, complex,
Ph and H2',3',5',6'; 7.58, d, J 9 Hz, H8.
6-(2',4'-Dichlorobenzylthio)-3-methoxy-2-phenethyl- 
imidazo[1,2-b]pyridazine (V.4j) (27%), after t.l.c.
(alumina; chloroform, light petroleum, 3:2). (Found: C, 
59.6; H, 4.2; N, 9.6. c22H19cl2N30S requires C, 59.5; H, 
4.3; N, 9.5%). 1H n.m.r.: 6 3.07, s, CH2CH2; 3.80, s, 
MeO; 4.50, s, CH2S; 6.72, d, J 9 Hz, H7; 7.15-7.43, 
complex, Ph and H3',5',6'; 7.59, d, J 9 Hz, H8.
3-Methoxy-6-(2'-nitrobenzylthio)-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4k) (33%), after t.l.c. (alumina;
chloroform). (Found: C, 62.8; H, 4.8; N, 13.3. 
c 33h 20n 4°3s requires C, 62.8; H, 4.8; N, 13.3%).
^H n.m.r.: 5 3.06, s, CH2CH2 ; 3.79, s, MeO; 4.79, s,
CH2S; 6.70, d, J 9 Hz, H7; 7.22-8.11, complex, Ph and 
H3' ,4' ,5',6'; 7.57, d, J 9 Hz, H8.
3-Methoxy-6-(4'-nitrobenzylthio)-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4m) (50%), after t.l.c. (alumina;
chloroform, light petroleum, 3:2). (Found: C, 62.9; H, 
5.1; N, 13.1. C22H20N4°3S requires C, 62.8; H, 4.8; N, 
13.3%). 1H n.m.r.: 6 3.06, s, CH2CH2; 3.75, s, MeO;
4.48, s, CH2S; 6.72, d, J 9 Hz, H7; 7.22, s, Ph; 7.59, d, 
J 9 Hz, H8; 7.65, d, 8.15, d, J 8.5 Hz, H2',3',5',6'.
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6 - (4'-Aminobenzylthio)-3-methoxy-2-phenethylimidazo- 
[1,2-b]pyridazine (V.4o) (41%), m.p. 117-119° after
t.l.c. (alumina; chloroform) and recrystallisation from 
light petroleum. (Found, for a sample dried at 
50°/0.1 mm Hg for 3 h: C, 67.3; H, 5.7; N, 14.1. 
c22h22n40S requires C, 67.7; H, 5.7; N, 14.3%).
■^H n.m.r.: 6 3.07, s, CH2CH2; 3.83, s, MeO; 4.34, s,
CH2S; 7.57, br, NH2; 6.71, d, J 9 Hz, H7; 7.20-7.28, 
complex, Ph and H2',3',5',6'; 7.55, d, J 9 Hz, H8 .
3-Methoxy-2-phenethyl-6-phenylthioimidazo[1,2-b]- 
pyridazine (V.4r) (46%), after t.l.c. (alumina;
chloroform, light petroleum, 1:1) (Found: C, 69.3; H,
5.6; N, 11.1. C21H19N30S requires C, 69.8; H, 5.3; N,
11.6%). 1H n.m.r.: 8 3.06, s, CH2CH2; 3.70, s, Me; 6.67, 
d, J7 /8 9 Hz, H7; 7.21-7.60, complex, ArH; 7.60, d, J7^3 
9 Hz, H8.
3-Methoxy-2-(4"-nitrobiphenyl-4'-yl)-6-phenoxyimidazo- 
[1,2-b]pyridazine (V.5i) (25%), m.p. 225-227° after
t.l.c. (alumina; chloroform, light petroleum, 2:3) and 
recrystallisation from methanol. (Found: C, 68.8; H,
4.3; N, 12.7. C25H18N404 requires C, 68.5; H, 4.1; N,
12.8%). 1 H n.m.r.: 8 4.01, s, MeO; 6.90, d, J 9 Hz, H7; 
7.25-8.36, complex, Ph, C6H4C6H4 and H8.
2-(Biphenyl-4'-yl)-3-methoxy-6-phenylthioimidazo[1,2-b]- 
pyridazine (V.5f) (33%), m.p. 127-128° after t.l.c.
(alumina; chloroform, light petroleum, 1:1) (Found, for
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a sample dried at 20°/0.1 mmHg for 20 h: C, 73.1; H,
4.8; N, 10.3. C25H19N3OS requires C, 73.2; H, 4.7; N, 
10.3%). 1H n.m.r.: 6 4.02, s, MeO; 6.72, d, J 9 Hz, H7; 
7.41-8.23, complex, Ph, C6H4PI1 and H8.
6-Benzyloxy-2-(biphenyl-4'-yl)-3-methoxyimidazo[l,2-b]- 
pyridazine (V.5g) (17%), m.p. 131-133° after t.l.c.
(alumina; chloroform, light petroleum, 1:1) and 
recrystallisation from light petroleum (Found: C, 76.7;
H, 5.2; N, 10.6. C26H21N3°2 requires C, 76.6; H, 5.2; N,
10.3%). 1H n.m.r.: 6 4.14, s, MeO; 5.45, s, CH2O; 6.68, 
d, J 9 Hz, H7; 7.38-8.23, complex, Ph, Cg^Ph and H8.
6-Benzylthio-2-(biphenyl-4' -yl)-3-methoxyimidazo[1,2-b]- 
pyridazine (V.5a) (19%), m.p. 178-179° after t.l.c.
(alumina; chloroform, light petroleum, 1:1) and 
recrystallisation from light petroleum (Found: C, 73.9;
H, 5.2; N, 10.1. C26H21N30S requires C, 73.7; H, 5.0; N, 
9.9%). ^H n.m.r.: S 4.13, s, MeO; 4.50, s, CH2S; 6.79, 
d, J 9 Hz, H7; 7.25-8.25, complex, Ph, C6H4Ph and H8 .
2-(Biphenyl-4'-yl)-3-methoxy-6-(2''-methoxybenzylthio)- 
imidazo[l/2-b]pyridazine (V.5b) (30%) after t.l.c.
(alumina; chloroform, light petroleum, 1:1) (Found: C,
71.7; H, 5.4; N, 9.3. C27H23N3O2S requires C, 71.5; H,
5.1; N, 9.3%). 1H n.m.r.: 6 3.89, s, 2'-OMe; 4.19, s, 3- 
OMe; 4.33, s, CH2S; 6.78, d, J 9 Hz, H7; 6.86-8.26, 
complex, C6H4Ph, H3',4',5',6 and 8.
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2-(Biphenyl-4'-yl)-3-methoxy-6-(3''-methoxybenzylthio)- 
imidazo-[1,2-b]pyridazine (V.5c) (27%) after t.l.c.
(alumina; chloroform, light petroleum, 1:1) (Found: C,
71.2; H, 5.2; N, 9.0. C27H23N3O2S requires C, 71.5; H,
5.1; N, 9.3%). 1H n.m.r.: S 3.80, s, 3'-OMe; 4.13, s, 3- 
OMe; 4.47, s, CH2S; 6.78, d, J 9 Hz, H7; 7.00-8.25, 
complex, Cß^Ph, H2',4',5',6' and 8.
2-(Biphenyl-4'-yl)-3-methoxy-6-(4''-methoxybenzylthio)- 
imidazo-[1,2-b]pyridazine (V.5d) (18%) after t.l.c.
(alumina; chloroform, light petroleum, 1:1) and 
recrystallisation from light petroleum. (Found: C,
71.5; H, 5.2; N, 9.3. C27H23N4OS requires C, 71.5; H, 
5.1; N, 9.3%). 1H n.m.r.: 6 3.80, s, 4'-OMe; 4.17, s, 3- 
OMe; 4.46, s, CH2S; 6.78, d, J 9 Hz, H7; 6.82-8.26, 
complex, CßH4Ph, H2',3',5',6 and 8 .
6-Benzylthio-3-methoxy-2-(4"-nitrobiphenyl-4'-yl)imidazo- 
[l,2-b]pyridazine (V.5h) (35%), m.p. 209-211° after
t.l.c. (alumina; chloroform, light petroleum, 1:1) and 
recrystallisation from ethanol. (Found: C, 66.3; H,
4.4; N, 12.0. C26H20N4°3S requires C, 66.6; H, 4.3; N,
12.0%). ^H n.m.r.: 8 4.19, s, MeO; 4.54, s, CH2S; 7.10, 
d, J 9 Hz, H7; 7.28-8.37, complex, Ph, C5H4C5H4 and H8.
2-t-Buty1-6-fluoro-3-methoxyimidazo[1,2-b]pyridazine
(V.7b) (33%), m.p. 83-85° after t.l.c. (alumina;
chloroform, light petroleum, 3:1) and sublimation.
(Found: C, 59.0; H, 6.2; N, 18.6. C11H14FN30 requires
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C, 59.2; H, 6.3; N, 18.8%). n.m.r.: 8 1.44, s, Bu^ ; 
4.06, s, MeO; 6.71, d, J 9 Hz, H7; 7.86, dd, J7/8 9 Hz, 
JHF 7 Hz, H8.
2-t-Butyl-6-chloro-3-methoxyimidazo[1,2-b]pyridazine
(V.7c) (30%), m.p. 82-84° after t.l.c. (alumina;
chloroform, light petroleum, 3:1) and recrystallisation 
from light petroleum. (Found, for a sample dried at 
25°/0.1 mm Hg for 3 h: C, 55.2; H, 6.0; N, 17.2.
c 11h 14c1n 3° requires C, 55.1; H, 5.9; N, 17.5%).
1H n.m.r.: 8 1.45, s, But; 4.07, s, MeO; 6.90, d, J 9 Hz, 
H7; 7.76, d, J 9 Hz, H8.
6-Benzyloxy-2-t-butyl-3-methoxyimidazo[1,2-b]pyridazine 
(V.7e) (30%) after t.l.c. (alumina; chloroform, light
petroleum, 1:1). (Found: C, 69.3; H, 7.0; N, 13.3.
c 18h21n3°2 requires C, 69.4; H, 6.8; N, 13.5%).
1H n.m.r.: 8 1.43, s, But; 4.01, s, MeO; 5.41, s, CH20;
6.61, d, J 9 Hz, H7; 7.30-7.45, complex, Ph; 7.71, d, J 
9 Hz, H8.
6-Benzylthio-2-t-butyl-3-methoxyimidazo[1,2-b]pyridazine 
(V.7a) (39%) after t.l.c. (alumina; chloroform). (Found, 
for a sample dried at 50°/0.1 mm Hg for 15 h: C, 66.2;
H, 6.7; N, 12.8. C18H2iN3OS requires C, 66.0; H, 6.5; N, 
12.8%). XH n.m.r.: 5 1.44, s, Bu1; 3.99, s, MeO; 4.46, 
s, CH2S; 6.73, d, J 9 Hz, H7; 7.25-7.55, complex, Ph;
7.62, d, J 9 Hz, H8.
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2-Cyclohexyl-6-fluoro-3-methoxyimidazo[1,2-b]pyridazine 
(V.8a) (10%) after t.l.c. (alumina; chloroform, light
petroleum, 1:1, then alumina; benzene). (Found, for a 
sample dried at 50°/0.1 mmHg for 2 h: C, 62.4 ; H, 6.4 ;
N, 16.6. C13H15FN3O requires C, 62.6; H, 6.5; N, 16.9%).
n.m.r.: 8 1.26-2.SI, complex, CgH^; 4.07, s, MeO; 
6.75, d, J 9 Hz, H7; 7.89, dd, J7/8 9 Hz, JHF 7 Hz, H8.
6-Chlor0-2-cyclohexyl-3-methoxyimidazo[1,2-to]pyridazine
(V.8b) (40%) after t.l.c. (alumina; chloroform, light
petroleum, 1:1, then alumina; benzene). (Found, for a 
sample dried at 50°/0.1 mmHg for 2 h: C, 58.7; H, 6.3;
N, 15.8. C13H16C1N3° requires C, 58.7; H, 6.3; N,
15.8%). 1H n.m.r.: 6 1.26-2.88, complex, OsH^; 4.09, s, 
MeO; 6.91, d, J 9 Hz, H7; 7.74, d, J 9 Hz, H8.
2-Cyclohexyl-3-methoxy-6-(2'-methoxyphenoxy)imidazo- 
[1,2-b]pyridazine (V.8c) (41%) after t.l.c. (alumina;
chloroform). (Found: C, 67.4; H, 6.7; N, 12.2%.
C21H25N3°2S requires C, 68.0; H, 6.6; N, 11.9%).
1H n.m.r.: 6 1.20-2.80, complex, CqHh ; 3.77, s, 3.81, s, 
2'-OMe, 3-OMe; 6.73, d, J 9 Hz, H7; 6.98-7.26, complex, 
H3,,4',5',6/; 7.73, d, J 9 Hz, H8.
6-Benzyloxy-2-cyclohexyl-3-methoxyimidazo[1,2-b]- 
pyridazine (V.8d) (22%) after t.l.c. (alumina;
chloroform). (Found: C, 70.9; H, 7.1; N, 12.3.
c20h23n 3°2 requires C, 71.2; H, 6.9; N, 12.5%).
1H n.m.r.: 6 1.26-1.90, complex, C^Hn; 4.01, s, MeO;
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5.40, s, CH20; 6.60, d, J 9 Hz, H7; 7.43, m, Ph; 7.66, d, 
J 9 Hz, H8.
2-Benzyl-6-chloroimidazo[1,2-b]pyridazine (V.9e) (58%),
m.p. 128-129° (from ethanol). (Found: C, 64.3; H, 4.1;
N, 17.2. C13H10C1N3 requires C, 64.1; H, 4.1; N, 17.2%).
XH n.m.r.: 5 4.20, s, CH2; 7.09, d, J 9 Hz, H7; 7.31, s, 
Ph; 7.62, s, H3; 7.95, d, J 9 Hz, H8.
2-Benzyl-6-(4'-chlorophenoxy)imidazo[1,2-b]pyridazine 
(V.9g) (46%) as colourless crystals, m.p. 84-86° [after
t.l.c. (alumina; chloroform, light petroleum, 1:1) and 
recrystallisation from light petroleum]. (Found, for a 
sample dried at 20°/0.1 mm Hg for 15h: C, 68.3; H, 4.2;
N, 12.6. C19H14C1N30 requires C, 68.0; H, 4.2; N,
12.5%). 1H n.m.r.: 5 4.11, s, CH2 ; 6.81, d, J 9 Hz, H7; 
7.05-7.45, complex, Ph and H3, 2',3',5',6'; 7.84, d, J 
9 Hz, H8.
2-Benzyl-6-(4'-methoxyphenoxy)imidazo[1,2-b]pyridazine
(V .9f) (32%), m.p. 68-70° after t.l.c. (alumina;
chloroform, light petroleum, 1:1) and recrystallisation 
from light petroleum. (Found: C, 72.3; H, 5.3; N, 12.7.
c 20h 17n 3°2 requires C, 72.5; H, 5.2; N, 12.7%).
1H n.m.r.: 6 3.80, s, MeO; 4.10, s, CH2; 6.78, d, J 9 Hz,
H7; 6.89, d, 7.09, d, J 9 Hz, H2',3',5',6'; 7.26, bs, Ph;
7.33, s, H3; 7.79, d, J 9 Hz, H8.
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2-Benzyl-6-phenylthioimidazo[1,2-b]pyridazine (V.9h)
(76%) after t.l.c. (alumina; chloroform, light petroleum, 
3:2). (Found: C, 71.8; H, 4.8; N, 13.4. C19H15N3S
requires C, 71.9; H, 4.8; N, 13.2%). 1H n.m.r.: 6 4.13, 
s, CH2; 6.71, d, J 9 Hz, H7; 7.28-7.70, complex, 2 x Ph 
and H3,8.
2-Benzyl-6-benzyloxyimidazo[1,2-b]pyridazine (V.9i)
(73%), m.p. 96-97° after t.l.c. (alumina; chloroform, 
light petroleum, 1:1) and recrystallisation from light 
petroleum. (Found: C, 76.6; H, 5.8; N, 13.4%.
c20h 17n3° requires C, 76.2; H, 5.4; N, 13.3%).
■^H n.m.r.: 5 4.13, s, CH2; 5.30, s, CH2O, 6.67, d, J 
9 Hz, H7; 7.31-7.42, complex, 2 x Ph and H3; 7.72, d, J 
9 Hz, H8.
2-Benzyl-6-(2'-methoxybenzylthio)imidazo[1,2-b]pyridazine
(V.9b) (43%), after t.l.c. (alumina; chloroform, light
petroleum, 1:1). (Found: C, 70.1; H, 5.6; N, 11.7. 
C21H19N3OS requires C, 69.8; H, 5.3; N, 11.6%).
^H n.m.r.: S 3.84, s, MeO; 4.14, s, CH2; 4.40, s, CH2S; 
6.75, d, J 9 Hz, H7; 6.87-7.42, complex, Ph and 
H3',4',5',6'; 7.55, s, H3; 7.61, d, J 9 Hz, H8 .
2-Benzyl-6-(3'-methoxybenzylthio)imidazo[l,2-b]pyridazine
(V.9c) (36%), after t.l.c. (alumina; chloroform, light
petroleum, 1:1). (Found: C, 69.6; H, 5.5; N, 11.6.
C21H19N3OS requires C, 69.8; H, 5.3; N, 11.6%).
1H n.m.r.: 5 3.78, s, MeO; 4.15, s, CH2; 4.35, s, CH2S;
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6.79, d, J 9 Hz, H7; 6.93-7.31, complex, Ph and 
H2' ,4' ,5' ,6'; 7.55, s, H3; 7.67, d, J 9 Hz, H8 .
2-Benzyl-6-(4'-methoxybenzylthio)imidazo[1,2-b]pyridazine
(V.9d) (51%), as yellow crystals, m.p. 82-84° after
t.l.c. (alumina; chloroform, light petroleum, 1:1) and 
recrystallisation from light petroleum). (Found, for a 
sample dried at 50°/0.1 mm Hg for 6 h: C, 69.7; H, 5.4;
N, 11.6. C2iH19N3OS requires C, 69.8; H, 5.3; N, 11.6%). 
^H n.m.r.: S 3.78, s, MeO; 4.15, s, CH2 ; 4.33, s, CH2S; 
6.76, d, J 9 Hz, H7; 6.78-7.37, complex, Ph and 
H2',3',5',6'; 7.55, s, H3; 7.63, d, J 9 Hz, H8 .
6-Chloro-2-phenethy1imidazo[1,2-b]pyridazine (V.91)
(86%), m.p. 99-101° after t.l.c. (alumina; chloroform, 
light petroleum, 7:3). (Found, for a sample dried at 
20°/0.1 mmHg for 3 h: C, 65.8; H, 4.8; N, 15.9.
C14H12CIN3 requires C, 65.2; H, 4.7; N, 16.3%).
XH n.m.r.: 6 3.14, s, CH2CH2; 7.06, d, J 9 Hz, H7; 7.25, 
s, Ph; 7.63, s, H3; 7.92, d, J 9 Hz, H8.
2-Phenethyl-6-phenylthioimidazo[1,2-b]pyridazine (V.9m)
(95%) after t.l.c. (alumina; chloroform, light petroleum, 
7:3). (Found: C, 72.3; H, 5.4; N, 12.9. C20H17N3S 
requires C, 72.5; H, 5.2; N, 12.7%). XH n.m.r.: 6 3.09, 
s, CH2CH2; 6.70, d, J 9 Hz, H7; 7.23-7.71, complex, 2xPh 
and H3,8.
202
6-Benzyloxy-2-phenethylimidazo[1,2-b]pyridazine (V.9n)
(85%), m.p. 109-110° after t.l.c. (alumina; chloroform, 
light petroleum, 7:3) and recrystallisation from light 
petroleum. (Found: C, 76.5; H, 6.2; N, 12.9. C21H19N3° 
requires C, 76.6; H, 5.8; N, 12.8%). 1H n.m.r.: 6 3.12, s, 
CH2CH2; 5.34, s, CH20; 6.76, d, J 9 Hz, H7; 7.26-7.90, 
complex, 2xPh and H3; 7.85, d, J 9.0 Hz, H8.
6-Benzylthio-2-phenethylimidazo[l,2-b]pyridazine (V.9j)
(95%), after t.l.c. (alumina; chloroform, light 
petroleum, 7:3). (Found: C, 72.8; H, 5.5; N, 12.0. 
c 21h 19n 3s requires C, 73.0; H, 5.5; N, 12.2%). 1H n.m.r.: 
6 3.10, s, CH2CH2; 4.39, s, CH2S; 6.78, d, J 9 Hz, H7; 
7.26-7.38, complex, 2xPh; 7.59, s, H3; 7.65, d, J 9 Hz,
H8 .
2-(Biphenyl-4' -yl)-6-chloroimidazo[1,2-b]pyridazine
(V .9p) (88%), m.p. 275-276° (from ethanol-chloroform).
(Found: C, 70.2; H, 4.2; N, 13.5. C^g^l2c-*-N3 requires C, 
70.7, H, 4.0; N, 13.7%). ^H n.m.r.: 6 7.01-8.26, complex, 
ArH.
2-(Biphenyl-4'-yl)-6-(2"-methoxyphenoxy)imidazo[1,2-b]- 
pyridazine (V.9q) (88%), m.p. 209-211° after t.l.c.
(alumina; chloroform) and recrystallisation from 
methanol. (Found: 76.1; H, 4.9; N, 11.0. C25Hi9N302 
requires C, 76.2; H, 4.9; N, 10.7%). 1H n.m.r.: S 3.80, 
s, MeO; 6.93, d, J 9 Hz, H7; 6.99-8.0, complex, C5H4 Ph 
and H3,8,3',4',5',6'.
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2-(Biphenyl-4'-yl)-6-(2"-methoxybenzylthio)imidazo- 
[1,2-b]pyridazine (V.9o) (93%) as yellow crystals, m.p.
174-176° (from methanol). (Found: C, 72.7; H , 5.0; N,
9.6. C26h 21n 3°5* °*5 Me0H requires C, 12.A; H, 5.3; N, 
9.6%). 1H n.m.r.: 6 3.89, s, MeO; 4.48, s, CH2S; 6.83, d, 
J 9 Hz, H7; 6.80-8.23, complex, C6H4Ph, H3 " , 4 " , 5 " , 6 " , 3 
and 8.
2-t-Butyl-6-chloroimidazo[l,2-b]pyridazine (V.9r) (84%),
m.p. 132-133° (from cyclohexane). (Found, for a sample 
dried at 20°/0.1 mmHg for 24 h: C, 57.5; H, 6.0; N, 20.2. 
c 10h 12c1n3 requires C, 57.3; H, 5.8; N, 20.0%).
■^ H n.m.r.: 5 1.41, s, Bu^; 6.99, d, J 9 Hz, H7; 7.72, s, 
H3 ; 7.85, d, J 9 Hz, H8.
6-Chloro-2-cyclohexylimidazo[1,2-b]pyridazine (V.9s)
(78%), m.p. 106-107° (from light petroleum) (Found, for a 
sample dried at 50°/0.1 mmHg for 5 h: C, 61.4; H, 6.1; N, 
17.9. C12h 14c1n3 requires C, 61.1; H, 6.0; N, 17.8%).
1H n.m.r.: 6 1.37-2.77, complex, CgHn ;  7.00, d, J 9 Hz, 
H 7 ; 7.69, s, H 3 ; 7.84, d, J 9 Hz, H 8 .
2-Benzyl-3-dimethylaminomethyl-6-(2'-methoxyphenoxy)- 
imidazo[1,2-b]pyridazine (V.lOd) (52%), after t.l.c. 
(alumina; chloroform, light petroleum, 7:3). (Found: C, 
71.5; H, 6.1; N, 14.2. C23H24N402 requires C, 71.1; H, 
6.2; N, 14.4%). XH n.m.r.: 6 2.07, s, Me2N ; 3.56, s,
CH2N ; 3.73, s, MeO; 4.17, s, Ctf2Ph; 6.83, d, J 9 Hz, H7;
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6.90-7.27, complex, Ph and H3',4',5' and 6'; 7.81, d, J 9 
Hz, H8.
2-Benzyl-3-dimethylaminomethy1-6-(4'-methoxyphenoxy)- 
imidazo[1,2-b]pyridazine (V.lOe) (57%) after t.l.c. 
(alumina; chloroform, light petroleum, 7:3). (Found:
71.1; H, 6.5; N, 14.6. C23H24N4O2 requires C, 71.1; H, 
6.2; N, 14.4%). 1H n.m.r.: 8 2.18, s, Me2N; 3.63, s,
CH2N; 3.83, s, MeO; 4.18, s, Ctf2Ph; 6.77, d, J 9 Hz, H7; 
6.91, d, 7.16, d, J 8.5 Hz, H2',3',5',6'; 7.26, s, Ph; 
7.81, d, J 9 Hz, H8.
2-Benzyl-3-dimethylaminomethy1-6-phenylthioimidazo- 
[1,2-b]pyridazine (V.10g) (75%) after t.l.c. (alumina;
chloroform, light petroleum, 7:3). (Found: 70.3; H, 6.2; 
N, 15.0. C22H22N4S requires C, 70.6; H, 5.9; N, 15.0%). 
1H n.m.r.: 5 2.17, s, Me2N; 3.66, s, CH2N; 4.19, s, 
CH2Ph; 6.75, d, J 9 Hz, H7; 7.25-7.56, complex, 2xPh; 
7.66, d, J 9 Hz, H8.
2-Benzyl-3-dimethylaminomethyl-6-(2'-methoxybenzylthio)- 
imidazo[1,2-b]pyridazine (V.lOa) (45%), after t.l.c. 
(alumina; chloroform, light petroleum, 7:3). (Found: C, 
68.6; H, 6.6; N, 13.5. C24H26N4OS requires C, 68.9; H, 
6.3; N, 13.4%). XH n.m.r.: 6 2.31, s, Me2N; 3.84, s,
CH2N; 3.81, s, MeO; 4.21, s, CH2Ph; 4.49, s, CH2S; 6.77, 
d, J 9 Hz, H7; 6.87-7.56, complex, Ph and H3',4',5',6';
7.62, d, J 9 Hz, H8.
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2-Benzyl-3-dimethylaminomethyl-6-(3'-methoxybenzylthio)- 
imidazo[1,2-b]pyridazine (V.lOb) (52%), after t.l.c. 
(alumina; chloroform, light petroleum, 7:3). (Found: C, 
68.7; H, 6.6; N, 13.1. C24H26N40S requires C, 68.9; H,
6.3; N, 13.4%). 1H n.m.r.: 5 2.29, s, Me2N ; 3.78, s, MeO 
and CH2N ; 4.21, s, CH2Ph; 4.43, s, CH2S; 6.79, d, J 9 Hz, 
H7; 6.99-7.33, complex, Ph and H2',4',5' and 6'; 7.65, d, 
J 9 Hz, H8.
2-Benzyl-3-dimethylaminomethyl-6-(4'-methoxybenzylthio)- 
imidazo[l,2-b]pyridazine (V.lOc) (45%) after t.l.c. 
(alumina; chloroform, light petroleum, 7:3). (Found:
68.4; H, 6.7; N, 13.1. C24H2gN40S requires C, 68.9; H, 
6.3; N, 13.4%). ^H n.m.r.: 6 2.31, s, Me2N; 3.78, s,
MeO; 3.81, s, CH2N; 4.21, s, CH2Ph; 4.41, s, CH2S; 6.77,
d, J 9 Hz, H7; 6.84, d, 7.39, d, J 8.5 Hz, H2',3',5',6'; 
7.27, s, Ph; 7.64, d, J 9 Hz, H8.
6-Chloro-3-dimethylaminomethyl-2-phenethylimidazo- 
[1,2-b]pyridazine (V.lOj) (54%) after t.l.c. (alumina; 
chloroform, light petroleum, 7:3). (Found: C, 64.9; H, 
6.2; N, 17.8. C17H19C1N4 requires C, 64.9; H, 6.1; N, 
17.8%). XH n.m.r.: 6 2.26, s, Me2N; 3.13, s, CH2CH2;
3.66, s, CH2N ; 7.00, d, J 9 Hz, H7; 7.23, s, Ph; 7.82, d,
J 9 Hz, H8.
6-Benzylthio-3-dimethylaminomethy1-2-phenethylimidazo- 
[1,2-b]pyridazine (V.lOh) (28%) after t.l.c. (alumina; 
chloroform, light petroleum, 7:3). (Found: 72.0; H, 6.7;
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N, 13.9. C24H26N4S requires C, 71.6; H, 6.5; N, 13.9%). 
1H n.m.r.: 6 2.26, s, Me2N; 3.11, s, CH2CH2; 3.68, s, 
CH2N; 4.46, s, CH2S; 6.80, d, J 9 Hz, H7; 7.25-7.45, 
complex, 2xPh; 7.67, d, J 9 Hz, H8.
3-(Dimethylaminomethy1)-6-(4'-methoxybenzylthio)-2 - 
phenethylimidazo[1,2-b]pyridazine (V.lOi) (38%) after 
t.l.c. (alumina; chloroform, light petroleum, 7:3). 
(Found: C, 69.0; H, 6.8; N, 12.7. C25H28N4°S requires C,
69.4; H, 6.5; N, 13.0%) . 1H n.m.r.: 6 2.27, s, Me2N;
3.11, s, CH2CH2; 3.68, s, CH2N; 3.79, s, MeO; 4.41, s,
CH2S; 6.78, d, J 9 HZ, H7; 6.84, d, 7.39, d, J 8.5 Hz,
H2 ' , 3' , 5 ' ,6 ' ; 7.24, s, Ph; 7.66, d, J 9 Hz, H8 .
2-(Biphenyl-4'-yl)-6-chloro-3-dimethylaminomethylimidazo- 
[1»2-b]pyridazine (V.lOk) (59%), m.p. 177-179° after 
t.l.c. (alumina; chloroform) and recrystallisation from 
light petroleum. (Found: 69.5; H, 5.3; N, 15.2%. 
c21h 19c1n4 requires C, 69.5; H, 5.3; N, 15.4%).
XH n.m.r.: 8 2.35, s, Me2N; 4.01, s, CH2N; 7.05, d, J 9 
Hz, H7; 7.25-8.24, complex, C6H4Ph; 7.91, d, J 9 Hz, H8.
2-(Biphenyl-4'-yl)-3-dimethylaminomethyl-6-(2"-methoxy- 
phenoxy)imidazo[1,2-b]pyridazine (V.101) (29%), m.p. 149-
151° after t.l.c. (alumina; chloroform) and 
recrystallisation from a mixture of acetone and light 
petroleum. (Found: C, 74.2; H, 6.1; N, 12.1. C28H26N4°2 
requires C, 74.6; H, 5.8; N, 12.4%). 1H n.m.r.: 6 2.12,
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s, Me2N; 3.68, s, CH2N; 3.75, s, MeO; 6.93, d, J 9 Hz,
H7; 7.00-8.71, complex, C6H4Ph, H3',4',5',6' and 8.
2- t-Butyl-6-chloro-3-dimethylaminomethylimidazo-
[1,2-b]pyridazine (V.lOm) (37%) after t.l.c. (alumina; 
chloroform, light petroleum, 3:1). (Found: 58.4; H, 7.3;
N, 21.1. C13H19C1N4 requires C, 58.5; H, 7.2; H, 21.0%).
1H n.m.r.: 6 1.51, s, But; 2.26, s, Me2N; 3.92, s, CH2N; 
6.95, d, J 9 Hz, H7; 7.82, d, J 9 Hz, H8.
6-Chloro-2-cyclohexyl-3-dimethylaminomethylimidazo- 
[1,2-b]pyridazine (V.lOn) (64%) after column 
chromatography. (Found: C, 61.3; H, 7.5; N, 18.9.
c 15h21c1n4 requires C, 61.5; H, 7.2; N, 19.1%).
■^H n.m.r.: 6 1.39-2.90, complex, CgH^; 2.33, s, Me2N; 
3.82, s, CH2N; 6.98, d, J 9 Hz, H7; 7.81, d, J 9 Hz, H8.
3- Acetamidomethyl-6-chloro-2-phenethylimidazo[1,2-b]-
pyridazine (V.lld) (39%), m.p. 144-146° after t.l.c. 
(alumina; chloroform) and recrystallisation from light 
petroleum. (Found: C, 61.9; H, 5.4; N, 16.7. C17H17C1N40 
requires C, 62.1; H, 5.1; N, 17.0%). -^H n.m.r.: 6 1.89,
s, MeCO; 3.12, complex, CH2CH2; 4.53, d, J 5.5 Hz, CH2N; 
7.02, d, J 9 Hz, H7; 7.20, s, Ph; 7.83, d, J 9 Hz, H8.
3-Acetamidomethyl-6-benzylthio-2-phenethylimidazo- 
[1,2-b]pyridazine (V.llb) (90%), m.p. 146-148° after
t. l.c. (alumina; chloroform) and recrystallisation from a 
mixture of acetone and light petroleum. (Found: 6.91; H,
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5.7; N, 13.4. C24H24N4OS requires C, 69.2; H, 5.8; N, 
13.5%). 1H n.m.r.: 6 1.75, s, MeCO; 3.08, s, CH2CH2;
4.40, s, CH2S; 4.50, d, J 5.5 Hz; CH2N; 6.84, d, J 9 Hz,
H7; 7.18-7.42, complex, 2xPh; 7.66, d, J 9 Hz, H8.
3-Acetamidomethyl-2-t-butyl-6-chloroimidazo[1,2-b]- 
pyridazine (V.llh) (8%), m.p. 159-161° after t.l.c. 
(alumina; chloroform) and recrystallisation from 
cyclohexane. (Found: C, 54.7; H, 6.0; N, 19.2.
C13H17CIN4O requires C, 54.6; H, 6.2; N, 19.6%).
^H n.m.r.: 6 1.50, s, Bu^; 1.99, s, MeCO; 4.99, d, J 5.5 
Hz, CH2N; 7.03, d, J 9 Hz, H7; 7.89, d, J 9 Hz, H8.
3-Acetamidomethyl-6-chloro-2-cyclohexylimidazo[1,2-b]- 
pyridazine (V.lli) (31%), m.p. 189-190° after t.l.c. 
(alumina; chloroform, light petroleum, 2:1) and 
recrystallisation from a mixture of methanol and 
cyclohexane. (Found: C, 58.9; H, 6.5; N, 18.1.
C15H19CIN4O requires C, 58.7; H, 6.2; N, 18.3%).
1H n.m.r.: 6 1.26-3.03, complex, CgHn; 1.98, s, MeCO; 
4.79, d, J 5.5 Hz, CH2N; 7.02, d, J 9 Hz, H7; 7.86, d, J 
9 Hz, H8.
3-Benzamidomethyl-6-chloro-2-phenethylimidazo[1,2-b]- 
pyridazine (V.lle) (23%), as a white solid, m.p. 159-160° 
after t.l.c. (alumina; ether, then chloroform) (Found, 
for a sample dried at 110°/0.1 mmHg for 6 h: C, 67.9; H, 
4.9; N, 14.6. C22H19C1N4° requires C, 67.6; H, 4.9; N, 
14.3%). ^H n.m.r.: 6 3.19, complex, CH2CH2; 4.75, d, J
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5.5 Hz, CH2; 6.65, bs, NH; 7.05, d, J 9 Hz; 7.20-7.76, 
complex, 2 x Ph; 7.89, d, J 9 Hz, H8 .
3-Benzamidomethyl-6-benzylthio-2-phenethylimidazo[1,2-b]- 
pyridazine (V.llc) (14%), as a white solid m.p. 151-152° 
after t.l.c. (alumina; ether, then chloroform and 
alumina; chloroform) and recrystallisation from 
cyclohexane. (Found, for a sample dried at 110°/710 mmHg 
for 6 h: C, 72.5; H, 5.8; N, 11.6. C29H26N4OS requires C, 
72.8; H, 5.5; N, 11.7%). ^H n.m.r.: 5 3.14, complex,
CH2CH2; 4.36, s, CH2S; 4.75, d, JcH2NH 5*5 Hz, CH2/ 6.86, 
d, J 9 Hz, H7; 7.16-7.56, complex, 2 x Ph; 7.69, d, J 
9 Hz, H8 .
3-Benzamidomethyl-6-chloro-2-(biphenyl-4'-yl)imidazo- 
[l,2-b]pyridazine (V.llg) (26%), m.p. 232-234° after 
t.l.c. (alumina; chloroform) and recrystallisation from a 
mixture of acetone and light petroleum. (Found: C, 71.1; 
H, 4.4; N, 12.6. C25H19CIN40 requires C, 71.15; H, 4.4;
N, 12.8%). ^H n.m.r.: 5 5.26, d, J 5.5 Hz, CH2N; 7.12,
d, J 9 Hz, H7; 7.40-8.18, complex, Ph, C6H4Ph and H8 .
3-Benzamidomethyl-6-chloro-2-cyclohexylimidazo[1,2-b]- 
pyridazine (V.llj) (67%), m.p. 178-179° after t.l.c. 
(alumina; chloroform) and recrystallisation from toluene. 
(Found: 65.4; H, 5.9; N, 15.1. C2oH21clN4° requires C, 
65.1; H, 5.7; N, 15.2%). 1H n.m.r.: S 1.43-3.07, complex, 
C6H11 i 5.02, d, J 5.5 Hz, CH2N; 7.06, d, J 9 Hz, H7; 
7.39-7.81, complex, Ph; 7.93, d, J 9 Hz, H8.
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6'-Methylnaphthalen-2'-ylglyoxal
6'-Methyl-2'-acetonaphthone was oxidised with 
selenium dioxide in dioxane by a procedure similar to 
that described for the preparation of phenylglyoxal.261 
The product was obtained as an oil which, after heating 
with water and cooling, gave crystals, m.p. 113-115°.
Part of this product was sublimed at 120°/0.1 mmHg and 
gave a yellow solid, m.p. 84-86°. (Found: C, 73.4; H,
5.5. C13Hio°2* °*8 h2° requires C, 73.6; H, 5.6%).
1H n.m.r.: 6 2.56, s, Me; 7.37-8.84, complex, ArH; 9.75,
s, CHO.
6-Chloro-3-methoxy-2-(6'-methylnaphthalen-2'-yl)imidazo- 
[1,2-b]pyridazine (V.6a)
A mixture of 6-chloropyridazin-3-amine (0.1 g), 6'- 
methylnaphthalen-2'-ylglyoxal (0.153 g), ethanol (2.0 ml) 
and concentrated hydrochloric acid (0.15 ml) was refluxed 
for 15 h. The solvent was evaporated under reduced 
pressure and stirred with excess ethereal diazomethane in 
ice and then at room temperature overnight. The ether was 
evaporated and the resulting oil was subjected to t.l.c. 
(alumina; chloroform) and the product recrystallised from 
light petroleum to give yellow crystals of the title 
compound, (0.070 g 28%), m.p. 117-118°. (Found: C, 67.1; 
H, 4.2; N, 13.1. C1gH14ClN30 requires C, 66.8; H, 4.4; N, 
13.0%.) 1H n.m.r.: 6 2.50, s, Me; 4.16, s, MeO; 6.90, d, 
J 9 Hz, H7; 7.25-8.72, complex, H8 and naphthalenyl.
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3-Methoxy-2-(6'-methylnaphthalen-2'-yl)-6-methyl- 
thioimidazo[1,2-b]pyridazine (V.6b) (34%), m.p. 177-178°
after t.l.c. (alumina; chloroform) and recrystallisation 
from light petroleum. (Found: C, 68.3; H, 5.0; N, 12.5. 
C19H17N3OS requires C, 68.0; H, 5.1; N, 12.5%).
1H n.m.r.: 6 2.52, s, MeC; 2.68, s, MeS; 4.21, s, MeO; 
6.81, d, J 9.5 Hz, H7; 7.26-8.54, complex, H8, and 
naphthalenyl.
CHAPTER VI
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CHAPTER VI Syntheses and binding studies of some 
substituted imidazo[l,2-b]pyridazines and related 
imidazo[1,2-a]pyridines, imidazofl,2-a]pyrimidines and 
imidazo[1,2-a]pyazines
VI-1 Introduction
The search for antianxiety agents without non-specific 
central nervous system (CNS) depressant side effects has 
stimulated the synthesis of new chemical structures, such 
as imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine 
compounds, which interact with the benzodiazepine 
receptors. They have been reported to show pharmacological 
profiles different from those of benzodiaze­
pines .101'102'262 Almirante and coworkers114,200 reported 
the syntheses and some pharmacological properties of 
derivatives of imidazo[1,2-a]pyridine, imidazo- 
[1,2-a]pyrimidines and imidazo[1,2-b]pyridazine. These 
compounds were examined for analgesic, antiinflammatory, 
antipyretic and anticonvulsant activity. For example, 2- 
(4'-methoxyphenyl)imidazo[1,2-a]pyridine200 could abolish 
tonic extensor seizures produced by supramaximal 
electroshock and antagonize convulsions elicited by 
pentamethylenetetrazole. Series of compounds with the 
imidazo[1,2-a]pyridine structure have recently been 
developed201,202,213,263-267 and shown to have 
anticonvulsant, hypnotic, sedative and anxiolytic activity. 
Within this class, zolpidem (Fig. 1-9, in Chapter I) has 
been used as an hypnotic agent, and alpidem (Fig. 1-9; in
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Chapter I) as an anxiolytic compound. Zolpidem inhibited
O  §[ H]diazepam binding to membranes from different brain 
areas (IC50 values in the low nanomolar range) and it was 
four-fold more potent at displacing [ HJdiazepam in 
cerebellar than in hippocampal neurones. It was
suggested that this imidazo[1,2-a]pyridine derivative may 
stimulate preferentially the Type I benzodiazepine 
receptor. Amongst a large number of different lmidazo- 
[1,2-a]pyridine compounds prepared and tested, a series of 
2-phenyl(and substituted phenyl)-imidazo[1,2-a]pyridin-3- 
ylacetamides were investigated by George and coworkers.155 
The influences of further substitution in the pyridine 
ring, in the 2-phenyl group and in the acetamide side chain 
were examined.155 The sedative-hypnotic properties were 
investigated by the effect of these compounds on the 
relative potency of drug-induced electrocorticographic 
(ECoG) sleep. These workers found that in 3- 
dialkylaminomethylimidazo[1,2-a]pyridines, the 6-methyl 
derivatives were more potent than the corresponding 6- 
chloro compounds; and a shift of the methyl group from the 
6-position to the 7- and 8-positions gave compounds which 
were devoid of activity. The effect of substitution in the 
2-phenyl group and its effect on hypnotic activity was 
examined in detail: para substituted phenyl compounds had 
strong sedative effects. The influence of the nature of 
the para substituent in the 2-phenyl group was very 
important. Electron-withdrawing groups decreased or 
abolished the activity, whereas electron-donating groups 
increased sedative activity in the following order: methyl
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P 6 R> methoxy - chloro > acetamido. A bulky group, such as
t-butyl, and an hydrophilic function, such as an 
hydroxymethyl group decreased or abolished sedative 
effects. Profiling of Alpidem (Fig. 1-9; in Chapter I) has 
revealed that it is a potent ligand at the Bz^ (Wl) and the 
peripheral benzodiazepine (BZp, W3) receptor subtypes,268 
whereas it has low affinity for BZ2 (W2) receptors.
Alpidem bound to the Bz^ and BZp receptor subtypes from 
human brain with Kd of 1.67 nM and 0.3 nM, respectively.260 
Its high affinity and high selectivity for the 
benzodiazepine receptor Type I and the peripheral 
benzodiazepine receptor (BZp) may explain its selective 
anxiolytic activity.268
Almirante and coworkers114 in 1966 reported the 
syntheses and testing of some imidazo[1,2-a]pyrimidines 
with analgesic, antiinflammatory, antipyretic and 
anticonvulsant activity. They found that several compounds 
of this series of imidazo[1,2-a]pyrimidines offered some 
protection against supramaximal electroshock and/or 
pentamethylenetetrazole induced seizures.114 A large 
number of 5,6,7-trisubstituted imidazo[1,2-a]pyrimidin-2-yl 
ketones101,269 as potential nonsedative anxiolytics and 2-
i nooxadiazolyl- and 2-thiazolyl-imidazo[1,2-a]pyrimidines 
as agonists and inverse agonists at benzodiazepine
1 0?receptors have been reported by Tully and coworkers.
They selected the most active of the 2-oxadiazolyl- 
imidazo[1,2-a]pyrimidines, as revealed in the conflict 
test, for further pharmacological study.102
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In this chapter, some imidazo[1,2-a]pyridines 
containing various substituents at C-3 and C-6 [such as 2- 
ary1-3-benzamidomethyl(acetamidomethyl, methoxy and 
unsubstituted)-6-chloro(alkoxy, alkylthio and phenylthio)- 
imidazo[1,2-a]pyridines, and some of the corresponding 
imidazo[1,2-b]pyridazines, imidazo[1,2-a]-
pyrimidines and imidazo[1,2-a]pyrazines] have been prepared 
and examined for their ability to bind at benzodiazepine 
receptors. The aim of the work described in this chapter 
was to examine the effect on biological activity of changes 
in the heterocyclic nucleus, such as the replacement of N-5 
by CH in substituted imidazo[1,2-b]pyridazines to give 
imidazo[1,2-a]pyridines, and to assess the effect of 
shifting the ring nitrogen at the 5-position in 
imidazo [ 1,2-jb] pyridazines to the 7- and 8-position, as in 
imidazo[l,2-a]pyrazines and imidazo[l,2-a]pyrimidines. The 
biological results are discussed in connection with these 
changes.
VI-2 Syntheses
The various heterobicyclic nuclei required in this 
work were prepared from the respective a-aminomono- 
heterocycle by fusion with a two carbon unit, followed by 
further elaboration to give the appropriate derivative.
In this way imidazo[1,2-a]pyridines were prepared from 
pyridin-2-amines, imidazo[1,2-a]pyrimidines from pyrimidin- 
2-amines, and imidazo[1,2-a]pyrazines from pyrazin-2-
amines.
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VI-2.1 Syntheses of some 3-acylaminomethyl (and 
methoxy)-6-chloro(methoxy, methylthio, propylthio and 
phenylthio)-2-phenyl(and substituted phenyl)imidazo- 
[1,2-a]pyridines
The starting materials required for the preparation of 
the compounds (VI.3 and VI.5) were appropriate 5- 
substituted pyridin-2-amines. 5-Chloropyridin-2-amine is 
available commercially. Pyridin-2-amine was iodinated to 
give 5-iodopyridine-2-amine270 (Scheme VI-1) and 
subsequently the iodo-substituent was replaced readily by 
methanethiolate, propanethiolate and benzenethiolate 
ions.271 5-Methoxypyridin-2-amine272 (Scheme VI-1) was 
prepared from pyridin-3-ol through 2-bromopyridin-3-ol, 2- 
bromo-3-methoxypyridine273 and 2-bromo-3-methoxy-6- 
nitropyridine272 which, with palladium on charcoal and 
hydrazine hydrate, gave the desired compound.
Compounds (VI.4 and VI.5; Scheme VI-2) were prepared 
readily by procedures similar to those reported for 
analogous compounds in the literature.213'274
The 5-substituted pyridin-2-amines (VI.1) condensed 
with 4-tolylglyoxal in ethanol containing hydrochloric acid 
to give the 6-substituted-2-(4'-tolyl)imidazo[1,2-a]- 
pyridin-3-ols (VI.2).275 These crude imidazo[1,2-a]- 
pyridin-3-ols were methylated with diazomethane, in a 
manner similar to that described for the preparation of 6- 
alkylthio- and 6-arylthio-3-methoxy-2-phenylimidazo[1,2-b]- 
pyridazines, and gave the 3-methoxyimidazo[1,2-b]-
pyridines (VI.3).
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Scheme VI-1
VI.2
VI.
3a
5a
4a
3b
5b
4b
3c
5c
3d
5d
3e
5e
3f
5f
5g
3g
5h
5i
4c
R=H , 
R 1
VI.3 R = Me
R2
Cl M e-p
Cl Me-p
Cl Me-p
OMe Me-p
OMe Me-p
OMe Me-p
OMe 0CH20-5',4'
OMe 0CH20-3',4 '
SMe Me-p
SMe Me-p
SPr Me-p
SPr Me-p
SPh H
SPh H
SPh H
SPh Me-p
SPh Me-p
SPh Me-p
SPh Me-p
R3
Ph
Ph
Ph
Ph
Me
Ph
Me
Ph
V I . 5
218
VI-2.2 Syntheses of some 3-benzamidomethyl(naphthalen-2'- 
ylamidomethyl and unsubstituted)- 2 - ( 3 4 ' -methylene- 
dioxyphenyl and 4'-tolyl)-6-propylthio (and methylthio)- 
imidazo[l,2-b]pyridazines
The starting materials (VI.6), 6-methylthio- and 6- 
propylthio-pyridazin-3-amines, required for the 
preparations in this section were prepared by literature 
procedures.161 The key intermediates, 3-unsubstituted 
imidazo[1,2-b]pyridazines (VI.7), were prepared from the 6- 
substituted pyridazin-3-amine by heating with the 
appropriate bromoacetyl compounds.103 The compounds (VI.8) 
were prepared by heating the compounds (VI.7) with N-
Scheme VI-3
CHoNHCOR
CH2NHCOPh
CH2NHCOPh
CH2NHCOC10H7-ß
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(hydroxymethyl)amides (by procedures similar to those 
described in Chapter II).
VI-2.3 Syntheses of some 3-acetamidomethyl(benzamido- 
methyl, methoxy and unsubstituted)-2-(4'-tolyl)- 
imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyrazines
The starting material required for the preparation of
3-acylaminomethy1-2-ary1-6-chloroimidazo[1,2-a]pyrimidines
was 5-chloropyrimidin-2-amine (VI.9) It was prepared by
the literature procedure from pyrimidin-2-amine by
9 7chlorination with N-chlorosuccinimide. 5-
Chloropyrimidin-2-amine condensed with a-bromo-4'- 
methylacetophenone232 in ethanol and gave 6-chloro-2-(4'- 
tolyl) imidazo[ 1,2-a]pyrimidine (VI.10). ’When this was 
heated with N-(hydroxymethyl)acetamide or N- 
(hydroxymethyl)benzamide in glacial acetic acid containing 
a catalytic amount of concentrated sulphuric acid, it gave 
3-acetamidomethyl (or 3-benzamidomethyl)-6-chloro-2-(4'- 
tolyl)imidazo[1,2-a]pyrimidines (VI.11a and b; Scheme 
VI-4).
The starting material required for the preparation of 
6-chloro-3-methoxy (and benzamidomethyl)-2-(4'-tolyl)- 
imidazo[1,2-a]pyrazines was 5-chloropyrazin-2-amine. Its 
preparation was first attempted by direct chlorination of 
pyrazinamine with N-chlorosuccinimide in refluxing 
chloroform (a procedure used successfully to prepare 5- 
chloropyrimidin-2-amine above). It gave a low yield of a
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Scheme VI-4
V I .10
CHoNHCOR
V I.11
R
VI. 11a Me 
l i b  Ph
mixture of 5-chloropyrazin-2-amine, 3-chloropyrazin-2-amine 
and a dichloropyrazin-2-amine.
The 5-chloropyrazin-2-amine was therefore prepared by 
literature procedures from lumazine.277-280 Lumazine (2,4- 
dihydroxypteridine) (Scheme VI-5) was decomposed by aqueous 
sodium hydroxide at elevated temperatures to 3- 
aminopyrazine-2-carboxylic acid in which the carboxylic 
acid group was used as a temporary blocking group during 
electrophilic substitution. This compound was esterified 
with methanol containing sulphuric acid and the resulting 
methyl 3-aminopyrazine-2-carboxylate was chlorinated in 
aqueous acetic acid to give methyl 2-amino-5-
p 7 o p 7 Qchloropyrazine-3-carboxylate. ' This was then
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hydrolysed and decarboxylated to give 5-chloropyrazin-2- 
amine.280
5-Chloropyrazin-2-amine (VI.12) condensed with 4- 
tolylglyoxal in ethanol with hydrochloric acid to give 6- 
chloro-2-(4'-tolyl)imidazo[1,2-a]pyrazin-3-ol (VI.13), 
which was methylated with diazomethane to give the 3- 
methoxy compound (VI.14).
5-Chloropyrazin-2-amine and a-bromo-4'- 
methylacetophenone readily gave 6-chloro-2-(4'- 
tolyl)imidazo[1,2-a]pyrazine (VI.15) which with N- 
(hydroxymethyl)benzamide gave 3-benzamidomethyl-6-chloro-2- 
(4'-tolyl)imidazo[1,2-a]pyrazine (VI.16).
222
Scheme VI-5
OHI
1^ c'OH N .COOMeI . . A .N NH.
Lumazine
COOH COOMe
V I.12
V I .15
R= HVI. 13
R= MeVI. 14
V I .16
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VI-3 1H n.m.r. Spectra
The H^ n.m.r. spectra of the 2-aryl-6-substituted 
imidazo[1,2-a]pyridines (VI.4) were determined and some 
data are listed in Table VI-1. An examination of the data 
for compounds (VI.4) revealed that the signal due to the 
protons of H-3 appeared in the range 6 7.70-7.84 for the 6- 
chloro(methoxy, methylthio, propylthio and phenylthio)-2- 
phenyl(4'-tolyl and 3',4'-methylenedioxyphenyl)- 
imidazo[1,2-a]pyridines (VI.4a-g) and the protons H5, H7 
and H8 of the pyridine ring appeared in the range 5 7.64- 
8.29 for H5, S 6.95-7.91 for H7 and 5 7.52-8.00 for H8, 
with coupling constants of 2.0-2.5 Hz and J7 8^ 9.0-9.5
Hz .
The chemical shifts for H5, H7 and H8 in 6-phenylthio- 
2 - (4'-tolyl)imidazo[1,2-a]pyridine (VI.4g; 6 8.27, 7.80 and 
7.89 respectively) are significantly downfield of those in 
6-methylthio-2-(4'-tolyl)imidazo[1,2-a]pyridine (VI.4d; 6 
8.10, 7.18 and 7.59 respectively) due to the stronger 
electron-withdrawing properties of the phenylthio group
n o /:(jpara 0.07) relative to the methylthio group (O p a r a  
0.00) . The electron-donating properties of the methoxy
group are evident in the 1H n.m.r. of 6-methoxy-2-(4'- 
tolyl)imidazo[1,2-a]pyridine (VI.4b) in which the signal 
due to H5, H7 and H8 are at 5 7.64, 6.95 and 7.52, 
respectively, all upfield of those in the 6-methylthio 
analogue (VI.4d).
The methylene protons in the 3-acylaminomethyl-2-aryl-
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Table VI-1 Some 1H n.m.r. spectral dataA for 2-aryl-3- 
methoxy (and unsubstituted)-6-variously substituted 
imidazo[1,2-a]pyridines
Compound H3 H5 H7 H8
VI. 4a 7.78 8.14 7.01 7.56
4b 7.77 7.64 6.95 7.52
4c 7.70 7.64 6.98 7.54
4d 7.79 8.10 7.18 7.59
4e 7.79 8.19 7.18 7.66
4 f 7.84 8.29 7.91 8.00
4g 7.80 8.27 7.80 7.89
AReported as parts per million (6) downfield from T.M.S.
as internal standard in deuterochloroform
6-(variously substituted)imidazo[1,2-a]pyridines (VI.5f and 
VI.5h) and (VI.5a-c, g and i) occurred as doublets 
(described in the Experimental section) in the ranges 5 
4.85-4.86 and S 5.04-5.12, respectively.
An examination of the data in Table VI-2 for the 3- 
unsubstituted imidazo[1,2 - b]pyridazine (II.3c; Chapter II), 
imidazo[1,2-a]pyrazine (VI.15) and imidazo[1,2-a]pyrimidine 
(VI.10) revealed that the signal due to H-3 was further 
downfield in compound (II.3c) and was more upfield in those 
compounds in which the influence of a second ring nitrogen 
atom was more remote, as in compounds (VI.15) and (VI.10).
The chemical shifts of the methylene group in the 
corresponding 3-benzamidomethyl derivatives (VI.6b, VI.16, 
VI.lib and VI.5a), reported in the Experimetal section, 
reveal a similar pattern.
Table VI-2 Some 1H n.m.r. spectral dataA for 6-chloro-2- 
(4' -tolyl)imidazo[1,2-b]pyridazine, imidazo[1,2-a]pyrazine, 
imidazo[1,2-a]pyrimidine and imidazo[l,2-a]pyridine
Compounds H3
X=N, Y=Z=CH
(11.3c) 8.18
Y=N, X=Z=CH
(VI. 15) 7.91
Z=N, X=Y=CH
(VI.10) 7.76
X=Y=Z=CH
(VI.4a) 7.78
^Reported as parts per million (6) downfield from T.M.S. 
as internal standard in deuterochloroform
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VI-4 In vitro binding results
The compounds prepared in this chapter were tested in 
the [ HJdiazepam binding assay as described in Chapter II-
5.3.
VI-4.1 Results of [3H]diazepam binding assay
The results of these binding studies were given in 
Table VI-3 as IC50 values (or % displacement at the 
concentration specified). The results for the imidazo- 
[1,2-a]pyridine compounds (VI.3,4 and 5) are presented 
first, followed by those for the imidazo[1,2-b]pyridazines, 
imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyrazines.
VI-4.2 Discussion of results
The results are shown in Table VI-3 for the in vitro 
binding by the imidazo[1,2-a]pyridines (VI.3, 4 and 5), 
imidazo[1,2-b]pyridazines (VI.7 and 8), imidazo[1,2-a]- 
pyrimidines (VI.10 and 11) and imidazo[1,2-a]pyrazines
(VI.14-16).
These revealed that among the series of 6-substituted 
imidazo[1,2-a]pyridines (VI.3,4 and 5), 3-benzamidomethyl- 
6-chloro-2-(4'-tolyl)imidazo[1,2-a]pyridine (VI.5a; IC50 11 
nM) had the strongest binding potency; and that the 2-aryl- 
6-chloro(methoxy, methylthio, propylthio and phenylthio)-3- 
unsubstituted imidazo[1,2-a]pyridines were all less active 
than the 3-acetamidomethyl, 3-benzamidomethyl and 3-methoxy 
analogues.
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Table VI-3 Results for the displacement of [3H]diazepam 
from rat brain by some substituted imidazo[l,2-a]pyridines 
(VI.3-5), imidazo[1,2-b]pyridazines (VI.7-8), imidazo- 
[1,2-a]pyrimidines (VI.10-11) and imidazo[1,2-a]pyrazines 
(VI.14-16).
Formula Compounds IC50 (nM)A (or %
number displ. at 1000 nM)
Substituted imidazo[1,2-a]pyridines
VI.4a 6-C1-3-H-2-C6H4Me-p (49%)
5a 6-Cl-3-CH2NHBz-2-C6H4Me-p 11
3a 6-C1-3-OMe-2-C6H4Me-p 146B
4b 6-OMe-3-H-2-C6H4Me-p (9%)
5b 6-OMe-3-CH2NHBz-2-C6H4Me-p 25
3b 6-OMe-3-OMe-2-C6H4Me-p 329
4c 6-OMe-3-H-2-C6H3(3',4/-OCH20-) 980
5c 6-OMe-3-CH2NHBz-2-C6H3(3',4/-OCH20-) 16
4d 6-SMe-3-H-2-C6H4Me-p (22%)
5d 6-SMe-3-CH2NHBz-2-C6H4Me-p 27
4e 6-SPr-3-H-2-C6H4Me-p (23%)
5e 6-SPr-3-CH2NHBz-2-C6H4Me-p 155
4 f 6-SPh-3-H-2-Ph (2%)
5f 6-SPh-3-CH2NHAc-2-Ph 455
5g 6-SPh-3-CH2NHBz-2-Ph (37%)
4g 6-SPh-3-H-2-C6H4Me-p (0%)
5h 6-SPh-3-CH2NHAc-2-C6H4Me-p 558
5i 6-SPh-3-CH2NHBz-2-C6H4Me-p (24%)
3c 6-SPh-3-OMe-2-C6H4Me-p (11%)
Substituted imidazo[1,2-b]pyridazines
7a 6-SPr-3-H-2-C6H4Me-p (53%)
8a 6-SPr-3-CH2NHBz-2-C6H4Me-p 24
7b 6-SPr-3-H-2-C6H3(3',4'-OCH2 0-) 254
8b 6-SPr-3-CH2NHBz-2-C6H3(3',4'-OCH20-) 8
8C 6-SMe-3-(CH2NHC0C10H7-^)C-2-C6H3-
(3",4"-OCH20-) 6
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Table VI.3 Continued
Formula Compounds IC50 (nM) A (or %
number displ.at 1000 nM)
Substituted imidazo[1,2-a]pyrimidines
10 6-Cl-3-H-2-C6H4Me-p (0%)
11a 6-Cl-3-CH2NHAc-2-C6H4Me-p 742
lib 6-C1-3-CH2NHBz-2-C6H4Me-p 504
(18%)B 'D11c 6-C1-3-OMe-2-C6H4Me-p
Substituted imidazo[1,2-a]pyrazines
15 6-C1-3-H-2-C6H4Me-p (3%)
16 6-C1-3-CH2NHBz-2-C6H4Me-p (6%)
14 6-C1-3-OMe-2-C6H4Me-p (10%)
a IC5q values are the concentrations required to displace 
50% of specific [3H]diazepam binding to rat brain membrane 
preparation
BPrepared by Dr M.M.L. Ngu
c/?-Naphthamidomethyl
°At 3000 nM
The 3-benzamidomethyl-6-chloro(methoxy, methylthio, 
propylthio and phenylthio)-2-(4'-tolyl)imidazo[1,2-a]- 
pyridines provided an interesting binding profile; the 
protency of the displacement of [H]diazepam from rat brain 
membrane by these compounds was in the order chloro (VI.5a; 
IC5o 11 nM) > methoxy (VI.5b; IC50 25 nM) > methylthio 
(VI.5d; IC50 27 nM) > propylthio (VI.54; IC50 155 nM) > 
phenylthio (VI.5i; 24% displacement at 1000 nM) (Fig.
VI-1). Clearly binding ability is not directly related to 
the electronic effects, and in these series increasing 
group size in the alkylthio or arylthio compounds was
detrimental.
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CHoNHCOPh
Com pound Num ber R IC50(nM ) (or % displacem ent)
V I.5a Cl 11
VI.5b O M e 25
VI.5d SM e 27
V I.5e SPr 155
V I.5i SPh (24%  at lOOOnM)
Fig.VI-1
A comparison of the 2-(3',4'-methylenedioxyphenyl) 
group with the 2-(4'-tolyl)substituent in 3- 
benzamidomethyl-6-methoxy-2-[(3 ' , 4 '-methylenedioxyphenyl) 
and 2-(4'-tolyl)]imidazo[1,2-a]pyridines (VI.5c, IC5Q 16 
nM; and VI.5b, IC50 25 nM, respectively) revealed that the 
2- (3', 4'-methylenedioxyphenyl) substituent was more 
effective than the 2-(4'-tolyl) group. However in the 3- 
(acetamidomethyl and benzamidomethyl)-2-phenyl (and 4'- 
tolyl)-6-phenylthioimidazo[1,2-a]pyridines (VI.5f-i) the 2- 
phenyl compounds (VI.5f,g; IC50 455 nM and 37% displacement 
at 1000 nM respectively) were slightly more effective than 
those containing the 2-(4'-tolyl) substituent (VI.5h,i;
IC50 558 nM and 24% displacement at 1000 nM respectively).
A comparison of the imidazo[1,2-a]pyridines with the 
corresponding imidazo[1,2-b]pyridazines revealed that 3- 
benzamidomethyl-6-methoxy-2-(4'-tolyl)imidazo[1,2-a]- 
pyridine (VI.5b; IC5 0 25 nM) had approximately the same 
activity as 3-benzamidomethyl-6-methoxy-2-(4'-tolyl)-
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imidazo [ 1,2-Jb] pyridazine (II. 6f; IC50 23 nM in Chapter II), 
whereas 3-benzamidomethyl-6-chloro-2-(4'-tolyl)imidazo- 
[ 1,2-Jb]pyridine (VI. 5a; IC50 11 nM) bound more strongly 
than 3-benzamidomethyl-6-chloro-2- (4 ' -tolyl) imidazo [ 1,2-jb] - 
pyridazine (II.6b; IC50 18 nM in Chapter II).
The binding results for all other imidazo[1,2-a]- 
pyridine compounds (VI.3,4 and 5) listed in Table VI-3 
revealed that they were less active than the corresponding 
imidazo[1,2-b]pyridazines. This difference was greatest 
between 3-benzamidomethyl-2-phenyl-6-phenylthio[1,2-a]- 
pyridine (VI.5g; 37% displacement at 1000 nM) and the 
corresponding 3-benzamidomethyl-2-phenyl-6-phenylthio- 
imidazo[1,2-b]pyridazine (II.6g; IC50 9 nM in Chapter II); 
a similar situation was also apparent between 3-acet- 
amidomethy1-2-phenyl-6-phenylthioimidazo[1,2-a]pyridine 
(VI.5f; IC50 455 nM) and the corresponding 3-acetamido- 
methyl-2-phenyl-6-phenylthio imidazo [1,2 -Jb ] pyridazine 
(II.5f; IC50 24 nM in Chapter II); and also between 3- 
benzamidomethyl-6-propylthio-2-(4'-tolyl)imidazo[1,2-a]- 
pyridine (VI.5e; IC50 155 nM) and 3-benzamidomethyl-6- 
propylthio-2-(4'-tolyl)imidazo[1,2-b]pyridazine (VI.8a;
IC50 24 nM).
Amongst the imidazo[1,2-b]pyridazines (VI.7 and 8), 
the 2-(4'-tolyl and 3',4'-methylenedioxyphenyl)-6- 
propylthioimidazo [ 1,2-jb] pyridaz ines (VI.7a and b; 53% 
displacement at 1000 nM and IC50 254 nM, respectively) were 
more active than the corresponding 6-methylthio analogues 
(II.3f and g; 35 and 40% displacement at 1000 nM, 
respectively, in Chapter II) but in the 3-benzamidomethyl
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derivatives, the situation was reversed and 3- 
benzamidomethyl-6-methylthio-2-(4'-tolyl and 3',4'- 
methylenedioxyphenyl)imidazo[1,2-b]pyridazines (II. 6d and 
e; IC50 values 7 and 2 nM, respectively in Chapter II) 
bound more strongly than the corresponding 6-propylthio 
compounds (VI.8a and b; IC50 values 24 and 8 nM, 
respectively).
A comparison of 6-methylthio-2-(3',4'-methylenedioxy- 
phenyl) - 3- (/3-naphthamidomethyl) imidazo [ 1,2-b] pyridazine 
(VI.8c, IC50 6 nM) with its 3-benzamidomethyl analogue 
(II.6e; IC50 2 nM, in Chapter II) revealed that the (ß- 
naphthamidomethyl) group was less effective than the 3- 
benzamidomethyl substituent.
The effect on biological activity of changing the 
position of nitrogen atom from 5 to 7 or 8 and a comparison 
of the results for the corresponding derivatives of the 
triazabicyclic systems revealed that the biological 
activities were in the order imidazo[1,2-b]pyridazines >> 
imidazo[1,2-a]pyrimidines :> imidazo[1,2-a]pyrazines. This 
was shown clearly by the data in Fig. VI-2 and the binding 
data for 6-chloro-3-methoxy-2-(4'-tolyl)imidazo[1,2-b]- 
pyridazine (GBLD 173),162 and corresponding imidazo[1,2-a]- 
pyrimidine (VI.11c) and imidazo[1,2-a]pyrazine (IV.14) 
which gave IC50 148 nM, and 18% displacement at 3000 nM, 
and 10% displacement at 1000 nM, respectively.
As in the series of imidazo[1,2-b]pyridazines (see 
Chapter II and III), the 3-acetamidomethyl group in 3- 
acetamidomethy1-6-chlor0-2-(4'-tolyl)imidazo[1,2-a]-
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pyrimidine (VI.11a, IC50 742 nM) was less effective than 
the corresponding 3-benzamidomethyl substituent in compound 
(VI.lib; IC 50 504 nM).
The results indicated that when N-5 of the pyridazine 
ring was removed (as in the imidazo[1,2-a]pyridines), a 
decrease of binding activity was generally observed, and 
insertion of a nitrogen atom at the 7- or 8-position, as in 
compounds (VI.16; 6% displacement at 1000 nM and VI.lib, 
IC50 504 nM), resulted in decreased binding.
Vl.Sa, IC30 l lnM u.6b, IC50 18 nM
VI.lib, IC50 504 nM VI. 16, 6 % displacement at lOOOnM
Fig.VI-2
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VI-5 Experimental
The general procedure, and experimental details for 
the [ HJdiazepam binding assay, are described in Chapter 
II-5.3, but samples for analysis were dried at 60-100°/0.1 
mmHg for 3-20 h unless otherwise specified.
6-Chloro-2-(4'-tolyl)imidazo[1,2-a]pyridine (VI.4a)
A mixture of 5-chloropyridin-2-amine (0.5 g) and a- 
bromo-4-methylacetophenone232 (0.836 g) in ethanol (10 ml) 
was refluxed with stirring in an oil bath at 
90-95° for 2 h. Sodium hydrogen carbonate (0.12 g) was 
added and the refluxing continued for 14 h. The product 
was recrystallised from ethanol and subjected to t.l.c. 
(alumina; chloroform, light petroleum, 2:1, developed 
twice] to give the title compound, (0.347 g) m.p. 228-229° 
(Found, for a sample dried at 75°/710 mmHg for 5 h: C,
69.2; H, 4.4; N, 11.4. C14H11C1N2 requires C, 69.3; H,
4.6; N, 11.5%). XH n.m.r.: 6 2.39, s, Me; 7.01, dd, J1/Q 
9 Hz, J 5 ^ 7 2 Hz, H 7; 7.23, dd, J 2 • f 3 / 8.5 Hz, J 3 / ^ 5 / 3 Hz, 
H 3',5'; 7.56, d, J 9 Hz, H 8; 7.78, s, H 3; 7.83, d, J 
8.5 Hz, H 2', 6'; 8.14, bs, H 5.
6-Benzamidomethyl-6-chloro-2-(4'-tolyl)imidazo- 
[1,2-a]pyridine (VI.5a)
6-Chloro-2-(4'-tolyl)imidazo[1,2-a]pyridine (0.1 g)
n 1 /*was added to a solution of N-(hydroxymethyl)benzamidez1 
(0.067 g) in acetic acid (1.0 ml) containing sulphuric acid
234
(0.1 ml) and the mixture refluxed with stirring in an oil 
bath at 120° for 5 h. The acetic acid was evaporated under 
reduced pressure, the residue diluted with water and 
adjusted with aqueous ammonia to pH 10, and extracted with 
chloroform. The solid obtained was subjected to t.l.c. 
(alumina; chloroform, developed twice) and the product 
(0.054 g) in the band at higher Rp was recrystallised from 
toluene to give white crystals of the title compound 
(0.030 g), m.p. 225-226° (Found, for a sample dried at 
110°/710 mmHg for 15 h: C, 70.3; H, 4.5; N, 10.9.
c22h 18c 1n 3° requires C, 70.3; H, 4.8; N, 11.2%).
1H n.m.r.: 8 2.40, s, Me; 5.11, d, J 5.5 Hz, CH2N; 6.6,
bs, NH; 7.11-8.40, complex, ArH.
5-Methoxypyridin-2-amine
9 7 9This compound was prepared from pyridin-3-ol 
through 2-bromopyridin-3-ol, 2-bromo-3-methoxy- 
pyridine,273 and 2-bromo-3-methoxy-6-nitropyridine.272
An attempt to prepare the title compound by heating 
5-iodopyridin-2-amine with sodium methoxide in the presence 
of copper powder at 150° for 22 h gave a low yield of 
impure product.
5-Methylthiopyridin-2-amine
A solution of sodium hydroxide (3.0 g) in water 
(30 ml) was saturated with methanethiol, 5-iodopyridin-2- 
amine270 (4.0 g) and copper powder (1.17 g) were added and 
the mixture heated in a screw-top Teflon-lined stainless 
steel reaction vessel at 150° for 15 h. The contents were
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extracted with chloroform to give the crude product 
(2.553 g). A sample was recrystallised from a mixture of 
benzene and light petroleum to give the title compound,
m.p. 68-70° (Found, for a sample dried at 25°/0.1 mmHg for 
5 h: C, 51.7; H, 6.0; N, 20.2. C6H8N2S requires C, 51.4;
H, 5.8; N, 20.0%). 1H n.m.r.: 6 2.40, s, MeS; 4.23, br,
NH2; 6.47, d, J 9.5 Hz, H 3; 7.50, dd, J3/4 9.5 Hz, J4 ^ 6 
2 Hz, H 4; 8.13, bs, H 6.
5-Propylthiopyridin-2-amine
This compound was prepared from 5-iodopyridin-2-
n 7 qamine and sodium propanethiolate by a procedure similar 
to that described for the methylthio analogue. The yield 
of crude product was 90%.
It was purified by t.l.c. (alumina; chloroform, light 
petroleum, 2:1) and recrystallised from a mixture of 
benzene and light petroleum to give the title compound, 
m.p. 48-50° (Found, for a sample dried at 25°/0.1 mmHg for 
18 h: C, 56.6; H, 7.2; N, 16.3. C8H12N2S requires C,
57.1; H, 7.2; N, 16.5%). XH n.m.r.: 6 0.98, t, J 7 Hz,
Me; 1.54, complex, MeCH2; 2.70, t, J 7 Hz, CH2S, 4.28, br, 
NH2; 6.45, d, J 9 Hz, H 3; 7.51, dd, J3 / 4 9 Hz, J4^6 2 Hz,
H 4; 8.15, bs, H 6.
5-Phenylthiopyridin-2-amine
This compound was prepared from 5-iodopyridin-2-amine
7 7and sodium thiophenolate as described by Bochis et al.
It had m.p. 124-125° (lit.,271 123-125°). 1H n.m.r.: 5
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5.4, br, NH2; 6.52, d, J 9 Hz, H 3; 7.17, s, Ph; 7.55, dd, 
J3/4 9 Hz J4/6 2 Hz, H 4; 8.21, bs, H 6.
3,6-Dimethoxy-2-(4'-tolyl)imidazo[1,2-a]pyridine (VI.3b)
A mixture of 5-methoxypyridin-2-amine (0.461 g),
4'-tolylglyoxal281 (0.8 g), ethanol (10 ml) and 
concentrated hydrochloric acid (0.9 ml) was refluxed with 
stirring in an oil bath at 90° for 16 h. The mixture was 
cooled and the precipitate was filtered off and washed with 
ether to give a yellow solid (0.421 g). This solid was 
stirred overnight with excess ethereal diazomethane at 0°. 
The solvent was evaporated and the oil was subjected to 
t.l.c. (alumina; benzene) to give an oil (0.062 g) which 
crystallised from light petroleum to give the title 
compound, m.p. 105-107° (Found: C, 71.8; H, 6.0; N, 10.5. 
C16H16N2°2 requires C, 71.6; H, 6.0; N, 10.4%). 1H n.m.r.: 
6 2.40, s, MeC; 3.86, s, 6-OMe; 3.95, s, 3-OMe; 6.87-8.00, 
complex, ArH.
6-Methoxy-2-(3 ', 4 '-methylenedioxyphenyl)imidazo- 
[1,2-a]pyridine (VI.4c)
9 7 9A mixture of 5-methoxypyridin-2-amine (0.6 g) and 
a-bromo-3,4-methylenedioxyacetophenone (1.207 g) in 
ethanol (20 ml) was refluxed for 2 h. Sodium hydrogen 
carbonate (0.5 g) was added and the refluxing continued for 
5 h. The solvent was evaporated, the residue diluted with 
water and the solid (1.264 g) filtered off and 
recrystallised from cyclohexane to give the title compound, 
m.p. 182-183° (Found: C, 67.2; H, 4.6; N, 10.2.
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c15h 12n 2°3 requires C, 67.2; H, 4.5; N, 10.4%). 1H n.m.r.:
5 3.83, s, MeO; 5.99, s, OCH2O; 6.81-7.70, complex, ArH.
3-Benzamidomethyl-6-methoxy-2-(3',4'-methylenedioxy- 
phenyl)imidazo[1,2-a]pyridine (VI.5c)
A mixture of 6-methoxy-2-(3',4'-methylenedioxy- 
phenyl)imidazo[1,2-a]pyridine (0.051 g), N-hydroxymethyl- 
benzamide (0.038 g), acetic acid (1.0 ml) and concentrated 
sulphuric acid (2 drops) was refluxed with stirring at 120° 
for 14 h. The mixture was diluted with water, adjusted 
with aqueous ammonia to pH 10 and extracted with 
chloroform. The extract gave an oil which was subjected to 
t.l.c. (alumina; chloroform) and recrystallised from 
toluene to give the title compound (0.029 g), m.p. 233-235° 
(Found: C, 68.9; H, 4.6; N, 10.2. C23H19N3°4 requires C,
68.8; H, 4.8; N f 10.5%). 1H n.m.r.: 6 3.80, s, MeO; 5.10,
d, J 5.5 Hz, CH2N; 5.98, s, 0CH20; 6.73-7.90, complex, ArH.
2-Phenyl-6-pheny1thioimidazo[1,2-a]pyridine (VI.4f)
A mixture of 5-phenylthiopyridin-2-amine (1.882 g) and 
a-bromoacetophenone (1.86 g) in ethanol (12 ml) was 
refluxed in an oil bath at 90° for 2 h. After cooling, 
sodium hydrogen carbonate (0.80 g) was added and the 
refluxing continued for 4 h, followed by dilution with 
water. The solid was filtered off, washed with ether and 
then recrystallised from ethanol to give the title compound 
(0.480 g), m.p. 164-165° (Found: C, 75.3; H, 4.7; N, 9.2.
c19h 14n2s requires C, 75.5; H, 4.7; N, 9.3%). 1H n.m.r.:
S 7.14-8.29, complex, ArH.
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3-Acetamidomethyl-2-phenyl-6-phenylthioimidazo[1,2-a]- 
pyridine (VI.5f)
2-Phenyl-5-phenylthioimidazo[1,2-a]pyridine (0.1 g) 
and N-(hydroxymethyl)acetamide216 (0.184 g) in acetic acid 
(2.0 ml) with concentrated sulphuric acid (0.2 ml) were 
heated in an oil bath at 120° for 14 h, and then the acetic 
acid was evaporated under reduced pressure. The residue 
was diluted with water, adjusted to pH 10 with aqueous 
ammonia and extracted with chloroform. The extract gave an 
oil which was subjected to t.l.c. (alumina; chloroform, 
light petroleum, 3:1) and the product (0.067 g) at lower Rp 
was recrystallised from light petroleum to give the title 
compound, m.p. 192-194° (Found: C, 70.9; H, 4.9; N, 11.1.
c22h 19n30S reguires C, 70.7; H, 5.1; N, 11.3%). XH n.m.r.:
6 2.01, s, MeCO; 4.85, d, CH2N; 7.26-8.45, complex, ArH.
The following imidazo[1,2-a]pyridines were prepared by 
procedures similar to those above:
6-Methoxy-2-(4'-tolyl)imidazo[1,2-a]pyridine (VI.4b) (42%)
as yellow crystals, m.p. 129-131° [after t.l.c. (alumina; 
chloroform, light petroleum, 1:1) and recrystallisation 
from light petroleum] (Found: C, 75.6; H, 5.9; N, 11.8.
c15h 14n 2° reguires C, 75.6; H, 5.9; N, 11.8%). 1H n.m.r.:
5 2.38, s, MeC; 3.82, s, MeO; 6.95, dd, J 9.5 Hz, ^ , 7
2.5 Hz, H 7; 7.22, d, 7.83, d, H 2',3',5',6'; 7.52, d, J
9.5 HZ, H 8; 7.64, d, J 2.5 Hz, H 5, 7.77, s, H3.
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3-Benzamidomethyl-6-methoxy-2-(4'-tolyl)imidazo[1,2-a]- 
pyridine (VI.5b) (27%) as white crystals, m.p. 215-217°
[after t.l.c. (alumina; chloroform) and recrystallisation 
from benzene] (Found: C, 74.7; H, 6.0; N, 11.5.
c23h 21n 3°2 requires C, 74.4; H, 5.7; N, 11.3%). XH n.m.r.
6 2.33, s, MeC; 3.76, s, MeO; 5.06, d, J 5.5 Hz, CH2N; 
6.68-8.21, complex, ArH.
6-Methylthio-2-(4'-tolyl)imidazo[1,2-a]pyridine (VI.4d)
(41%) as yellow crystals, m.p. 117-119° (after column 
chromatography over alumina in a mixture of chloroform and 
light petroleum (1:1) and recrystallisation from light 
petroleum) (Found, for a sample dried at 25°/0.1 mmHg for 
5 h: C, 70.5, H, 5.8; N, 11.0. C15H14N2S requires C,
70.8; H, 5.6; N, 11.0%). XH n.m.r.: S 2.40, s, MeC; 2.49
s, MeS; 7.18, d, J 9 Hz, H 7; 7.24, d, J 8 Hz, H 3',5';
7.59, d, J 9 Hz, H 8; 7.79, s, H 3; 7.84, d, J 8 Hz,
H 2',6'; 8.10, s, H 5.
3-Benzamidomethyl-6-methylthio-2-(4'-tolyl)imidazo- 
[1,2-a]pyridine (VI.5d) (63%), m.p. 224-226° [after t.l.c.
(alumina; chloroform) and recrystallisation from benzene] 
(Found: C, 71.1; H, 5.5; N, 10.8. C23H21N3OS requires C,
71.3; H, 5.5; N, 10.8%). XH n.m.r.: 5 2.38, s, MeC; 2.48
s, MeS; 5.12, d, J 5.5 Hz, CH2N; 6.77. bs, NH; 7.09-8.40, 
complex, ArH.
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6-Propylthio-2-(4'-tolyl)imidazo[1,2-a]pyridine (VI.4e)
(44%), m.p. 85-87° [after chromatography over a column of 
alumina in a mixture of chloroform and light petroleum 
(1:1) and recrystallisation from light petroleum] (Found, 
for a sample dried at 25°/0.1 mmHg for 5 h: C, 72.6; H,
6.7; N, 10.1. C17H18N2S requires C, 72.3; H, 6.4; N,
9.9%). 1H n.m.r.: 5 1.01, t, J 7 Hz, MeCH2; 1.60,
complex, MeCH2; 2.40, s, MeC; 2.83, t, J 7 Hz, CH2S; 7.14- 
8.19, complex, ArH.
3-Benzamidomethyl-6-propylthio-2-(4'-tolyl)imidazo- 
[1,2-a]pyridine (VI.5e) (41%) as white crystals, m.p. 182-
184° [after t.l.c. (alumina; chloroform) and 
recrystallisation from a mixture of benzene and light 
petroleum] (Found: C, 71.8; H, 6.2; N, 9.8. C25H25N30S 
requires C, 72.3; H, 6.1; N, 10.1%). 1H n.m.r.: 8 0.94, 
t, J 7 Hz, MeCH2; 1.54, complex, MeCH2; 2.34, s, MeC; 2.79, 
t, J 7 Hz, CH2S; 5.04, d, J 5.5 Hz, CH2N; 7.04-8.16, 
complex, ArH.
3-Methoxy-6-phenylthio-2-(4'-tolyl)imidazo[l,2-a]pyridine 
(VI.3c) (10%), m.p. 109-110° [after t.l.c. (alumina;
benzene) and recrystallisation from light petroleum]
(Found: C, 72.5; H, 5.6; N, 7.9. C21H18N20S requires C,
72.8; H, 5.2; N, 8.1%). 1H n.m.r.: 8 2.40, s, MeC; 3.95,
s, MeO; 7.05-8.15, complex, ArH.
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6-Benzamidomethyl-2-phenyl-6-phenylthioimidazo- 
[1,2-a]pyridine (VI.5g) (40%), as colourless crystals, m.p.
174-176° [after t.l.c. (alumina; chloroform) and 
recrystallisation from a mixture of benzene and 
cyclohexane] (Found: C, 74.8; H, 5.1; N, 9.5. C27H21N30S
requires C, 74.5; H, 4.9; N, 9.6%). n.m.r.: 5 5.08, d,
J 5.5 Hz, CH2N; 6.76, br, NH; 7.12-8.42, complex, ArH.
6-Phenylthio-2-(4'-tolyl)imidazo[1,2-a]pyridine (VI.4g)
(33%), m.p. 151-152° (after recrystallisation from ethanol) 
(Found: C, 75.7; H, 5.1; N, 8.7. C20H16N2S requires C,
75.9; H, 5.1; N, 8.9%). XH n.m.r.: 6 2.40, s, MeC; 7.14-
8.27, complex, ArH.
3-Acetamidomethyl-6-phenylthio-2-(4'-tolyl)imidazo- 
[1,2-a]pyridine (VI.5h) (36%), m.p. 161-163° [after t.l.c.
(alumina; chloroform, light petroleum, 3:1) and 
recrystallisation from light petroleum] (Found: C, 69.5;
H, 5.8; N, 10.2. C23H2iN3OS 0.5 H20 requires C, 69.6; H, 
5.6; N, 10.6%). 1H n.m.r.: 6 2.02, s, MeCO; 2.39, s, MeC; 
4.86, d, J 5.5 Hz, CH2N; 6.09, br, NH; 7.70-8.37, complex, 
ArH.
3-Benzamidomethyl-6-phenylthio-2-(4'-tolyl)imidazo- 
[1,2-a]pyridine (VI.5i) (41%), m.p. 196-198° [after t.l.c.
(alumina; chloroform) and recrystallisation from a mixture 
of benzene and cyclohexane] (Found: C, 75.2; H, 5.4; N,
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9.3. C28H23N3OS requires C, 74.8; H, 5.2; N, 9.3%).
■^H n.m.r.: S 2.38, s, MeC; 5.08, d, J 5.5 Hz, CH2N; 6.80,
bs, NH; 7.15-8.40, complex, ArH.
Imidazo[1,2,-a]pyrimidines
6-Chloro-2-(4'-tolyl)imidazo[1,2-a]pyrimidine (VI.10)
A mixture of 5-chloropyrimidin-2-amine276 (0.5 g) and 
a-bromo-4-methylacetophenone232 (1.3 g), in ethanol (20 ml) 
was refluxed in an oil bath for 2 h, sodium hydrogen 
carbonate (0.51 g) added and the refluxing continued for 
20 h. The mixture was diluted with water and extracted 
with chloroform and the product from the extract applied in 
benzene to a column of alumina which was then eluted with 
chloroform. The material eluted first was recrystallised 
from ethanol to give the title compound (0.142 g), m.p. 
287-289° (Found, for a sample dried at 105°/0.1 mmHg for 
3 h: C, 64.0; H, 4.0; N, 17.1. c 13Hiqc 1n3 requires C,
64.1; H, 4.1; N, 17.2%). XH n.m.r.: S 2.40, s, MeC; 7.26, 
d, 7.90, d, J 8 Hz, H 2',3',5',6'; 7.76, s, H 3; 8.43, s,
H 5,7.
3-Benzamidomethyl-6-chloro-2-(4 '-tolyl)imidazo[1,2-a]- 
pyrimidine (VI.lib)
A mixture of 6-chloro-2-(4'-tolyl)imidazo[1,2-a]- 
pyrimidine (0.070 g), N-(hydroxymethyl)benzamide (0.1 g), 
acetic acid (1.5 ml) and concentrated sulphuric acid (3 
drops) was refluxed in an oil bath at 120° for 15 h.
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The acetic acid was evaporated under reduced pressure, 
the residue diluted with water, adjusted with aqueous 
ammonia to pH 10 and extracted with chloroform. After 
evaporation of the solvent the residue was subjected to 
t.l.c. (alumina; chloroform, developed twice) and the 
yellow solid (0.068 g) was recrystallised from toluene to 
give white crystals of the title compound (0.020 g), m.p. 
252-254° (Found: C, 67.1; H, 4.9; N, 14.6. C2iH17C1N40
requires C, 66.9; H, 4.5; N, 14.9%). 1H n.m.r.: 5 2.27,
s, MeC; 4.94, d, J 5.5 Hz, CH2N; 6.80-8.48, complex, ArH.
3-Acetamidomethyl-6-chloro-2-(4'-tolyl)imidazo[1,2-a]- 
pyrimidine (Vl.lla) was prepared as described above for the 
3-benzamidomethyl analogue. The product (20%) was 
subjected to t.l.c. (alumina; chloroform) and 
recrystallised from benzene to give the title compound, 
m.p. 250-251° (Found: C, 61.3; H, 5.1; N, 17.5.
c16h 15c 1n4° requires C, 61.0; H, 4.8; N, 17.8%).
■^H n.m.r.: 5 2.21, s, MeCO; 2.38, s, MeC; 4.74, d, J
5.5 Hz, CH2N; 7.09, d, 7.37, d, J 8 Hz, H 2',3',5',6';
8.36, d, 8.51, d, J 3 Hz, H 5,7.
Pyrazines and imidazo[1,2-a]pyrazines 
5-Chloropyrazin-2-amine
This compound was prepared from lumazine through 3- 
aminopyrazine-2-carboxylic acid,277 methyl 3-aminopyrazine-
n n o2-carboxylate, methyl 3-amino-6-chloropyrazine-2-
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9 7 4carboxylate and 3-amino-6-chloropyrazine-2-carboxylic 
acid.280 It had m.p. 129-131° (lit.,280 129-130°).
Attempted chlorination of pyrazin-2-amine with N-chloro- 
succinamide
Pyrazin-2-amine (1.9 g) and N-chlorosuccinamide (2.7 
g) in chloroform (40 ml) were refluxed at 90-92°C for 50 
min. The mixture was cooled at 20° and evaporated to 
dryness to give an oil. This oil was diluted with acetone 
and the solid filtered off. The filtrate was evaporated 
and the residue subjected to column chromatography in 
chloroform over alumina. The main fraction (1.618 g) was 
dissolved in benzene and on standing gave a crystalline 
solid (0.250 g). This solid (0.150 g) was subjected to 
t.l.c. (alumina; benzene) and gave 5-chloropyrazin-2-amine 
(0.054 g), m.p. 134-136° (from a mixture of benzene and 
light petroleum) (lit.282 m.p. 130-132°), 1H n.m.r.: 6 
7.76, d, J3/6 1 Hz' ; 8.01, d, 1 Hz, H6; 3-chloropyrazin- 
2-amine (0.011 g) m.p. 167-168° (from light petroleum), 
(lit.282 m.p. 167-168°) 1H n.m.r.: 6 7.71, d, J5/6 2.5 Hz, 
H6; 7.93, d, 2.5 Hz, H5; and a dichloropyrazin-3-amine 
(0.006 g) (from light petroleum), m.p. 131-132° (lit. 140- 
141° 283, 140-142° 284), 1H n.m.r.: 6 7.96, s.
6-Chloro-3-methoxy-2-(4'-tolyl)imidazo[1,2-a]pyrazine 
(VI.14)
A solution of 5-chloropyrazin-2-amine (0.13 g), 4- 
tolylglyoxal hydrate261'281 (0.21 g), ethanol (2.0 ml) and 
concentrated hydrochloric acid (0.3 ml) was refluxed with
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stirring in an oil bath at 90° for 14 h. The ethanol was 
evaporated under reduced pressure and the residue 
evaporated with benzene. The oily residue was dissolved in 
a little methanol and stirred with excess ethereal 
diazomethane in ice overnight. After evaporation of the 
solvents, the residue was diluted with chloroform, washed 
with water and the chloroform evaporated to give an oil. 
This was subjected to t.l.c. (alumina; chloroform and then 
alumina; benzene) to give a light yellow solid (0.024 g) 
which was recrystallised from light petroleum and gave the 
title compound (0.010 g), m.p. 179-181° (Found: C, 61.1;
H, 4.7; N, 15.5. C14H12C1N30 requires C, 61.4; H, 4.4; N,
15.4%). 1H n.m.r.: S 2.42, s, MeC; 4.00, s, MeO; 7.31, d,
J 8 Hz, H 3',5'; 7.97, d, 8 Hz, H 2' ,6'; 7.97, s, H 7;
8.78, s, H 5.
6-Chloro-2-(4'-tolyl)imidazo[1,2-a]pyrazine (VI.15)
A mixture of 5-chloropyrazin-2-amine (0.305 g) and a-
n o obromo-4-methylacetophenone (0.543 g) in ethanol (5 ml) 
was refluxed for 2 h, sodium hydrogen carbonate (0.543 g) 
was added and the refluxing continued for 6 h. The solvent 
was evaporated and the residue extracted with chloroform 
and subjected to t.l.c. (alumina; chloroform). A solid 
(0.2 g) was obtained which was recrystallised from 
cyclohexane to give the title compound (0.070 g), m.p. 197- 
200° (Found: C, 64.4; H, 4.0; N, 17.1. C13H10C1N3
requires C, 64.1; H, 4.1; N, 17.2%). ^H n.m.r.: 5 2.41,
s, MeC; 7.29, d, J 7 Hz, H 3',5'; 7.88, d, J 7 Hz, H2',6''* 
7.91, s, H 3; 8.14, s, H 8; 8.90, s, H 5.
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3-Benzamidomethyl-6-chloro-2-(4'-tolyl)imidazo[1,2-a]- 
pyrazine (VI.16)
A mixture of N-(hydroxymethyl)benzamide (0.050 g) , 
6-chloro-2-(4'-tolyl)imidazo[l,2-a]pyrazine (0.036 g) in 
acetic acid (1.0 ml) with concentrated sulphuric acid 
(3 drops) was refluxed with stirring in an oil bath at 120° 
for 14 h. The acetic acid was evaporated under reduced 
pressure, the residue diluted with water (10 ml), adjusted 
with agueous ammonia to pH 10 and extracted with 
chloroform. The product was subjected to t.l.c. (alumina; 
chloroform) and recrystallised from ethanol to give the 
title compound (0.017 g), m.p. 270-272° (Found: C, 67.2;
H, 4.6; N, 14.8. C21H17C1N4° requires C, 66.9; H, 4.6; N,
14.9%). 1H n.m.r.: 5 2.44, s, MeC; 5.15, d, J 5.5 Hz,
CH2N ; 6.44, br, NH; 7.25-7.85, complex, Ph and 
H 2',3',5 ',6'; 8.54, bs, H 7; 8.89, bs, H 5.
Imidazo[1,2-b]pyridazines
6-Propylthio-2-(4'-tolyl)imidazo[1,2-b]pyridazine (VI.7a)
A mixture of 6-propylthiopyridazin-3-amine161 (0.3 g)
popand a-bromo-4-methylacetophenone (0.376 g) in ethanol 
(4.5 ml) was refluxed with stirring for 2 h. Sodium 
hydrogen carbonate (0.17 g) was added and the refluxing 
continued for 4 h. The mixture was cooled and the 
precipitate was filtered off and washed with water. It was 
recrystallized from light petroleum to give crystals of the
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title compound (0.325 g), m.p. 126-128° (Found: C, 68.0; H, 
6.2; N, 14.6. C16H17N3S requires C, 67.8; H, 6.1, N,
14.8%) 1H n.m.r.: 6 1.09, t, J 7 Hz, MeCH2; 1.78,
complex, MeCif2; 2.39, s, MeC; 3.18, t, J 7 Hz, C#2S; 6.82, 
d, J 9 Hz, H7; 7.25, d J 7 Hz, H3',5'; 7.70, d, J 9 Hz, H8; 
7.83, d, J 7 Hz, H2',6'; 8.11, s, H3.
2- (3',4'-Methylenedioxyphenyl)-6-propylthioimidazo-
[1,2-a]pyridazine (VI.7b) (87%), was prepared in a similar
manner from 6-propylthiopyridazin-3-amine and a-bromo- 
3',4'-methylenedioxyacetophenone.228 It had m.p. 120-122° 
(after recrystallisation from ethanol) (Found: C, 61.0;
H, 4.9; N, 13.2. C16H15N302S requires C, 61.3; H, 4.8; N,
13.4%). 1H n.m.r.: 5 1.09, t, J 7 Hz, MeCH2; 1.78,
complex, MeCH2; 3.19, t, J 7 Hz, CH2S; 6.01, s, 0CH20; 
6.77-8.04, complex, ArH.
In a similar manner the following compounds were 
prepared:
3- Benzamidomethyl-2-(3',4'-methylenedioxyphenyl)-6-
propylthioimidazo[1,2-a]pyridazine (VI.8b) (23%), m.p. 200-
202° [after t.l.c. (alumina; chloroform, light petroleum, 
2:1) and recrystallisation from toluene] (Found: C, 64.5;
H, 4.7; N, 12.4. C24H22N403S requires C, 64.6; H, 5.0; N,
12.5%). ^H n.m.r.: 6 1.00, t, 7 Hz, MeCH2; 1.72, complex,
MeCtf2; 3.13, t, J 7 Hz, CH2S; 5.13, d, J 5.5 Hz, CH2N;
5.98, s, 0CH20; 6.74-7.96, complex, ArH.
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3-Benzamidomethyl-6-propylthio-2-(4'-tolyl)imidazo- 
[1,2-b]pyridazine (VI.8a) (58%) as colourless crystals,
m.p. 202-203° [after t.l.c. (alumina; chloroform, light 
petroleum, 2:1) and recrystallisation from toluene]
(Found: C, 69.0; H, 5.9; N, 13.8. C24H24N4OS requires C,
69.2; H, 5.8; N, 13.4%). XH n.m.r.: 6 0.98, t, J 7 Hz,
MeCH2; 1.72, complex, MeCtf2 /’ 2.36, s, MeC; 3.11, t, J 7 Hz, 
CH2S; 5.13, d, J 5.5 Hz, CH2N; 6.68-7.99, complex, ArH.
2- (3 ', 4 '-Methylemedioxyphenyl)-6-methylthio-3-0- 
napthamidomethylimidazo[1,2-b]pyridazine (VI.8c)
6-Methylthio-2-(3',4'-methylenedioxypheny1)imidazo- 
[1,2-b]pyridazine (0.11 g) was added to a solution of N- 
(hydroxymethyl)-ß-naphthamide [0.092 g, m.p. 139-142°
(^ H n.m.r.: 5 5.04, d, J 6 Hz, CH2; 7.50-833, complex,
ArH), prepared from /3-naphthamide, m.p. 195-197° (lit.285 
m.p. 195°) by heating with aqueous formaldehyde] in glacial 
acetic acid (3.0 ml) containing sulphuric acid (0.1 ml) and 
the mixture was refluxed with stirring in an oil bath at 
120° for 5 h. The mixture was cooled to 20° and the 
residue was diluted with water (60 ml), adjusted with 
aqueous ammonia to pH 10 and the mixture extracted with 
chloroform to give a mixture of some solid and oil (0.246 
g). This crude product was subjected to t.l.c. (alumina; 
chloroform) and gave the title compound (0.117 g), m.p. 
222-224° (toluene) (Found: C, 66.9; H, 4.2; N, 12.0. 
c26h 20n 4°3s requires C, 66.7; H, 4.3; N, 12.0%).
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1H n.m.r.: 6 2.58, s, MeS; 5.21, d, J 5.0 Hz, CH2N; 5.97, 
s, OCH20; 6.70, d, J 9.5 Hz, H7; 6.79-8.43, complex, 
H2',5',6',8 and naphthalenyl.
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